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Abstract 
The present PhD thesis represents a contribution to the IndiTreat project which started on January 1st 
2011 supported by the Danish Council for Strategic Research. The main goal of the project is to 
improve chemotherapeutic treatment of patients suffering from colorectal cancer (CRC). In this thesis 
we investigate the use of polymers for drug screening assays. The aim of this study is the development 
of a polymer platform that enables to overcome some of the limitations that characterize the existing 
screening methods, by requiring very small amounts of tissues and permitting a fast and low-cost 
screening of individual drugs as well as combined drugs. Human colorectal adenocarcinoma cell line 
(HT-29) has been selected as cell culture model because easy to handle and phenotypically stable. The 
responsiveness of HT-29 cells to the individual and combined drug regimens normally selected for 
colorectal cancer therapy is finally evaluated using our technologies. Two main platforms are 
proposed: one is based on the use of poly(ethylene glycol) diacrylate (PEGDA) hydrogels for controlled 
drug release, and the second one consists on the use of poly(3,4-(1-azidomethylene)-dioxythiophene) 
(PEDOT-N3) micro-electrodes for co-localization of drug-loaded nanoparticles (liposomes) and cancer 
cells.  
PEGDA hydrogels are widely used in different fields including tissue engineering and in vivo drug 
delivery. A home-made setup for the fabrication of PEGDA hydrogels through visible-light photo-
polymerization is described in detail. The method is utilized to create gels in which various clinically 
relevant drugs are embedded within the polymer network. The release profile of these molecules is 
determined and the anti-proliferative effect of passively released drugs is evaluated on HT-29 cultures. 
Individual drugs and combinations of chemotherapeutics are embedded within PEGDA gels as free 
molecules or loaded into nanoparticles (liposomes). The release of molecule from liposomes is 
temporally controlled through heat treatment and stable nanoparticles embedded within polymer 
networks are achieved. With the developed technology, various hydrogel architectures and sizes are 
produced allowing the confinement of targeted molecules within defined volumes of gel. From our 
described findings, the PEGDA-based hydrogel platform can ideally be applied for the screening of 
different compounds and to explore in vitro, various pathological cell lines. 
In this thesis is presented also an alternative methodology for drug screening purposes, consisting on 
the fabrication of a micro- and nano-platform for drug-loaded liposomes immobilization and cell 
capture. PEDOT-N3 micro-electrodes are fabricated through printed dissolution that, contrarily to the 
traditional lithography processes, preserves the biochemical properties of the exposed substrates. 
Cyclic olefin copolymers (COC) supports are used for PEDOT-N3 deposition and in situ polymerization. 
Various chemical modifications to create a coating onto the support surface are also explored. A variety 
of highly hydrophilic poly(ethylene glycol) (PEG)-based molecules are photo-chemically grafted onto 
COC supports to form protein repellent surfaces. Post-fabrication covalent modifications of polymer 
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micro-electrodes are investigated and the use of “click-chemistry reaction” permits to modify free 
available azide groups presented at the surface of micro-electrodes. By covalently attaching 
appropriate bi-functional molecules onto a thin PEDOT-N3 film, chemical reactive liposomes (~100nm 
in diameter) are immobilized onto electrodes.  
In addition to these findings, an extensive optimization of electrodes fabrication, liposomes stability 
and chemical engineering of the support areas between the electrodes for cell capture purposes, is 
necessary. We find that it would be highly relevant for future studies to explore the mechanisms 
involved on co-localization of liposomes, that are triggered for drugs release, and specific cell lines.  
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Dansk resume   
 
Denne ph.d. afhandling er et bidrag til IndiTreat projektet, der startede 1. januar 2011 støttet af Det 
strategiske Forskningsråd. Projektets hovedmål er at forbedre kemoterapi af patienter med kolorektal 
cancer. I denne afhandling har vi udforsket anvendelse af polymerer i systemer til at måle effekten af 
forskellige typer medicin ("screening"). Formålet med dette studie er at udvikle en polymer-baseret 
teknologi, der undgår begrænsninger i eksisterende screening-systemer ved at muliggøre analyse på 
meget små vævsmængder og analyse af både individuelle aktive stoffer og kombinationer af stoffer. En 
human kolorektal adenocarcinoma cellelinie (HT-29) blev valgt som cellemodel da den er let at arbejde 
med og fænotypisk stabil. Den udviklede teknologi er blevet anvendt til at eksponere HT-29 celler til 
individuelle stoffer eller kombinationer af stoffer, der normalt anvendes ved behandling af kolorektal 
cancer, hvorefter stoffernes indvirkning på cellerne er evalueret. To forskellige teknologiplatforme 
bliver foreslået. Den ene platform gør brug af poly(ethylenglykol)-diakrylat (PEGDA) hydrogeler til 
styret frigivelse af aktive stoffer. Den anden platform er baseret på poly(3,4-(1-azidomethylen)-
dioxythiophen) (PEDOT-N3) mikroelektroder til at samlokalisere stof-fyldte nanopartikler (liposomer) 
og cancerceller. 
PEGDA hydrogeler anvendes i mange arbejdsområder inklusive vævs regenerering og 
medicinfrigivelse i kroppen (in vivo). En instrumentel opstilling og eksperimental procedure til 
fremstilling af PEGDA hydrogeler ved fotopolymerisering med synligt lys er detaljeret beskrevet. 
Metoden er blevet anvendt til at fremstille geler med klinisk relevante stoffer indlejret i 
polymernetværket. Den tidslige profil for frigivelse af disse molekyler samt den væksthæmmende 
effekt af passivt frigivne stoffer på HT-29 cellekulturer er blevet analyseret. Individuelle stoffer såvel 
som kombinationer af kemoterapeutiske stoffer blev indlejret i PEGDA geler som frie molekyler eller 
indkapslet i nanopartikler (liposomer). Frigivelsen af molekyler fra liposomer kan tidsligt styret ved en 
varmebehandling, og stabile nanopartikler indlejret i polymere netværk blev fremstillet. Den udviklede 
teknologi blev anvendt til at producere en række forskellige hydrogel-former og -størrelser, hvilket 
tillod afgrænsning af de ønskede aktive stoffer til veldefinerede gel-volumener. Vores resultater 
muliggør anvendelse af den PEGDA-hydrogel baserede teknologiplatform til screening af forskellige 
stoffer og til at udføre laboratorieforsøg (in vitro) på forskelllige cellelinier. 
Denne afhandling præsenterer også en alternativ metode til medicin-screening baseret på fremstilling 
af en mikro- og nano-platform til at immobilisere medicin-fyldte liposomer og indfangne celler. 
PEDOT-N3 mikro-elektroder blev fremstillet med metoden "opløsning ved stempling", der, til forskel 
fra traditionelle litografiske processer, bevarer de biokemiske egenskaber af det eksponerede 
underlag. Underlag fremstillet i cyklisk olefin copolymer (COC) blev anvendt til deponering og in situ 
polymerisering af PEDOT-N3, og forskellige typer af kemiske modificeringer af overfladen blev udført 
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og karakteriseret. En række meget hydrofile poly(ethylen glykol)-baserede molekyler blev fotokemisk 
bundet til COC underlagene for at skabe proteinafvisende overflader. Kovalent modificering af de 
fremstillede polymer mikro-elektroder blev undersøgt, hvor "klik-kemi" blev anvendt til modificering 
af de tilgængelige azid-grupper på overfladen af mikro-elektroderne. Kovalent binding af udvalgte bi-
funktionelle molekyler på en tynd PEDOT-N3 film gjorde det muligt at immobilisere kemisk reaktive 
liposomer (~100 nm i diameter) på elektroderne. 
I tillæg til de opnåede resultater vil det være nødvendigt at udføre en omfattende optimering af 
elektrodefremstilling, liposomstabilitet, og kemisk styring af områderne af underlag mellem 
elektroderne for indfangning af celler. Vi mener at det vil være meget relevant i fremtidige studier at 
undersøge de underliggende mekanismer bag samlokalisering af specifikke cellelinier og liposomer 
der er blevet stimuleret til stoffrigivelse. 
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List of abbreviations and IUPAC 
nomenclature 
 
Bz 
 
4-benzoyl benzylamine hydrochloride or benzophenone 
CAFs  Cancer-associated fibroblasts 
Carboplatin cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II) 
Cisplatin (SP-4-2)-diamminedichloroplatinum(II) 
COC Cyclic olefin copolymers 
CRC ColoRectal Cancer 
CuAAC Copper(I)-catalyzed azide-alkyne Huisgen 1,3-dipolar cycloaddition 
DACH Diaminocyclohexane 
DLS Dynamic Light Scattering 
DMEM Dulbecco´s Modified Eagle Medium 
DSPC [(2R)-2,3-di(octadecanoyloxy)propyl]2-(trimethylazaniumyl)ethylphosphate 
or Distearoyl phosphatidylcholine 
DTCs Disseminated tumor cells 
dTMP Deoxythymidine monophosphate 
dUMP Deoxyuridine monophosphate 
ECM Extracellular matrix  
EDOT 3,4-ethylenedioxythiophene 
EDOT-N3 3,4-(1-azidomethylethylene)-dioxythiophene 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FdUMP Fluorodeoxyuridine monophosphate 
FITC Fluorescein isothiocyanate 
FOLFIRI FOL: folinic acid; F: 5-fluorouracil; IRI: irinotecan 
FOLFOX FOL: folinic acid; F: 5-fluorouracil; OX: oxaliplatin 
FOLFOXIRI FOL: folinic acid; F: 5-fluorouracil; OX: oxaliplatin; IRI: irinotecan 
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Folinic Acid, FA  
 
(2S)-2-{[4-[(2-amino-5-formyl-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-
yl)methylamino]benzoyl]amino}pentanedioic acid or Leucovorin 
HCT Human colorectal carcinoma cells 
HT-29 Human colorectal adenocarcinoma cell line 
I2959 1-[4-(2-Hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one or 
IrgaCure 2959 
ICP-MS Inductively coupled plasma mass spectrometry 
Irinotecan, CPT-11 (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H- 
pyrano[3’,4’:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4’bipiperidine]-1’-
carboxylate 
LAP Lithium phenyl-2,4,6-trimethyl-benzoylphosphinate 
Lurtotecan, GW211 (S)-8-ethyl-8-hydroxy-15-((4-methylpiperazin-1-yl)methyl)-11,14-dihydro-
2H-[1,4]dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolone-
9,12(3H,8H)-dione   
LUVs Large unilamellar vesicles 
MDSCs Myeloid-derived suppressor cells 
MLVs Multilamellar vesicles 
MMPs Matrix metallopeptidases 
MTS  [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium] 
NCF Normal human colonic fibroblasts 
NCM Normal human colonic mucosa cells 
NHS N-Hydroxysuccinimide group 
Oxaliplatin, OxPt [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II) 
PBS Phosphate buffer solution 
PC [(2R)-3-hexadecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropyl]2-
(trimethylazaniumyl)ethyl phosphate or Phosphatidylcholine 
PE [(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-
2-yl] icosanoate or Phosphatidylethanolamine 
PEDOT Poly(3,4-ethylenedioxythiophene) 
PEDOT-N3 Poly(3,4-(1-azidomethylethylene)-dioxythiophene) 
PEDOT-N3:TsO p-doped PEDOT-N3 containing tosylate anions 
PEG Poly Ethylene Glycol 
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PEGDA Poly Ethylene Glycol Diacrylate 
POC Point-of-care 
PS-N3 Poly(4-(azidomethyl)styrene) 
PSS Poly(styrene sulfonic acid) 
rpm Revolutions per minute 
SN-38 7-Ethyl-10-hydroxy-camptothecin 
SUVs Small unilamellar vesicles 
TAMs Tumor associated macrophages 
Tm Phase transition temperature of liposomes 
TME Tumor microenvironment 
TNM T, N, M are the categories of the universal staging system used to classify 
tumors 
Topo I Topoisomerase I 
TS I Thymidylate synthase 
TsO Tosylate group Fe(III)TsO 
Vitamin B9, folic 
acid 
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino] 
pentanedioic acid 
WHO World Health Organization 
XPS X-ray photoelectron spectroscopy 
5-fluorouracil, 5-FU 5-Fluoro-1H,3H-pyrimidine-2,4-dione 
9-AC 9-aminocamptothecin 
9-NC 9-nitrocamptothecin 
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1 Introduction 
 
The IndiTreat project: from prevention to personalized medicine 
The present PhD thesis represents a contribution to the IndiTreat project. This project, which started 
on January 1st 2011 supported by the Danish Council for Strategic Research, aims at improving 
chemotherapeutic treatment of patients suffering from colorectal cancer (CRC). The main purpose is to 
develop a micro- and nano-platform able to test different combinations of available chemotherapeutic 
compounds on each malignant tissue collected from individual patient and thereby enable a 
personalized medical treatment. To fulfill the project´s goals, nanotechnology researchers, medical 
doctors, cell biologists, and a private company collaborate to develop the system and establish its 
efficiency for treatment of colorectal cancer.[1] 
At the moment, colorectal cancer is the second leading cause of cancer-related death in Denmark and it 
is the most diagnosed cancer in European countries. CRC is a highly heterogeneous disease with 
multiple interconnected extra- and intra-cellular pathways implicated on the cancer onset.[2] The 
complexity of processes involved on colorectal malignancy is reflected on patients with a diverse 
responsiveness to standard chemotherapeutic treatments. Nowadays, various chemotherapeutical 
treatments (FDA approved) are daily used together with surgery to cure CRC. Some examples are the 
application of antibodies against the epidermal growth factor receptor, EGFR such as cetuximab and 
panitumumab. It has been shown that these antibodies are effective only when the related protein 
KRAS involved in the intracellular signaling pathway is un-mutated.[3] Therefore, in patients where 
KRAS protein is mutated, different chemotherapeutic treatments are needed. Currently, 47 new drug 
candidates are under evaluation in CRC trials and 42 of them are administrated in combination 
regimens.[3] Thus, in vitro screening assays to predict individual patient responsiveness to drugs or 
combinations of drugs are required and their demand is gradually increasing. Recently, various cell-
handling techniques prove a great correlation of in vitro results with the in vivo physiological condition 
of patients.[4–9] Such correlation between in vitro and in vivo data has led the US Government social 
insurance program, Medicare, to evaluate the in vitro efficiency of adjuvant medical treatment for 
individual cancer patient. Normally, patients presenting primary tumor are subjected to surgery and 
adjuvant chemo- or radio-therapy, whereas patients with primary metastasis or recurrent malignancy 
are offered combination chemotherapies as palliative treatment and to prolong survival. The aim of 
IndiTreat is to improve the responsiveness to chemo-treatment and decrease the risk of resistance to 
the selected treatment raising the clinical response rates. 
In the light of that, the overall objective is to develop a micro- and nano-technology platform that 
enables fast, reliable and inexpensive efficacy and resistance test of the colorectal drug combination 
therapies used clinically in small tissue volumes from individual patients. The nano-technological 
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platform should identify the optimum drug combinations for the treatment of colorectal cancer and 
introduce the established technology for the in vitro study of various pathological diseases.  
 
1.1 Multi-drug screening in vitro and in vivo  
One of the major challenges encounters on chemosensitivity screening is the evaluation of in vitro and 
in vivo correlation. To determine the cytotoxic or apoptotic effect induced by anticancer drugs, in vitro 
evaluation in cell culturing systems is required, and a subsequent chemosensitivity assessment in 
animal models is essential. Many studies have shown the substantial evidence that in vitro 
chemosensitivity is associated with in vivo drug response.[10,11] As a consequence, the understanding of 
drug sensitivity of a specific tumor for a certain drug can help doctors to choose and plan 
chemotherapy treatment for each patient. There are many fundamental questions at which scientists 
should answer when evaluating in vitro drug screening assay: i) are the in vitro results obtained with 
tumors of a specific histological cell line similar to those clinically observed for the same tumor type? 
ii) can the selected chemotherapy improve the patient survival after a prolonged time of drug 
exposure? iii) are the in vitro results comparable to those in vivo? When malignant cells deriving from 
tumor biopsy are cultured for drug screening purposes, they are subjected to an extensive 
manipulation that could alter their drug response. Moreover, the in vitro growth rate of tumor cells 
may be much faster than in vivo and false-positive results may be obtained.[7] Another concern is 
whether the tumoral cells selected for in vitro assays are representative of the cancer cells in patient´s 
tumors. In fact, primary tumors and metastasis are highly heterogeneous in terms of cell populations 
and it could be that the cell line used in vitro is predictive for only a small portion of the patient´s 
tumor.[7] Although the in vitro chemosensitivity study is a simplified approach for the investigation of 
in vivo cell responsiveness on tumor, it is necessary to predict the sensitivity, accuracy and specificity 
of chemotherapeutics. Among the existing in vitro assays, one should select the one which better 
satisfy the following requirements: the results should correlate with clinical response and survival; the 
outcome of the assay must be related to the effect of drugs on a certain cell line; the assay information 
must be easy to interpret and apply; and the test should be inexpensive. The most common in vitro 
assays used to evaluate drug-induced cell proliferation are various: clonogenic,[12] cell suspension,[13] 
differential staining cytotoxicity,[14] Kern,[15] and collagen gel droplet drug sensitivity[16] tests are 
usually employed to evaluate the dose-response curves. Another class of drug screening assays is 
based on the measurement of the cell metabolic activity in response to therapy, such as the ATP 
bioluminescence,[17] the coloration with sulfo-rhodamine, the fluorescence generated from cellular 
hydrolysis of fluorescein diacetate,[18] the coloration with reduction of MTS or MTT,[19] the 
measurement of extra-cellular acidification rate[20] or quantification of cellular protein content. An 
alternative technique to evaluate the effect of drugs on a cell line is to measure the DNA damage at the 
chromosome level, for instance rearrangement, loss, breakage of chromosomes, cell division inhibition, 
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cell apoptosis and necrosis.[21] No matter which in vitro assay is chosen, all the listed methods must 
provide a drug sensitivity index in order to compare outcomes obtained using different approaches. 
Moreover, when multi-drug regimens are adopted for curative therapy, the in vitro assay must also 
assess the drug interactions providing eventual synergism, additivity or antagonism behavior.[7]  
In general, the study of in vivo chemosensitivity in preclinical tumor-bearing animal models must be 
also evaluated. In fact, in vitro assays do not take into account many relevant concerns: the distribution 
of drug to tumor is poor or absent due to a missing vascularization system, the need for drug 
activation, difference in tumor growth rate in vitro and in vivo, pharmacological barriers.[7] In 
conclusion, in vitro results obtained from one site of solid tumor may not be representative of other 
sites in the same patient, thus new approaches able to correlate drug treatment to tumor cell 
sensitivity are required. 
 
1.2 Fabrication of miniaturized platforms for drug-screening in 
colorectal cancer therapy 
The existing point-of-care (POC) devices have a proven role in diagnosis and assessment of colorectal 
cancer. Although many of the screening tests previously described are well established and validated 
in diverse commercially available POC devices, their accuracy remains an important drawback.[22] The 
POC diagnostic industry is gradually expanding with an estimated 35% share of the in vitro diagnostic 
market within United States and was valued at $15.1 billion in 2011.[23] Despite the increasing number 
of screening strategies and the emerging technologies in molecular marker application, not all methods 
satisfy the criteria required for screening tests in 
population programs.[24] Another issue that must 
be considered is the current discovery of new 
FDA-approved drugs. Only few novel drugs for 
colorectal cancer therapy have been developed 
and anyhow, the traditional drugs for colorectal 
cancer treatment remain the favorited and 
mostly used (Figure 1.1) due to the observed 
survival rate. On the other hand, because of the 
large heterogeneity of colorectal cancer and 
patient´s responsiveness to drug therapy, a 
personalized chemotherapeutical treatment for 
individual patients is required. Nanotechnology is an emerging discipline in the fields of drug delivery 
and drug screening. Micro- and nano-systems are widely used in cell culture based studies due to their 
unique physico-chemical and biological properties, small sizes (ranging between 10-100nm in at least 
Figure 1.1 Overall survival of patients with colorectal 
cancer diagnosed after prolonged chemotherapeutic 
treatment (data reported from 1980 to 2015).[200] 
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one dimension), and their ability to protect encapsulated molecules susceptible to the environment 
(pH, enzymatic degradation, ionic strength) and enhancing drug biodistribution when involved in in 
vivo applications.[25] However, to achieve these goals offered by nanodelivery systems, many issues 
which include the development of toxic-free system, improved biocompatibility, effective drug loading, 
and release process, must be assessed.[25,26] In particular, biocompatibility and biodistribution are 
crucial key points in achieving in vitro and in vivo successful outcome for drug development. The 
properties of these delivery systems are strictly influenced by the synthetic process by which they are 
produced, the coating materials, the particles size, the route of administration and the method used to 
induce drug release.[27,28] Over the last six decades, more than 85000 compounds were screened 
against cancers using cancer nanotechnology because of its emerging interdisciplinary research and 
great potential in diagnosis and treating cancers.[29] In vitro models are characterized by the absence of 
immune effect, blood proteins, and endocrine systems, thus limiting the use of cell culture-based 
results obtained with nanotechnology to animal models.[30] However, animal systems are extremely 
complicated with unique bio-distribution, clearance mechanism, immune response and metabolism; 
therefore, in vitro studies can complement animal studies in assessing nanodelivery systems.[26] 
The IndiTreat project provides a distinct technology that selects specific drug treatment based on 
cellular responsiveness of tissues from individual patient. The micro- and nano-technologies proposed 
here may overcome some of the limitations that characterize the existing screening methods, by 
requiring very small amounts of tissue and permitting a fast and low-cost drug screening of individual 
drugs and combinations of them. In this thesis, human colorectal adenocarcinoma cell line (HT-29) 
have been selected as cell culture model because ease to handle (cells can be passaged many times, up 
to 200 passages) and they are phenotypically stable. The responsiveness of HT-29 cells to the 
individual and combined drug regimens normally selected for colorectal cancer therapy is finally 
determined using the developed nanotechnologies. 
 
1.2.1 Development of PEG-based hydrogel for multi-drug release 
Hydrogels are a large class of biomaterials with numerous advantages and widely applied for 
simultaneous encapsulation of cells and biomolecules. Poly(ethylene glycol) (PEG)-based hydrogels 
have been extensively used as matrices for controlling drug delivery, as well as cell delivery vehicles 
for promoting tissue regeneration. Particularly interesting is the use of poly (ethylene glycol) di-
acrylate (PEGDA) hydrogels in many biomedical applications due to their cytocompatibility, poor cell 
adhesion and ease to handle.[31,32] Some of the PEGDA applications include hydrogel development for 
drug delivery, tissue engineering, wound healing and electrospinning processes.[33–35] In this thesis, 
PEGDA hydrogels have been fabricated through visible-light photo-polymerization for drug release 
purposes, in particular creating three-dimensional (3D) hydrogel structures in which different drugs 
are embedded. The release of each anti-colorectal cancer drug (5-FU, oxaliplatin, SN-38 and folinic acid 
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described in detail in the following sections) is characterized and tuned to guarantee a release for 
three days. Moreover, drug-loaded nanoparticles (liposomes) are employed and embedded within 
hydrogels to protect and control the release of oxaliplatin, otherwise rapidly lost during washing 
process (Figure 1.2).  
 
 
Figure 1.2 Schematic of the nanotechnology presented in this thesis. The system involves three-dimensional (3D)-hydrogel 
structures composed of PEGDA and anti-colorectal cancer drugs embedded within polymeric network. Human colorectal 
adenocarcinoma cells (HT-29) are cultured onto the hydrogel surface and the effect of released compound doses on cell 
proliferation is evaluated. Drugs are embedded within the network as free drugs or loaded into nanoparticles (liposomes) which 
are thermally triggered. The passively released molecules are collected into the supernatant and quantified. 
 
The effect of individual embedded drug and combinations of embedded compounds is evaluated by 
culturing human colorectal adenocarcinoma cells onto the hydrogel surface, and the response of cells 
exposed to different drug doses is determined (cell proliferation or cell cytotoxicity). Among the 
existing drug releasing systems, the proposed nanotechnology has a number of advantages:  
a) PEGDA hydrogels are easily fabricated through photo-polymerization (the process takes 1 
minute to completely crosslink a solution of polymer and photo-initiator);  
b) the material is biocompatible due to the choice of light source, photo-initiator and reactants 
concentration;  
c) multiple solutions can be polymerized at the same time (12 wells are crosslinked in 1 minute);  
d) traditional disposable may be employed for hydrogel curing and drug release study (96 well-
microtiter plates);  
e) drugs with a determined concentration are directly embedded within polymeric network 
during photo-polymerization; 
f) after a washing step, the drug-hydrogel system is utilized for cell culture purposes and 
because of the miniaturized technology, various parameters may be tested in the same 
experiment (for instance drug dose and cell concentration); 
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g) the release of drugs can be tuned by changing the physico-chemical properties of hydrogel 
(small and hydrophilic compounds are quickly released from hydrogel); 
h) the use of drug-loaded nanoparticles embedded within hydrogel ensures a protection of 
molecules from the environment and controls drug release through the application of a proper 
trigger (thermo-sensitive liposomes are sensitive to temperature changes, so their content is 
released only when a certain temperature is reached); 
i) a direct dose-cytotoxicity outcome is obtained using conventional proliferation assays (for 
example metabolic activity assays) with a high reproducibility. 
Besides the specific employment of PEGDA hydrogels for drug screening in colorectal cancer therapy, 
the described nanotechnology may be transferred to other types of solid cancers and can be further 
developed for large-scale production and perhaps at a smaller scale. A detailed description of the PEG-
based hydrogel nanotechnology is found in Chapter II. 
 
1.2.2 Fabrication of inter-digitated PEDOT-N3 electrodes for co-localization of 
nanoparticles and colorectal cancer cells 
In this thesis, a micro- and nano-technology platform has been also explored with the aim of co-
immobilizing drug-loaded nanoparticles (liposomes) on functionalized polymer micro-electrodes and 
human colorectal adenocarcinoma cells (HT-29) on the surrounding electrodes areas. More 
specifically, we wanted to capture cell subpopulations, in particular cancer stem cells.  
Conductive and semi-conductive polymers are an extensive class of materials largely used for bio-
medical devices due to their ability to replace expensive metals and semiconductors. Conductive 
polymers have the capability to act as conductors and bio-molecules may be embedded within the 
polymer during polymerization process or attached by post-polymerization coupling chemistry. The 
release of certain molecules may be induced as an example, upon an electrical trigger without altering 
the physico-chemical properties of the targeted compound.[36,37] Specifically, poly(3,4-(1-
azidoymethylethylene)-dioxythiophene) (PEDOT-N3) has been used for the fabrication of such system 
due to its ease of handling, chemical stability, cellular compatibility and post-fabrication chemical 
functionalization. Briefly, PEDOT-N3 electrodes are fabricated using printed dissolution technique on a 
PEG-coated support which is used to discourage protein and cell adsorption (Figure 1.3).  
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Figure 1.3 Schematic of the micro- and nano-technology platform. Polymer micro-structures (width around 100µm) are 
fabricated through printed dissolution method and subsequently functionalized via “click chemistry” to ensure drug-loaded 
liposomes immobilization. A specific antibody against cell-membrane antigen expressed by colorectal cancer cell line (HT-29) is 
stabilized onto the areas surrounding the electrodes. The application of a certain current through the polymer electrodes 
enhances a thermal leakage of nanoparticles and the effect of released drugs is evaluated. 
 
The printed dissolution technology, previously investigated in our group, is based on the use of 
agarose stamps presenting micro-structures on their surface; the contact of such stamps with polymer 
films allows the removal of polymer only from the areas which were in contact with the stamp. After 
fabrication, drug-loaded liposomes are immobilized on the electrodes surface through “click 
chemistry” (Copper(I)-catalyzed azide-alkyne Huisgen 1,3-dipolar cycloaddition or CuAAC) and biotin-
avidin conjugation.  
Such micro- and nano-technology presents many benefits:  
a) No need for cleanroom facilities for the micro-electrodes fabrication; 
b) the miniaturization of the drug screening system (the polymer electrodes have a width of 
100µm and liposomes have an average diameter of 100nm); 
c) a spatially-controlled liposomes immobilization; 
d) the overall electrodes area may be increased by maximizing the number of micro-electrodes  
in order to augment the concentration of immobilized drug-loaded liposomes and potentiate 
the cytotoxic effect of released drugs. 
However, the fabrication method used to produce micro-electrodes was challenging and an extensive 
optimization of the process was required. The lack of a technique able to create reproducible and 
defined polymer electrodes led us to explore other fabrication methods. A deeper explanation of the 
described micro- and nano-technology is reported in Chapter III.  
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In future, the integration of nanofabricated PEDOT-N3 electrodes with the already established 
electrode functionalization will be explored in more detail. Ideally, once the liposomes are immobilized 
onto PEDOT-N3, a certain current may be applied on the conductive electrodes. The electrical current 
through the electrodes will lead to resistive heating and consequently drug molecules loaded into 
liposomes may be released from the aqueous interior compartment due to temperature changes.  
 
1.3 ColoRectal Cancer (CRC)  
Colorectal cancer (CRC) is a pathology in which malignant cells form a tumor in the tissues of colon and 
rectum. The colon is part of the digestive system in which nutrients are processed and removed from 
the body. The digestive system is composed of the esophagus, stomach, small and large intestines. The 
colon, also defined as large bowel, is the first tract of the large intestine and is about 1.5 meters long, 
and the rectum represents the final part of the large intestine (circa 20 centimeters long) (Figure 1.4A). 
The large intestine is a muscular tube and its wall is formed by several and different layers (Figure 
1.4B), from the lumen to the outer: the mucosa which is composed by many layers including a thin 
muscle layer, the submucosa (mainly fibrous tissue), the muscularis propria (a thick layer of muscle 
that contracts to force the nutrients of the intestines along), the subserosa (a thin stratum of 
connective tissue) and the serosa, the second and outer layer of connective tissue.  
 
Figure 1.4 (A) Anatomy of the lower digestive system showing the colon and other organs.[23] (B) Layers composing the colon 
wall.[38]  
 
1.3.1 Tumor cell properties  
The development of cancer occurs when an imbalance of cell homeostasis and unregulated 
proliferation of cells are found. Cancer cells grow and divide in an uncontrolled manner and are 
represented by highly heterogeneous neoplastic cell populations. This heterogeneity is dynamic, 
changing continuously over time and in certain cases, it can turn to irreversible state with an increased 
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biological aggressiveness of tumor in terms of spreading in normal tissues and organs, and metastatic 
features.[39] The generalized loss of growth control showed by cancer cells derives from an increased 
number of abnormalities in cell regulatory systems and it is recognizable in several aspects of cell 
behavior that discern cancer cells from their normal counterparts.[40] The tumoral cells possess defined 
characteristics: accelerated cell cycle, genomic alterations, invasive growth, enhancement of cell 
mobility, changes in the cellular surface and morphology, and a variation of the secreted molecules 
pool.[41] At the cellular level, cancer cells present large nucleus, irregular size and morphology, 
increased number of nucleoli and a poor density of cytoplasm. Further, changes on the organization of 
the genetic material and proliferation are displayed: a scarce content of heterochromatin, a higher 
number of nuclear membrane pores, and atypical structures formed during mitosis process are 
discovered on multinucleate cells. The cell membrane of cancer cells plays also a crucial role in the 
tumor progression: proteins and surface receptors undergo important modifications, thus losing their 
normal sensitivity towards natural ligands; rather, new molecules are exposed on the surface where 
mainly act as antigens favoring the recruitment of immune system response. 
 
1.3.2 Colorectal cancer staging 
Staging of the disease and a complete visualization of colon regions are required once colorectal cancer 
is diagnosed.[42] There are two main questions that patients ask to doctors in order to learn how 
survive to a disease: firstly, what is the prognosis to be followed in order to achieve the greatest 
recovery and survival; and secondly, what treatment should be applied. A possible answer to these 
questions is given by the knowledge of the type of cancer and how advanced it is.[38] The staging of 
cancer is one of the crucial parameters to take into account because it defines the growth and the 
location of cancer. Once the stage is known, then the doctor may be able to predict the course of tumor 
and the best suitable treatment for each individual patient. The TNM staging system is a universal and 
standardized method for doctors to classify the spreading degree of cancers. Except for leukemia and 
brain cancer, it is applicable to any kind of disease: 
- T category: it is used for primary tumors where tumors are localized in a specific region 
and/or a specific cell line; 
- N category: it is referred to regional metastasis (or primary metastasis) in which the 
malignant cells have spread to the nearby tissues, for instance lymph nodes; 
- M category: it is used to indicate distant metastasis (or secondary metastasis); this class 
includes all the malignant cells which have invaded organs or distant areas of the body. 
Once the patient´s tumor has been recognized within a T, N, M class, the illness degree is evaluated, 
normally after surgery in order to define the progression and the severity of the tumor (expressed in 
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Roman numerals from stage 0 to stage IV) (Figure 1.5). Despite surgery is the first treatment for many 
people with colorectal cancer, some of them may receive radiation and/or chemotherapy before 
surgery. Thus, the stage of cancer after treatment is an important information for doctors to evaluate 
the prognosis and treatment choice for each patient. 
 
 
                                                    Figure 1.5 Schematic of the invasiveness of tumors in different stages.[43] 
 
 
1.3.3 Pathogenesis 
Colorectal cancer is a very heterogeneous disease that, as many other cancers, is caused by the 
interaction of genetic alterations and environmental factors. Most of the CRCs arise at a certain age 
(usually after 40 years) and only a small proportion of these cancers (20-25%) are connected to 
hereditary component, such as familial adenomatous polyposis.[44] Generally, colorectal cancer is 
provoked by a gradual accumulation of genetic and epigenetic changes, leading normal colonic mucosa 
cells to phenotypically transform into malignant and invasive cells. The majority of CRC cancers 
develop from adenomas which are able to become neoplastic cells within 10-15 years.[24]  
Once colorectal cancer is diagnosed, the following treatment consists on the surgical removal of 
primary tumor combined with a pre- and post-surgical therapy which may be radiotherapy, 
chemotherapy or adjuvant chemo-radiotherapy. Often adjuvant chemo-radiotherapy is applied for 
loco-regional cancer treatment because of great improvements on the eradication of malignant 
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metastasis.[45] As reported in literature, important progresses have been done on the research of new 
drugs or new combinations of individual drugs. As widely demonstrated by MOSAIC project,[46] 
increased survival rates are obtained when FDA-approved chemotherapies (FOLFOX and FOLFIRI) are 
administrated to patients with primary colorectal tumor. In light of the fact that approximately half of 
the patients diagnosed with CRC develop metastasis, especially in the liver, specific treatments are 
needed. Surgical removal of small and large metastasis is still necessary and other techniques 
(radiofrequency ablation,[47] hepatic arterial chemotherapy[48] and radioembolization with yttrium-90 
microspheres[49]) have been incorporated as a complement to surgery to achieve resectability.[24] For 
neo-adjuvant treatments of resectable liver metastasis, FOLFOX, FOLFIRI and FOLFOXIRI have shown 
high response rates with similar survival outcomes of 30% for FOLFOX and FOLFIRI[50] and 66% for 
FOLFOXIRI treatment,[51] respectively. 
 
 
1.4 Chemotherapeutics approved for CRC treatment 
Colorectal cancer refers to cancer of the colon (bowel) and rectum. When cancer is diagnosed, 
screening tests are used to characterize the type of colorectal cancer, the stage (meaning how far the 
cancer has progressed), the localization and the grade of tumor. These characteristics are then used to 
determine the most suitable treatment for each individual patient. Nowadays, the drugs approved by 
Food and Drug Administration (FDA) for colorectal cancer are commonly used as combinations of 
individual drugs (FDA-approved), while drug combinations themselves are not approved (Table 
1.1).[52] In this thesis, four drugs against colorectal cancer have been selected and studied: SN-38 (the 
active metabolite of Irinotecan), 5-fluorouracil, oxaliplatin and leucovorin hydrochloride (also known 
as folinic acid). These drugs were used as individual treatment and as well as combinations of drugs; 
further, their anti-proliferative effect was evaluated on human colorectal adenocarcinoma (HT-29) cell 
line. The cellular function and molecular characteristics will briefly be discussed in the following 
subsections. 
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    Table 1.1 Individual drugs and drugs combinations approved by FDA for the treatment of ColoRectal Cancer.[52]  
 
 
1.4.1 Camptothecin and its chemical analogues 
Irinotecan and SN-38 are derivatives of camptothecin, a water-insoluble natural alkaloid produced by 
Camptotheca acuminate[53] and Mappia foetida[54] Asian trees. This compound demonstrated excellent 
anti-cancer activity in early clinical trials for gastric cancer treatment, but also important side effects 
such as hemorrhagic cystitis, gastrointestinal toxicities and myelosuppression.[55,56] The main 
mechanism of antitumor activity of camptothecin was assessed as inhibitor of topoisomerase I (Topo I) 
enzyme.[57] Due to poor water-solubility and severe side effects of camptothecin, researchers began to 
synthesize analogue compounds of it, and currently the most clinical used analogues are Topotecan 
and Irinotecan. Topotecan, commercialized as Hycamtin® is used for the treatment of patients with 
metastatic ovarian cancer, while Irinotecan (Campto®) is widely applied in several European countries 
as second-line treatment of recurrent metastatic colorectal cancer. Even though Irinotecan induces 
remissions in 11-23% of the 5-fluorouracil (5FU)-resistant tumors,[58] the combination of Irinotecan 
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with 5FU and Leucovorin (also known as Folinic Acid, FA) has been approved as first-line 
chemotherapy for patients with metastatic colorectal cancer.[59] As depicted in Figure 1.6, all 
camptothecin analogues have a common chemical structure composed of a planar five-ring system 
with a lactone group. Further substitutions at positions 7, 9 and 10 are usually responsible for an 
enhanced Topo I inhibitory activity,[60,61] whereas substitutions at carbons C-12 and C-11 result on a 
activity neutralization.[60]  
 
Figure 1.6 Structures of camptothecin and analogues: Topotecan, Irinotecan (CPT-11), Lurtotecan (GW211), 9-
aminocamptothecin (9-AC), 9-nitrocamptothecin (9-NC) and DX-8951.[62]  
 
 
The biological function of the nuclear enzyme topoisomerase I is to remove torsional stress generated 
during DNA replication and transcription preserving the three-dimensional DNA conformation. As 
reported by Takimoto et al.,[63] topoisomerase I interacts with supercoiled double strands DNA forming 
a transient catalytic intermediate (cleavable complex), in which the enzyme is covalently bound to 
DNA and torsionally relaxed single-stranded DNA are produced. With a rapid re-ligation mechanism, 
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original double-strands of DNA are reformed. Camptothecins inhibit the re-ligation process by non-
covalently association to the Topo I-DNA cleavable complex, and single strand DNA breaks are 
therefore accumulated within the cell (Figure 1.7).  
 
Figure 1.7 Mechanism of Topotecan action: the stabilization of DNA-topoisomerase I cleavable complex in presence of ongoing 
DNA replication generates cytotoxic DNA damage.[63]  
 
Cytotoxicity of camptothecins can be attributed to the arrest of the replication fork and finally 
cessation of RNA synthesis.[64] Since the activity of Topo I is often higher in colorectal tumors than in 
normal colonic tissues, it may confer tumor specificity of the Irinotecan-mediated effects.[65] This 
cytotoxic DNA damage in some cancer cell lines leads to programmed cell death or apoptosis,[66] and 
because of the need of ongoing DNA synthesis, camptothecin is mostly active during S-phase of the cell 
cycle. The cytotoxic potency of camptothecin analogues against human colorectal adenocarcinoma 
(HT-29) cells differs widely with the following order of anti-proliferative activity: SN-38 (the active 
metabolite of irinotecan) > camptothecin > 9-AC > topotecan >> irinotecan.[67] The effect of irinotecan 
itself is minimal, whereas when a rapid hydrolysis of irinotecan to SN-38 occurs a higher anti-
proliferative effect is observed. All camptothecin derivatives commonly used in clinical trials possess a 
lactone ring which is chemically unstable; however the need of an intact lactone group is essential for 
the interaction of drug with DNA-enzyme complex. Under acidic conditions (pH<4), the lactone moiety 
prevails whereas under basic conditions (pH>10), an open-ring state is mostly present.[68] As depicted 
in Figure 1.8, at physiological pH all camptothecins are converted to the carboxylate form except for 
SN-38. 
In vitro studies have shown that the treatment of HT-29 cell line with SN-38 is 100-1000 fold more 
potent than the water-soluble irinotecan.[67] It has been also reported that irinotecan (also known as 
CPT-11) induces a dose-dependent apoptosis or premature senescence in a large variety of cell 
lines.[69] Rudolf et al. evaluated irinotecan cytotoxicity in normal human colonic fibroblasts (NCF), 
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normal human colonic mucosa cells (NCM) and human colorectal carcinoma cells (HCT).[70] The treated 
HCT and NCM cell lines showed typical apoptotic morphologies (cell rounding, shrinkage and 
blebbing), while these phenomena were significantly reduced in NCF cells which displayed alternative 
morphologies, enlargement of cell bodies and a reduced cellular density. When HT-29 carcinoma cell 
line is subjected to SN-38 treatment, a dose- and exposure duration-dependent anti-proliferative 
activity of drug is established.[71] 
 
Figure 1.8 Schematic representation of the reversible pH-dependent hydrolysis of the lactone ring (A) into the carboxylate form 
(B) of camptothecin analogues.[62] 
 
 
SN-38 is considered an S-phase cytotoxic compound and it has a very small effect on apoptosis and 
percentage survival in HT-29 during the first 48h for concentrations lower than 5ng mL-1. Conversely, 
when higher SN-38 doses are used (100 ng mL-1), an immediate arrest in the S-phase is achieved.[71] At 
the moment, irinotecan is used as an effective chemotherapeutic agent for advanced colorectal cancer 
as first- and second-line treatment. Irinotecan has been reported to be active also in gastric cancer, 
non-small lung cancer and small-cell lung cancer, as individual therapy or in combination with other 
cytotoxic agents.[72]  
 
1.4.2 5-fluorouracil (5-FU) 
5-fluorouracil (5-FU) is a fluoro-pyrimidine compound largely used in the treatment of a broad range 
of cancers, such as colorectal and breast cancers and tumors of the aerodigestive tract. Although 5-FU 
in combination with other chemotherapeutics improves the response and survival rates in breast, neck 
and head cancers, it is in colorectal cancer that 5-FU explicates the greatest anti-tumor activity.[73] 5-FU 
has a dual anti-tumor mechanism: it inhibits essential biosynthetic processes and is directly 
incorporated into nucleic acid molecules (RNA and DNA) impairing their normal function. 5-
fluorouracil is an analogue of uracil and presents a fluorine atom at the carbon C-5 (Figure 1.9A). When 
cells are treated with this drug, it rapidly enters the cell using the same transport mechanism of uracil, 
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and once located into cytoplasm, 5-FU is converted intracellularly to various active metabolites.[74] 
These active metabolites are responsible for the interruption of RNA synthesis and the enzymatic 
activity of thymidylate synthase (TS). Briefly, this enzyme catalyzes the reductive methylation of 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), normally used as 
essential component for DNA replication and repair. The metabolite of 5-FU (fluorodeoxyuridine 
monophosphate, FdUMP) covalently occupies the substrate-binding site of TS forming a stable ternary 
complex, and thus inhibiting the DNA replication[75,76] (Figure 1.9B). 
 
Figure 1.9 Structure of fluoropyrimidine 5-FU (A) and mechanism of thymidylate synthase inhibition by 5-FU (B). The active 
metabolite FdUMP (fluorodeoxyuridine monophosphate) blocks the binding site of TS normally occupied by the natural 
substrate dUMP (deoxyuridine monophosphate). A consequent deoxynucleotide (dNTP) pool imbalances cause the inhibition of 
DNA synthesis and DNA damage.[73]   
 
5-FU-based chemotherapy improves overall survival of patients with resected stage III colorectal 
cancer.[77]  Despite that, the response rates for the 5-FU treatment as first-line therapy for advanced 
colorectal cancer are only 10-15%.[78] Consequently, the combination of 5-FU with other 
chemotherapies such as Irinotecan or oxaliplatin has enhanced the response rates for advanced 
colorectal cancer to 40-50%.[79,80]  
 
1.4.3 Oxaliplatin and platinum-based chemotherapeutics 
Although for more than four decades 5-FU has been the most commonly used drug for the treatment of 
colorectal cancer, the development of new active drugs for CRC treatment, such as oxaliplatin, has 
improved clinical outcome and has offered alternative therapeutic options.[81] In particular, platinum-
based drugs including cisplatin, carboplatin and oxaliplatin, have been widely studied and used for the 
treatment of lung, colorectal, ovarian, breast, head, neck and testicular cancers.[82] Cisplatin was 
approved as anti-cancer drug in 1978 and within a decade, a second-generation platinum drug 
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(carboplatin) replaced cisplatin due to higher stability. Nowadays, oxaliplatin (OxPt), the third-
generation platinum drug, is the standard compound used for the treatment of advanced and 
metastatic colorectal cancers in combination with 5-fluorouracil and leucovorin. An improved survival 
among stage III-patients when OxPt/5-FU/leucovorin poly-chemotherapy is observed compare to 5-
FU/leucovorin therapy showed an inferior response.[83] Cisplatin, carboplatin and oxaliplatin 
chemically differ in solubility, reactivity, structure, pharmacokinetics, and toxicology (Figure 1.10A).[84] 
Each compound has a different chemical structure and oxaliplatin contains a diaminocyclohexane 
(DACH) group which is more reactive with nucleophiles than the other drugs.  
 
Figure 1.10 (A) Chemical structure of platinum-based drugs: cisplatin, carboplatin, oxaliplatin. (B) Schematic of cisplatin uptake 
inside cell and consequent aquation into the cytoplasm. The compound is then translocated into the nucleus where it explicates 
its toxicity.[85] (C) Schematic of different complexes formed by the interaction of platinum-based molecules and double-stranded 
DNA and nuclear proteins. 
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Platinum-based drugs undergo hydrolysis reaction by which one or both oxygenated groups are 
replaced by molecules of water, thus resulting in positively charged molecules (Figure 1.10B). The 
aquation reaction represents the crucial step by which drugs manifest their toxicity: only when the 
drugs are in the charged state are able to form covalently stable adducts with double-stranded DNA.[86] 
The cross-linking of platinum-drug molecules to DNA leads to the inhibition of synthesis and repair of 
DNA and finally to apoptosis (Figure 1.10C).[87,88] Even though the cellular damage is thought to be 
induced by the formation of these DNA adducts, additional complexes of platinum-DNA-protein have 
been demonstrated as potentiating mechanism of cytotoxicity.[89] Nevertheless, these platinum agents 
have also shown a significant neurotoxicity (cisplatin > oxaliplatin >> carboplatin). Therefore, the 
efficacy of platinum-based drugs is often impaired because the substantial risk for severe toxicities.[82] 
Indeed, the FDA reported that more than 70% of the patients receiving oxaliplatin as main 
chemotherapy are affected by some degree of sensory neuropathy.[90]  
 
1.4.4 Leucovorin  
Leucovorin is also called folinic acid (FA) or 5-formyltetrahydrofolate and is generally administered as 
calcium or sodium folinate. Commonly, FA is an adjuvant used in cancer chemotherapy in combination 
with methotrexate,[91] or with 5-fluorouracil in treating colorectal, head and neck, esophageal cancers, 
and other cancers of the gastrointestinal tract. FA should be distinguished from folic acid which is a 
necessary vitamin (B9), even though FA is an analogue of folic acid and has the full vitamin activity of 
vitamin B9. FA is not a drug itself and has almost no side effects but when used in combination with 
methotrexate it acts as chemo-protectant because it preserves the bone marrow and gastrointestinal 
mucosa cells from methotrexate side effects.  Contrarily, the effect of folinic acid in combination with 5-
FU is to enhance the cytotoxic effect of 5-FU by further inhibition of thymidylate synthase enzyme and 
by prolonging the availability of 5-FU in cancer cells. FA is a 5-formyl derivative of tetrahydrofolic acid 
(Figure 1.11) and when administered, it is rapidly converted to other folinic acid analogues 
(tetrahydrofolate).  
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                                               Figure 1.11 Chemical structure of Leucovorin (folinic acid, FA). 
 
Therefore, FA has a vitamin activity comparable to folic acid and because it does not require the action 
of enzymes for its conversion, FA biological function as vitamin is always guaranteed. Leucovorin is 
also used by itself for the treatment of anemia defects when folic acid deficiency is present. 
 
1.5 Effect of drugs combinations on the treatment of CRC 
Although the approved chemotherapeutics (Irinotecan, oxaliplatin, 5-FU and Leucovorin) have proved 
to be active for the treatment of colorectal cancer when used as single agents, combinations of these 
drugs have reported great results and an increased survival rate.[92] Nowadays, the significant 
reduction in the risk of death even in patients having earlier-stage colorectal cancer, is attributed to 
the use of combination regimens such as FOLFOX and FOLFIRI. FOLFOX corresponds to the 
chemotherapy combination FOLinic acid/Fluorouracil/OXaliplatin, and FOLFIRI is the common name 
used to indicate the combined drugs FOLinic acid/Fluorouracil/IRInotecan. To the extent that 5-FU 
and irinotecan each have a substantial single agent activity and they appear to be relatively non-cross-
resistant, researchers have started to explore modes in which both drugs may be used simultaneously 
as front-line systemic therapy for the treatment of advanced colorectal cancers.[93] Preclinical studies 
have demonstrated that the simultaneous administration of Irinotecan and 5-FU resulted in a reduced 
cytotoxicity of the active metabolite SN-38, suggesting that 5-FU may interfere with the metabolic 
conversion of irinotecan to SN-38.[94] Indeed, the addition of leucovorin to irinotecan and 5-FU 
combination enhances the overall cytotoxicity of therapy.[95] Moreover, Mullany et al.[96] have proposed 
a sequence-dependent synergy between SN-38 and 5-FU/FA and provided a possible mechanistic 
model for this observation. Briefly, the in vitro cytotoxicity obtained after the simultaneous or 
sequential drugs treatment (SN-38 followed by 5-FU/FA or 5-FU/FA followed by SN-38) were found to 
be different. As described for FOLFIRI therapy, also the FOLFOX treatment has shown successful 
results: despite oxaliplatin-based therapy has been used for many decades as powerful treatment 
against colorectal cancers as single agent, when combined with 5-FU/FA, the response rate and overall 
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survival are improved more than double.[79] FOLFOX and FOLFIRI are therefore widely used as first-
line and second-line chemotherapy for metastatic colorectal cancer. However, in some cases, especially 
those with metastatic lesions, solid tumors may acquire chemo-resistance to therapy. Most solid 
tumors present a central area which is characterized by a poor vascularization, intratumoral perfusion 
and a hypoxic environment.[94] It is well-known that tumor cells under hypoxic conditions are more 
resistant to ionizing radiation and chemotherapy.[97] The effect of hypoxic environment on the chemo-
sensitivity of human colorectal adenocarcinoma (HT-29) cells exposed to FOLFOX and FOLFIRI 
treatments has been evaluated.[94] The addition of FOLFOX at different doses to HT-29 cells under 
normoxia conditions strongly affected their proliferative activity; contrariwise, the effect of FOLFOX 
therapy was completely abrogated when cells were cultured under hypoxia. Unexpectedly, the 
cytotoxicity of FOLFIRI chemotherapy was still maintained even under hypoxic conditions, overcoming 
the chemoresistance developed by intra-tumoral cells.  
In conclusion, the success of FOLFOX and FOLFIRI regimens has been demonstrated to provide clinical 
benefit in the treatment of colorectal cancer which are not reported only in an advanced stages, but 
also earlier-stages of tumor. In particular, FOLFOX has been approved by FDA as adjuvant therapy for 
resected stage III colon cancer.[46] 
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2 PEGDA hydrogels for drug screening assays 
 
In this chapter, a technology based on the use of poly(ethylene glycol) diacrylate (PEGDA) hydrogels 
for drug screening purposes is described in detail. Hydrogels are widely applied in many fields, for 
instance in tissue engineering, for in vivo drug delivery and for the fabrication of micro- and nano-
structures. Here, we want to focus on the application of hydrogels for in vitro molecules embedding 
and their consequent release through passive diffusion or stimulated by the application of a proper 
trigger. Hydrogels are polymeric 3D networks which are formed via chemical or physical crosslinking 
and they are characterized by a high water content. Different methods are generally used to create gels 
and in situ radical photo-polymerization has been selected to embed compounds within PEGDA 
hydrogel. An extensive study of the fabrication conditions (photo-initiator compound, source light, 
PEGDA and photo-initiator concentrations, PEG length chain and exposure time) are explored. 
Furthermore, a technology able to create 3D shaped PEGDA hydrogels has been adopted in order to 
entrap molecules within certain volumes of gel. The passive release of different molecules in terms of 
size and chemical properties from hydrogels is also determined. On the basis of the observed release 
profiles, the properties of PEGDA gels are tuned to enhance the diffusion of molecules which are slowly 
released and to prevent a rapid diffusion of released compounds. In this case, molecule-loaded 
liposomes are employed to control the release of such molecules applying a thermal-trigger which 
destabilize the lipid bilayer. The developed system is then used to embed multiple drugs (which are 
selected as relevant candidates for the treatment of human colorectal adenocarcinoma cell line, HT29) 
within the gel. Finally, the cytotoxic effect of individual and combined drugs is evaluated culturing 
HT29 cells onto the surface of 3D shaped hydrogels.  
The drug screening technology presented here is characterized by different properties:  
 
a) the developed technology is fast since the polymerization process takes place within 30-60 
seconds to create a completely crosslinked polymer network; 
b) the equipment adopted to produce the gels has a low cost because composed of a modified 
projector which has an emitting intensity at 410nm, a stage where the support used to contain 
pre-polymer solutions can be located, and a computer mainly utilized to illuminate the 
samples with a desired digital mask; 
c) multiple hydrogels may be produced simultaneously reducing the fabrication time; 
d) different 3D architectures can be obtained according to the final application of the gels in 
aqueous media; 
e) multiple molecules can be embedded within defined volumes of hydrogel and afterwards 
release them into a reservoir; on the basis of the chemical nature and size of targeted 
molecules, nanoparticles can be included within the matrix to prevent rapid diffusions; 
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f) once the drugs are embedded within the hydrogel the system can be stored at 5 ˚C in a 
humidified atmosphere and on demand, the cytotoxic effect of releasing drugs on the 
proliferation of a specific cell line can be studied; 
g) ideally this technology can be applied for any type of pathological condition once the release 
kinetics of drugs is optimized and the PEGDA hydrogel features are tuned. 
In this chapter, an overview of the applications of hydrogels in bio-medicine and drug delivery fields is 
given, with a particular focus on the mechanisms involved on the encapsulation and release of bio-
active molecules when embedded within PEGDA hydrogels. Moreover, the use of liposomes as 
potential drug carrier for controlled release is also discussed. A detailed description of the photo-
polymerization of PEGDA gels and the optimization of the parameters affecting the process (light 
source, photo-initiator and equipment) is provided. A new technology recently developed in our group 
for the crosslinking of PEGDA hydrogels is reported and applied for controlled in situ embedding of 
relevant drugs used for the treatment of ColoRectal Cancer (CRC) cells. The release kinetics of these 
compounds is characterized and controlled by tuning the hydrogel physical and chemical properties or 
introducing drug-loaded nanoparticles within the polymer network. Further, an extensive study of the 
cytotoxic effect induced by drug releasing hydrogel systems is evaluated using the human colorectal 
adenocarcinoma cell line (HT29). Finally, a short conclusion summarizes the key points encountered 
on the fabrication of hydrogel systems used for drug screening purposes, and what are the benefits and 
the future improvements of our developed technology. An experimental section at the end of the 
Chapter II is also included and all the materials, equipment and protocols adopted for our experimental 
results are described. 
 
 
2.1 Hydrogels and liposomes as drug carrier 
During the last few decades, hydrogels have reached increasing interest with more than 2000 papers 
published up to now. A widely range of definitions exists for terming ‘hydrogel’ and the most referred 
definition is the one given by Peppas.[98] Hydrogels are water-swollen cross-linked polymeric 
structures which either present covalent bonds deriving from the reaction of one or more co-
monomers, or are physically cross-linked due to polymer chains entanglements or hydrogen bonds 
and van der Walls interactions between chains.[99] In general hydrogels are hydrophilic polymer 
networks able to absorb from 10%-20% up to thousands times their dry weight in water. They may be 
chemically stable or may degrade and eventually disintegrate and dissolve. Hydrogels in a cross-linked 
state reach an equilibrium swelling in aqueous solutions which depends on the polymer cross-linking 
density. In fact, when a dry hydrogel starts to absorb water from the environment the first water 
molecules entering the matrix, also called primary bound water, hydrate the polar and hydrophilic 
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chemical groups of the network. As soon as these groups are hydrated, the overall matrix swells 
meaning that also the hydrophobic groups are exposed to water molecules and new hydrophobically-
bound water molecules are included within the structure (secondary bound water). The additional 
swelling water that is imbibed after ionic, polar and hydrophobic groups become saturated is called 
free water and it is assumed to fill the space between network chains. In case of degradable polymer, 
the matrix will begin to disintegrate and dissolve with a certain rate depending on its composition and 
cross-linking degree.[100] The volume fraction of water contained within the polymeric matrix 
influences the absorption and diffusion of solutes through the gel. Indeed, the release of molecules 
from a hydrogel is mainly controlled by the pore size, pore volume fraction, pore interconnections, 
molecule dimension, and strength of interaction between the embedded compound and polymer 
chains. The space available between macromolecular chains is responsible for molecule diffusion; 
moreover, highly cross-linked hydrogels have a tighter structure in which the overall chains mobility is 
hindered and a lower swelling is observed. Therefore, the application of hydrogels for drug release 
purposes is strictly dependent on these concerns and when designing a 3D-network for controlled 
drug release, the polymer composition and the cross-linking density should be tuned according to the 
molecules size and physical-chemical properties.[100] Moreover, other parameters like the processing 
conditions, the method of polymerization, and the incorporation of various polymers to achieve a 
biomaterial with determined characteristics are extremely important.[101]   
Hydrogels are classified on the basis of different parameters such as the preparation method used to 
cross-link them, the overall monomer or macromer charge and the mechanical and structural features. 
For instance, according to the preparation method, hydrogels can be defined as homo- or co-polymer 
hydrogels and they may have a neutral, anionic, or cationic charge depending on the building blocks 
charges. Further, hydrogels can exist as amorphous, semi-crystalline, hydrogen-bonded, 
supramolecular or hydro-colloidal physical state. The reason for the extensive study and application of 
hydrogels is their great retain of large amount of water and excellent biocompatibility, so they are 
mostly applied in the medical field because mimicking a favorable environment for cell proliferation. 
Moreover, hydrogels have a poor tendency to adsorb proteins from body fluids due to a low interfacial 
tension, whereas natural polymers (such as collagen or gelatin) are prone to protein adsorption.[102] 
Many studies have demonstrated the need of extra-cellular matrix proteins deposition onto the 
hydrogel surface to achieve cell adhesion. Other applications concern the use of hydrogels as drug 
releasing system where different release profiles are obtained by tuning hydrogel properties.[103] The 
applicability of hydrogels as biomedical materials depends mainly on their bulk structure. Some of the 
most relevant parameters characterizing the network structure are the molecular weight of polymer 
chains, the corresponding mesh size, and the network density which are measurable through 
equilibrium-swelling theory and the rubber-elasticity theory.[99]  
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2.1.1 Loading and release mechanisms of biomedical relevant molecules  
The delivery and release study of various biomedical relevant molecules has been the subject of 
intensive research. The compounds which are embedded within polymer networks are different in 
terms of size (low and high molecular weight molecules), nature (proteins, peptides, DNA, RNA and 
drugs) and physical-chemical properties. Hydrogels are a class of materials greatly suitable for delivery 
and molecules release applications because of their ability to encapsulate biomolecules and tailor the 
gel´s physical and chemical structure.[104] Many improvement have been reported in drug delivery 
hydrogel-based systems, and over the numerous polymers applied for that purpose, poly(ethylene 
glycol) (PEG)-based hydrogels are extraordinarily promising biomaterials.[104] Over the past few 
decades, PEG hydrogels have been extensively used as matrices for controlling drug release, as well as 
cell delivery vehicles for promoting tissue regeneration.[105–108] PEG polymer is water soluble and 
resists recognition by the immune system.[108] It also exhibits a rapid clearance from the body and has 
been approved for many applications. The versatility of PEG macromer chemistry[109] together with its 
excellent biocompatibility resulted on the development of many smart-designed hydrogel systems for 
regenerative medicine applications.[104] Further, PEG hydrogels provide a unique niche for cell 
encapsulation because of high biocompatibility to cells under proper polymerization conditions,[32] and 
the coupling of biological molecules to PEG usually contributes to its biological activity.[108] In the 
context of drug delivery, one of the most relevant requirement is the capacity of the hydrogel to 
provide an extended release of the embedded therapeutics, prevent unfavorable reactions and 
maintain the bioactivity of compounds. Consequently, several considerations must be assessed: the 
gelation and loading/release mechanisms, the molecular characteristics of the drug to be delivered, the 
possible interaction with polymeric chains and the method used to cross-link the hydrogel. For 
example, PEG-hydrogels are usually cell-repellent materials meaning that the adhesion of cells onto 
their surface is discouraged; thus the introduction of moieties like RGD-peptide (an Arg-Gly-Asp 
tripeptide) within the network promotes the adhesion and survival of encapsulated cells such as 
osteoblasts.[110]  Targeted molecules may be embedded within polymeric networks using two different 
approaches: one consists on in situ polymerize the compound and polymer chains at the same time, 
and the second one in based on the embedding after hydrogel polymerization (Figure 2.1A). The in situ 
polymerization has important advantages due to the simultaneous molecule loading and hydrogel 
network cross-linking; thus, multiple and highly concentrated compounds may be entrapped in a rapid 
manner within the matrix.  
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Figure 2.1 Schematic of loading strategies used to embed therapeutics within hydrogels. (A) Compounds can be entrapped 
through in situ polymerization or after hydrogel fabrication; (B) drugs are bound to degradable linkers included in the polymer 
structure and molecules release is induced by enzymatic degradation of the linkers; (C) drug-loaded micro- or nano-particles are 
directly embedded within the hydrogel during polymerization .Figure reproduced from [104]. 
 
On the other hand, depending on the polymerization method adopted to cross-link the mixture, 
potential reactions between molecules and polymer may occur with the risk of affecting the final 
compound bioactivity. The embedding of drugs after polymerization consists on the incubation of pre-
formed hydrogels with highly concentrated molecule solutions which are entrapped within the matrix 
through osmotic driving force until solute equilibrium is reached.  Despite this approach preserves 
drug bioactivity, it does not permit accurate control over the amount of drug loading because of 
partitioning limitations.[104] Moreover, it appears difficult to fabricate hydrogels with multiple drugs at 
defined concentration for sophisticated bio-medicine applications. Although the loading method used 
to embed compounds within hydrogel is extremely important, release mechanisms are likewise 
relevant for the design of controlled release systems. Because of the diversity in the chemistry and size 
of released molecules, the criteria for controlled release from hydrogels may widely differ from one 
application to another. In general, for drug release purposes two major concerns must be considered: 
the availability and the stability of released therapeutics. In fact, to achieve a desired therapeutic effect 
in vitro or in vivo, the drugs should be delivered at a right dosage (availability) and with preserved 
molecular structure and bioactivity (stability). The commonly used mechanisms of molecular release 
from hydrogels include diffusion-, swelling-, and chemically-controlled delivery.[104] When the 
releasing compounds are small in terms of size and molecular weight such as drugs, peptides or small 
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proteins, the high permeability of hydrogels towards small molecules does not permit to control their 
release kinetics.  
At the moment, different methods suitable to control the release profile and to tune the gel 
permeability are normally used. One of these approaches is based on modulating the cross-linking 
density, thus by increasing the cross-linking density, the number of network chains per unit volume 
also increases and a smaller network mesh size limits rapid molecule diffusion. However, this method 
relies on size-exclusion concept, so the release of small compounds like drugs is not controlled in any 
case; further, an increase on the cross-linking density results on a reduced hydrophilicity of hydrogel 
which corresponds to a poor cytocompatibility.[104] Another strategy primarily used for drug 
encapsulation is the use of pro-drug molecules: in this approach drugs can be covalently immobilized 
within hydrogel network via functional groups. The introduction of degradable linkers between drug 
and tether allows the liberation and release of molecules when enzymatic degradation of linkers 
occurs (Figure 2.1B).[111,112] The pro-drug strategy is effective on controlling drug release but has an 
important drawback: the covalent association of drugs to degradable linkers may impair the 
bioactivity of molecules especially when fragile peptides and proteins are the target therapeutics.[104] 
Furthermore, the chemistry adopted to include linkers into polymer structure must be biocompatible 
and designed in such way that completely degradation of linkers occurs.[113] However, the use of pro-
drug molecules requires the synthesis of a new compound which is a modified version of an already 
existing drug, thus a consequent approval of the new pro-drug is needed. A third strategy to entrap 
drugs within hydrogel consists on the incorporation of drug-loaded micro- or nano-particles into the 
network prior to polymerization (Figure 2.1C). In particular, drug-loaded liposomes have been 
extensively studied and applied for different purposes. According to the chemical properties of the 
molecule loaded into liposomes and the lipid composition of these nanoparticles, a controlled release 
can be achieved. In conclusion, the maintenance of drug stability is of critical importance not only for 
drug release purposes but also for biocompatibility issues; in fact it has been shown that the 
entrapment of proteins and peptides into hydrogel induces their denaturation and their consequent in 
vivo immunogenic effect.[114]  
 
2.1.2 Diffusion of drugs from hydrogels and liposomes 
The diffusion of drugs from hydrogels or other drug carriers depends on various parameters. A slow 
release of drug from network corresponds to a therapeutic but non-toxic concentration and a 
prolonged release profile, meaning that less frequent administrations of drug are needed since the 
therapeutic concentration is not reached.[115] On the other hand, when drug compounds diffuse rapidly 
from a matrix, a toxic concentration may be obtained; a controlled drug releasing system is therefore 
necessary to achieve the right therapeutic dose. Mathematical models are normally used to predict the 
41 
 
 
 
temporal release of encapsulated cargo molecules as well as to describe the release mechanisms 
supported by experimental verification.[116] Since diffusion of drugs strictly depends on the structure 
through which the diffusion takes place, models that assess polymer morphology and properties are 
needed.[116,117] The mechanism of drug release from hydrogels can be i) diffusion-controlled; ii) 
chemically controlled; iii) osmotically controlled; and iv) swelling- and/or dissolution-controlled.[117]  
Drug release from different carriers consists on the movement of molecules through the bulk of 
polymer, a process that can be described by Fick´s laws of diffusion for transport in one dimension 
(Equation 2.1 and Equation 2.2): 
𝑗𝑖 = −𝐷𝑖𝑝
𝑑𝑐𝑖
𝑑𝑥
 Eq. 2.1 
  
𝜕𝑐𝑖
𝜕𝑡
= 𝐷𝑖𝑝
𝜕2𝑐𝑖
𝜕𝑥2
 Eq. 2.2 
 
Here, the concentration and mass flux of species i are designated as ci and ji, respectively; Dip is the 
diffusion coefficient of species i in the polymer matrix and x and t are position and time, 
respectively.[98] A semi-empirical power law equation (Higuchi kinetic equation)[118] widely used to 
describe diffusion- controlled drug release from semi-solid polymeric systems is stated in Equation 
2.3: 
 
Here, Mt and M∞ are the cumulative amounts of drug released at time t and at the equilibrium point, 
respectively; k represents structural and geometrical information regarding the device and n is 
indicative of the drug release mechanism. The presented equation is the result of a detailed 
mechanistic process that includes diffusional process (Fickian) and additional relaxational or 
convection mechanisms. Further, the mathematical solutions of Equation 2.1 for Fickian drug diffusion 
result in release kinetics with n = 0.5, whereas when the release is zero-order, n = 1.[117] Therefore, the 
diffusion of drug from polymeric systems can be obtained directly from the slope of the linear part of 
plots Mt/M∞ versus t1/2, as shown in Figure 2.2.[119]  
𝑀𝑡
𝑀∞
= k𝑡𝑛 
 
Eq. 2.3 
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Figure 2.2 Release of Lidocaine Hydrochloride from gel (open squares) and from liposomes embedded within the gel (half-filled 
diamonds).Figure reproduced from [119]. 
 
 
The linear part of curves corresponds to pure diffusion according to Eq.2.3 and Figure 2.2. A later stage 
of drug release up to equilibrium point is characterized by a non-linear behavior until approaching 
steady state where the driving force for mass transfer of drug diffusion gradually slows. In Figure 2.2 
should be also noted that, as expected, the diffusion of lidocaine hydrochloride from a gel is faster than 
the diffusion of the same compound when loaded into liposomes and mixed to the gel.  
 
2.1.3 Liposomes for controlled drug release 
Over the last 30 years, the application of liposomes as drug carriers in pharmaceutical and medical 
fields is considerably increased.[120,121] Liposomes are self-assembled spherical soft-matter particles 
consisting of a central aqueous compartment surrounded by one or more concentric phospholipids 
layers, also called lamellas (Figure 2.3).[122,123] Liposomes, as analog of natural membranes, are formed 
by auto assembling of natural or synthetic lipids. The application of liposomes for drug and gene 
delivery purposes is extensively studied because of liposomes amphiphilic nature; in fact, liposomal 
particles are used as vehicle for both lipophilic and hydrophilic compounds. Hence, hydrophilic 
molecules are loaded in the interior aqueous compartment while lipophilic compounds are entrapped 
within the lipid bilayers. Liposomes constitute a physical barrier and can protect the loaded substances 
from the surrounding environment and degradation processes (induced for example by pH changes). 
Due to the variable nature of lipids, liposomes are classified in terms of composition, size, number of 
bilayers forming the vesicle and according to the mechanism of release/delivery.[122]  
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Figure 2.3 Schematic illustration of self-assembly process involved on the liposomes formation from individual phospholipid 
molecules (a) to a bilayer membrane (b), followed by organization into liposomes (c). Normally, a single bilayer has a thickness 
around 5nm which consists of arranged single lipid molecules with their hydrophobic tails facing each other and their 
hydrophilic headgroups facing toward the internal and external aqueous compartment (d). Figure reproduced from [123]. 
 
 
Among the variety of available phospholipids involved in the process of liposome production, 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are the main structural components of 
biological membranes. Further, liposome membrane may also contain other constituents, for instance 
cholesterol, largely used to improve the membrane fluidity and stability, and hydrophilic polymer-
conjugated lipids such as PEG-based lipids. Nowadays, the methods available for liposomes synthesis 
are various and they can be applied singularly or as combination of processes. A suitable method for 
liposome manufacture must ensure a high degree of structural homogeneity in order to achieve the 
optimal performance of vesicle as molecule-carrier.[124] The method mostly used for liposome 
synthesis is the classical hydration technique (also called Bangham method).[125] This approach 
consists on the dispersion of lipids in an organic solvent which is removed after solubilization through 
evaporation; a thin dried lipidic film is obtained. Then the film is hydrated in aqueous buffer solution 
under stirring at a temperature above the lipid transition temperature. The dispersed phospholipid 
populations form a suspension of multilamellar liposomes (MLVs) which are characterized by a high 
heterogeneity in terms of size and shape (usually ranging from 1 to 5µm in diameter). The synthesis of 
small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs) is achieved by extruding the lipid 
suspension through a polycarbonate filter which has the appropriate pore size in diameter to obtain 
the final desired size of liposomes (for example 100 or 200µm). Among the traditional multi-step film 
hydration technique, an alternative method can be adopted and it is called DELOS approach. In this 
case, advanced equipment composed of a system for the compression of fluid (CO2) and pressurized 
chambers are needed. The depressurization of an expanded liquid organic solution has proved to 
provide crystalline solids having a high purity.[126] Elizondo et al.[127] have demonstrated by Cryo-TEM 
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microscopy that liposomes prepared with traditional film hydration method are a mixture of 
multilamellar, unilamellar and multivesicular particles, whereas homogeneous populations of 
unilamellar liposomes are achieved with DELOS procedure. Independently from which technique is 
used for liposomes synthesis, the chemical and physical properties of vesicles must be assessed in 
order to guarantee their stability as drug nanocarrier. The main parameters affecting liposome 
features are: i) the size, expressed as average mean diameter; ii) the polydispersity index which 
provides the degree of suspension homogeneity; iii) the surface charge, or zeta potential; iv) the 
lamellarity; v) the encapsulation efficiency; vi) the in vitro drug release and mostly important vii) the 
liposomes stability. One of the major concerns for liposomes use as drug carrier is their stability, 
meaning that stable vesicles must maintain their physical integrity over time and they should not 
influence the chemical integrity of the encapsulated cargo. However, liposomes naturally tend to be un-
stable because of aggregation and leakage processes when they are kept upon long term storage; 
further, the interaction of lipids with the loaded cargo may interfere with drug availability and 
stability. Normally, liposomes are characterized through dynamic light scattering (DLS) to evaluate the 
average mean size and polydispersity index; moreover, the overall charge of liposomes surface is 
established via zeta potential which is a good index to predict the stability of colloidal suspension.  
 
Figure 2.4 Illustration of three different physical states adopted by a lipid bilayer in aqueous medium. Tm stays for phase 
transition temperature. Figure reproduced from [128]. 
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Two issues become immediately relevant when trying to encapsulate drugs into liposomes: firstly, the 
encapsulation of molecules is more difficult and inefficient as the size of compound increases, and 
secondly, the encapsulation efficiency strictly depends on the method adopted to load drugs into the 
bilayer. Therefore, a liposomal drug carrier must be stable whilst circulating (drug retention) and 
render the drug bioavailable when it reaches the targeted site (drug release). These parameters are 
strictly dependent on the bilayer permeability properties: the liposome bilayer is a selective barrier 
and membrane permeability varies for different types of solutes, such as water, electrolytes and non-
electrolytes. Moreover, the membrane features can be regulated by changing the lipid composition, for 
instance the saturation number of lipids, length of fatty acid chains and charge of headgroup, or by 
introducing cholesterol molecules which are responsible for liposome stabilization. Phospholipids 
have a phase transition temperature (Tm) which defines their physical state (Figure 2.4): when heated, 
phospholipids undergo a shift from a well-ordered and tightly packed gel phase to a fluid and 
disordered liquid-crystalline state.[128,129]  
In this thesis and in other numerous published applications, heat is employed to induce drug release 
from liposomal vesicles through temperature changes. Thermo-sensitive liposomes containing drug 
molecules into the aqueous cavity are studied; the effect of temperature and lipid composition is 
evaluated in order to achieve the maximum released drug amount. When a certain heat treatment is 
applied above the transition temperature, the lipid membrane of thermo-sensitive liposomes 
undergoes a gel-to-liquid-crystalline conformation transition which results on an increased 
permeability towards water and solutes due to an augmented phospholipids mobility.[130]  
 
 
2.2 Development of PEGDA hydrogels for digital drug dosing 
Poly(ethylene glycol) diacrylate (PEGDA) hydrogels are largely used in many biomedical applications 
and their study is gradually increasing due to favorable properties: excellent biocompatibility, poor cell 
attachment, ease of use and PEG-chemistry versatility. These hydrogels are employed for various 
purposes including tissue engineering, wound healing, electrospinning processes and drug delivery.[33–
35] In this thesis, PEGDA hydrogels are fabricated through visible-light photo-polymerization for drug 
release purposes: different drugs commonly used for the treatment of colorectal cancer are embedded 
within PEGDA hydrogels via in situ polymerization. Further, the release kinetics of chemotherapeutics 
and their cytotoxic effect on human colorectal adenocarcinoma cell line (HT-29) are evaluated. For this 
purpose, various issues are considered: 
a) the cross-linking method used to polymerize PEGDA monomers and consequent embedding of 
various molecules (drugs and proteins); 
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b) the release study of embedded compound and tuning of chemical and physical hydrogel 
properties; 
c) the use of drug-loaded nanoparticles (liposomes) embedded within PEGDA hydrogels and 
study of controlled drug release; 
d) fabrication of 3D hydrogel structures for drug confinement in a small scale; 
e) multi-drug dosing within PEGDA hydrogel for drug screening purposes; 
f) evaluation of cytotoxic effect of different drug releasing systems. 
 
2.2.1 Photo-polymerization of PEGDA gels 
Among various method of gelation (physical, ionic or through covalent interactions), chemical- or 
covalent-crosslinking leads to relatively stable hydrogel with tunable physiochemical features. 
Nowadays, photopolymerization is one of the preferable way to fabricate hydrogels because is a rapid 
process (quite often the polymerization is completed within few seconds) and is suitable for 
encapsulation of cells and fragile molecules.  
In this thesis, PEGDA hydrogels are fabricated through in situ photopolymerization which is a process 
that requires photoinitiator species and a light source. This approach provides a spatial and temporal 
control over the formation of the material. When a solution of PEGDA monomer and photoinitiator is 
exposed to a specific wavelength, gelation will occur. During the reaction the photoinitiator species are 
decomposed into reactive radicals which are responsible for polymerization initiation. Photoinitiators 
are normally classified into two classes: type I (or cleavage type) includes photoinitiators that are split 
into two radical species after photon absorption, and type II comprises photo-initiating systems that 
after photon absorption are in an excited state and a second co-initiator species extract from them a 
hydrogen atom.[131] When selecting the photoinitiator to use for a certain application, it is important to 
consider a variety of parameters. Most of the photoinitiators commonly used for polymerization 
process are water-insoluble and they must be dissolved in organic solvents which are cytotoxic; thus, 
the use of these initiators precludes the possibility to photo-encapsulate fragile molecules and living 
cells. Moreover, the majority of photoinitiators require UV light to initiate the polymerization with the 
risk of generating damages on the encapsulated molecules, such as double-strand DNA breaks in 
encapsulated cells.[132] Eosin Y for example is a widely used photoinitiator because of its great 
cytocompatibility, water solubility and photon absorption in the visible range.[133] However, eosin Y 
suffers from many drawbacks: first it requires a co-initiator and accelerant species to produce enough 
radicals for initiating the process; secondly, the eosin Y absorption and emission spectra overlap with 
many fluorophores commonly used in cellular imaging.  
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2.2.1.1 Fabrication of PEGDA hydrogel using IrgaCure 2959 photoinitiator 
For the fabrication of photopolymerized three-dimensional PEGDA hydrogels, the commercially 
available compound IrgaCure™ 2959 (I2959) is selected as photoinitiator candidate. This initiator is 
the most commonly used compound for cellular encapsulation within hydrogels, despite its low 
solubility (less than 2%wt). I2959 is a type I photoinitiator meaning that when these molecules are 
irradiated in the UV light range, they are decomposed into two radical forms (Figure 2.5A). Then, in 
presence of PEGDA monomeric molecules, these free radicals propagate through double bonds of 
PEGDA chemical structure and chain polymerization occurs (Figure 2.5B). 
 
 
Figure 2.5 UV-photopolymerization of PEGDA and IrgaCure 2959 solutions. (A) Mechanism of radicals formation from I2959 
UV-light exposure; (B) Polymerization of PEGDA monomers together with free I2959 radicals to form a three-dimensional 
hydrogel. 
 
A preliminary study is conducted to evaluate optimal concentrations of PEGDA (MW 700Da) and I2959 
needed to obtain homogeneous and transparent hydrogels. As depicted in Figure 2.6A, different 
concentrations of PEGDA (700Da) dissolved in MilliQ water and IrgaCure 2959 dissolved in 
acetone/milliQ water (1:1) are tested. In a 24 well-microtiter plate these pre-polymer solutions are 
exposed to UV-light in a photo-reactor for 1 hour. From the photo of the obtained gels, it is notable that 
partially formed hydrogels are found (red circles on the first plate column), suggesting that the 
initiator concentration may be too low to ensure a complete crosslinking of the solutions. On the other 
hand, PEGDA hydrogels are formed when IrgaCure amount is equal or higher than 0.5%w/v. However, 
the fabricated hydrogels are extremely heterogeneous and colored even though the entire solutions 
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are crosslinked. Further, some particles are found on the bottom of the wells which can indicate a low 
solubility of the initiator when diluted in the polymer solution. Since the efficiency of 
photopolymerization depends on how many photons are absorbed by the initiator molecules and on 
the amount of radicals produced after photon absorption, the UV-vis spectra of different 
concentrations of I2959 dissolved in acetone/water (1:1) not exposed to UV-light are reported (Figure 
2.6B). It should be noted that as the initiator concentration increases, a linearly proportional UV-vis 
absorption is measured. In fact, for low concentration of IrgaCure the absorption at 365nm is 
negligible, whereas it starts to absorb at this wavelength for concentrations higher than 0.5%w/v. 
These results obtained from the UV-vis analysis are in agreement with what is observed from the 
polymerization of gels after exposure. In fact, the fabrication of completely crosslinked solutions is 
achieved for concentration of IrgaCure 2959 higher than 0.5%w/v, as shown in the photo of the well 
plate (Figure 2.6A). Therefore, to fabricate PEGDA hydrogels using I2959 as photoinitiator, a suitable 
concentration is needed (at least 0.5%w/v). Despite hydrogels can be produced when a certain 
concentration of initiator is used, there still an issue that should be clarified or at least optimized: the 
color of gels suggests a low solubility of I2959 when added to polymer solution due to its low water 
solubility (less than 2%w/v). 
 
To further improve the quality of hydrogels, a different polymer composition is used to evaluate how 
the physical and chemical properties of PEGDA affect the hydrogel fabrication. Thus, PEGDA having 
different PEG chain lengths (1kDa, 5kDa and 6kDa) and concentrations are mixed with PEGDA (700Da) 
and a constant amount of IrgaCure 2959 (1%w/v) is used. In a 24-well microtiter plate, the solutions 
are UV-exposed for 1 hour in the photo-reactor (Figure 2.7). The resulting hydrogels are less colored 
than those obtained from the mixtures of PEGDA (700Da) and I2959, but they are still imperfect 
because of high heterogeneity and extremely soft materials. These characteristics are important to 
accomplish the desired drug releasing platform, meaning that hydrogels must be ease to reproduce, 
colorless, homogenous in terms of composition and thickness, and it should be possible to polymerize 
gels within a shorter exposure time (less than 1 hour) and eventually create desired 3D-structured 
hydrogels. In light of these considerations, a preliminary test for the fabrication of 3D-shaped PEGDA 
hydrogels is conducted by mixing different amounts of PEGDA700Da with IrgaCure 2959 as 
photoinitiator and UV-irradiated through a traditional photolithography aligner (Figure 2.8A). 
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Figure 2.6 PEGDA hydrogel fabrication via UV-light photo-polymerization. (A) Photo of a 24 well-microtiter plate of various 
concentrations of PEGDA (700Da) and IrgaCure 2959 after exposure to UV-light (emitting range 330-380nm) for 1h. In the first 
column of the plate it is notable the incomplete polymerization of pre-polymer solutions and the presence of holes in the center 
of well (red circles) (B) UV-vis spectra of different concentrations of I2959 dissolved in acetone/water (1:1) not UV-exposed.  
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Figure 2.7 Hydrogel fabrication using 1%w/v IrgaCure 2959 dissolved in acetone/water (1:1). PEGDA (700Da) solutions are 
mixed with various concentrations of different PEGDA chain lengths (1kDa, 5kDa and 6kDa). Photo of a 24 well-microtiter plate 
where the mixed PEGDA compounds are exposed to UV-light for 1 h in presence of photoinitiator. Less colored and softer 
hydrogels are obtained when PEGDA 700Da is mixed with different PEG chain lengths, and all the tested amounts generate a 
crosslinked solution even though with some inhomogeneity.   
 
 
Different solutions composed of PEGDA (700Da), photoinitiator and fluorescein are poured inside a 
GeneFrame® and sealed with a coverslip. For the polymerization of 3D-structured hydrogels, two 
different chrome masks are employed: one of them consists of square grids of different diameters 
(Figure 2.8B); the other mask is made up of dual sets of interdigitated electrodes 200µm wide and 
3.5mm long and with 200µm spacing (Figure 2.8C). The gene frame is exposed for 10min to UV-light 
(365nm) using one of these photomasks and the obtained structures are washed several times with 
MQ water to remove un-exposed compounds. In Figure 2.9, some examples of 3D structures are 
reported: well-defined structures are obtained when a square grid with diameter of 25µm, a center-to-
center interspace of 66µm and 5 x 5 structures is applied (Figure 2.9A and D). Conversely, when a 
larger square grid with the same diameter (25µm) and interspace (66µm) but 20 x 20 total structures 
is applied, a hydrogel with not defined squares, rather with circle-like morphology with a central cavity 
is obtained (Figure 2.9B and E).  
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Figure 2.8 Schematic of the process used to photo-polymerize 3D-structured PEGDA hydrogels. (A) The steps involved on the 
hydrogel structures fabrication are: a gene frame of the dimension of 1.5 x 1.5cm is used to contain the pre-polymer solution (1); 
a solution of PEGDA 700Da, IrgaCure 2959 and fluorescein is poured into the gene frame (2); the solution is covered with a cover 
slip and protected from light (3); a chrome mask is used to create 3D hydrogel structures by illuminating the solution to UV-light 
for 10min using the UV-aligner (4); the cover slip is removed (5) and the obtained shaped hydrogel is washed with water to 
remove un-reacted compounds (6). The produced hydrogels are observed through confocal microscope using an excitation light 
at 488nm and collecting the fluorescence for wavelengths longer than 505nm (7). (B) and (C) represent the chrome mask 
designs employed to create the structures within the gene frame. In Figure 2.8A, the confocal picture of the obtained hydrogel 
structures (step 7) is produced by exposing the solution to UV-light using the mask reported in Figure 2.8C which is composed of 
interdigitated electrodes having a width of 200µm and a spacing of 200µm. The mask reported in Figure 2.8B includes a pattern 
of squares having a dimension of 60µm and spacing 60µm. 
 
Defined 3D-electrode shaped hydrogels are achieved when the fluorescent PEGDA/photoinitiator 
solution is exposed to UV-light through the second mask (Figure 2.9C and F); as depicted in Figure 
2.9F, the fluorescence profile across the electrodes reveals a width of each structure approximately of 
230µm, not far from the line width on the photo-mask (200µm). 
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Figure 2.9 Confocal microscope images of the 3D-structured PEGDA hydrogels obtained after curing. (A) and (D): square design 
with a diameter of 25µm, interspacing of 66µm and the pattern is composed of 5 x 5 squares; (B) and (E): square design with a 
diameter of 25µm, interspacing of 66µm and the pattern is formed of 20 x 20 squares; (C) and (F): inter-digitated electrodes 
design characterized by an electrode width of 200µm, 3.5mm long and 200µm spacing. In F), the fluorescence profile of 
fluorescein across the electrodes is shown. 
 
The method proposed here to fabricate hydrogels should be then applied for drug molecules 
embedding and consequent release study. As described in the introduction, different suitable ways for 
molecule entrapment may be used: inclusion of compounds within the network during polymerization, 
or chemical bonding of molecules to a pre-formed matrix, or the embedding of molecule-loaded micro- 
or nano-particles within the gel. A preliminary study for drug encapsulation within PEGDA hydrogels is 
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conducted. The approach which is intended to use for that purpose consists on the in situ photo-
polymerization of pre-polymer solution together with drug molecules. Ideally using this technique, the 
initial concentration of the targeted compound should be entirely confined within a certain volume of 
gel. Further, the release kinetics can be determined by quantifying the number of molecules diffused 
into the supernatant. For that purpose, the drug SN-38 commonly used for the treatment of colorectal 
cancer (CRC) is chosen as model molecule. SN-38 is a small molecule (MW = 392.4 g/mol), 
hydrophobic, poorly soluble in water and has a major UV-vis absorption peak at 374nm. Therefore, for 
the fabrication of SN38 embedded molecules within PEGDA hydrogels, different concentrations of 
PEGDA (700Da) and IrgaCure2959 with a constant amount of SN-38 are cured for 1 hour through UV-
light exposure in a photo-reactor. After polymerization, milliQ water is added into the well and the 
released drug molecules are quantified via UV-vis spectrophotometry. From the analysis of collected 
supernatants, no peaks are detected, especially the characteristic doublet peak of SN-38 (365-385nm, 
as shown in Figure 2.10A). Furthermore, when a PEGDA and SN-38 mixture is exposed to UV-light for 1 
hour without gelling due the absence of the photoinitiator, the corresponding visible spectra are totally 
comparable to the one observed without UV-exposure. Indeed, in Figure 2.10B is reported the 
spectrum of a PEGDA solution (green line) and the spectrum of PEGDA-SN38 solution (red line) after 
exposure. Contrarily to that, a solution of I2959-SN38 irradiated to UV-light for 1 hour presents a 
spectrum with a single peak, which is the result of two overlapped peaks (Figure 2.10C). The 
impossibility to quantify the concentration of released SN38 due to a problematic overlapping of 
IrgaCure absorption with the compound spectrum, limits the use of UV-vis spectrophotometry as 
detection tool. Other methods to measure the released SN38 may be applied, for instance 
chromatography techniques or mass spectrometry; on the other hand, an analytical method as simple 
as possible should be recommended for a fast measurement. Also notable is the available volume of 
supernatant in which compounds are released; in fact, the polymerization of gels may be adapted to 
smaller support including 96-well microtiter plates or even tinier.  
The need of a different quantification method to identify the released drug is not the only issue: in fact, 
the presence of I2959 into the supernatants even after an extensive washing of hydrogels is detected, 
indicating a possible accumulation of the photoinitiator molecules within the network as unmodified 
compound or as radical species. Moreover, after curing, the hydrogels with embedded SN-38 appear 
more colored than those fabricated in absence of drug which is also confirmed by the UV-vis spectra of 
I2959-SN38 after exposure. A long tail of their spectrum is observed when drug and initiator spectra 
are overlapped even for wavelengths longer than 400nm that may confer to gels a stronger color in 
comparison to those without drug. 
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Figure 2.10 UV-vis spectrophotometric characterization of PEGDA, I2959 and SN-38 solutions. (A) UV-vis spectrum of a solution 
composed of 30%w/v PEGDA (700Da), 0.5%w/v I2959 and 100µM SN-38 not exposed to UV-light. The relevant absorption 
peaks of the drug at 365nm and 385nm are marked. (B) UV-vis spectra of 30%w/v PEGDA (700Da) in green and 30%w/v 
PEGDA (700Da) with 100µM SN-38 in red after 1h UV-exposure. (C) UV-vis spectrum of a solution composed of 0.5%w/v I2959 
with 100µM SN-38 after 1h irradiation to UV-light.  
 
Taking into account all these considerations, the use of IrgaCure 2959 as photoinitiator to 
photopolymerize PEGDA hydrogels is not particularly satisfying for many reasons: firstly the 
photoinitiator is poorly soluble in water, thus fresh solution of I2959 dissolved in acetone/water (1:1) 
need to be prepared all time to avoid acetone evaporation during handling; secondly, to achieve a 
complete crosslinking of PEGDA solutions, a high concentration of photoinitiator has to be used (≥ 
0.5%w/v) and a long UV-exposure time (1 hour for hydrogels with a thickness of 1.5 mm or more and 
10min for thickness of 200µm). Moreover, when trying to produce 3D-structured hydrogels only large 
sized patterns can be fabricated since smaller features are obtained with a low resolution precluding 
the possibility to create miniaturized gels (as described in Figure 2.9B and E). Regarding the 
embedding process of desired molecules, a rapid and ease method to evaluate the released molecule 
amount even at smaller volume scale is fundamental. An efficient and reliable polymerization may be 
achieved using an initiator that greatly absorbs on the range of the emitting light source. The molar 
extinction coefficient of I2959 at 365nm is very low (ε365 = 4 M-1 cm-1 in acetone) and trails off almost 
entirely before 370nm, thus limiting the polymerization kinetics at or near these wavelengths. 
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Polymerization at longer wavelengths such as in the visible or violet light may be also possible but for 
I2959 is completely precluded because of negligible absorption of light in that range. As widely 
reported in literature, although IrgaCure 2959 is relatively cytocompatible for many cell lines at 
concentration between 0.03-0.1%, it has been demonstrated that various cell types show differential 
toxicity towards both photoinitiator and UV-light.[32,134] It has been also reported that the UV photo-
encapsulation of proteins or nucleic acids causes important damages like protein degradation or DNA 
breaks.[132] 
Therefore, according to all these issues, the photopolymerization of PEGDA hydrogel with an 
alternative photoinitiator which may satisfy some of the described features is explored. 
 
2.2.1.2 Fabrication of PEGDA hydrogels using LAP photoinitiator 
In the light of the discussed limitations on using IrgaCure 2959 as photoinitiator, another compound is 
evaluated for PEGDA hydrogel polymerization. This compound is a lithium acylphosphinate salt, 
shortly called LAP, which has been synthesized according to the protocol published by Majima et al.[135] 
The detailed synthesis of LAP photoinitiator is reported in the Experimental section of the manuscript 
in Appendix 1. 
LAP is a type-I photoinitiator, water soluble, cytocompatible and largely used for the encapsulation of 
cells within photopolymerized PEGDA hydrogels.[136] Contrarily to IrgaCure 2959, LAP is highly water 
soluble and has a significant absorbance at 365nm (molar extinction coefficient at 365nm, ε = 218 M-1 
cm-1).[136] Additionally, as reported in Figure 2.11A, the photoinitiator absorbs, albeit weakly, also in 
the visible range between 400-420nm (molar extinction coefficient, ε = 51 M-1 cm-1) which 
corresponds to purple light. When the LAP is exposed to UV-light, a change of its absorption is 
observed: in fact the molecule is photo-cleaved into two reactive radical species (Figure 2.11C). As the 
acylphosphinate is cleaved, the chromophore responsible for LAP absorption is lost (black line, Figure 
2.11B). Therefore, after UV-exposure a much lower absorption is detected between 365-420nm (red 
line, Figure 2.11B) due to the chromophore loss. The features of LAP photoinitiator are particularly 
interesting for our application since it has a good solubility in water, eventually it is possible to 
polymerize hydrogels with visible light (from 400nm to longer wavelengths), is cytocompatible[136] and 
has a higher absorption than IrgaCure 2959. Moreover, the absence of LAP absorption after UV-
exposure for wavelengths longer than 365nm may be useful for the spectrophotometry detection of 
molecules released from gels which absorb in this range. Hence, the conditions involved on the 
polymerization process with PEGDA polymer and LAP photo-initiator are studied and optimized in 
order to obtain successful drug releasing hydrogels.  
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Figure 2.11 UV-vis spectrophotometric characterization of LAP photoinitiator. (A) Spectra of different concentrations of LAP 
dissolved in MilliQ water. (B) Spectra of a solution 0.1%w/v LAP before (black line) and after (red line) 10min exposure. (C) 
Mechanism of photo-cleavage of LAP molecule induced by UV-light exposure. 
 
In order to determine the optimal photopolymerization conditions for PEGDA hydrogels fabrication, 
various experimental parameters are considered. In a 24well-microtiter plate, different concentrations 
of PEGDA700Da and LAP, both dissolved in MQ water are mixed and exposed to UV-light in a photo-
reactor for 10min. Already after 2min of exposure a complete gelation of all tested solutions occurs. As 
shown in Figure 2.12A, when a solution of highly concentrated LAP (1%w/v) without polymer is 
exposed to UV-light, a whitish solution is produced. On the other hand, when a constant concentration 
of LAP is mixed with various amounts of PEGDA, the color disappears as the PEGDA concentration 
increases until colorless, homogeneous and completely photo-crosslinked hydrogels are achieved. The 
Figure 2.12B shows the UV-vis characterization of formed hydrogels which are prepared by mixing a 
large excess of LAP (1%w/v) and increasing concentrations of PEGDA (between 0.1-1-5%w/v). A 
strong absorbance in the visible range (from 400 to 500nm) is observed and its magnitude decreases 
as the concentration of PEGDA increases. This behavior is probably due to an abundant amount of 
photoinitiator which produces a large number of radical species that, in presence of low PEGDA 
molecules, crosslink all the PEGDA monomers and confer to the final gel a whitish coloration due to 
light scattering by particulates.  
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Figure 2.12 Fabrication of PEGDA hydrogel in presence of the LAP photoinitiator. (A) Photo of a 24 well-microtiter plate where 
various concentrations of PEGDA are crosslinked in presence of 1%w/v LAP dissolved in MQ water upon UV-exposure in a 
photo-reactor for 10min. As the concentration of PEGDA added to the pre-polymer solution increases, the whitish color of 
exposed LAP solution disappears. (B) UV-vis characterization of hydrogels showed in Figure 2.12A. (C) UV-vis spectra of gels 
composed of a constant PEGDA concentration (5%w/v) and variable amounts of photoinitiator after 10min of curing. 
As the concentration of polymer molecules increases, the overflow of radicals still crosslinks 
completely the polymer and the hydrogels look less colored. A similar behavior is observed when a 
constant concentration of polymer is used (5%w/v) and excess amounts of LAP are used (Figure 
2.12C): the addition of 0.01%w/v of LAP to 5%w/v of PEGDA already results on a completely cured 
hydrogel after 2min of exposure. Although PEGDA hydrogels are formed in all the tested conditions, 
the gels have varying appearances: as described above, some of the gels are strongly colored because 
of an excess amount of LAP compared to that of the monomer, whereas others are completely colorless 
but extremely soft due to a low content of polymeric molecules. According to these considerations, a 
PEGDA (700Da) concentration of 20%w/v and 0.5%w/v of LAP are chosen as optimal concentrations 
for the fabrication of reproducible, un-colored, completely crosslinked and homogeneous gels in terms 
of thickness and shape.   
The use of LAP as candidate photoinitiator results in improved polymerization rate since the time 
required for a complete crosslinking of PEGDA solutions is one order of magnitude lower for LAP than 
for I2959 with 365nm illumination at the same intensity and initiator concentration. Further, when 
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LAP is used as initiator the polymerization takes place also for longer wavelength light (between 400-
420nm), contrarily to IrgaCure 2959. In general, the polymerization rate is proportional to the square 
root of the initiation rate, Ri[137]  which is given by:  
 
𝑅𝑖 =
2𝜙𝜀𝑓𝐼𝐶𝑖
𝑁𝐴 ℎ𝜐
 Eq. 2.4 
 
Here, 𝐼 is the incident light intensity (units of power per area) and 𝐶𝑖  is the initiator concentration. The 
initiator properties that influence the photo-initiated polymerization rate are 𝜀, the molar extinction 
coefficient; 𝜙, the quantum yield or cleavage events that occur per photon absorbed; 𝑓, the 
photoinitiator efficiency or the ratio between initiation events and total radicals generated by 
photolysis. The Avogadro´s number, 𝑁𝐴 ; the Planck´s constant, ℎ and the frequency of initiating light, 𝜐 
are included for unit conversion. From this equation it is clear that the utility and performance of a 
photoinitiator are affected by various parameters. Usually, to increase the polymerization rate, 𝐼 or 𝐶𝑖  
are increased, but high light intensity and initiator concentration can induce important cytotoxic effect. 
In the case of I2959 is not possible to increase its concentration because of poor water solubility which 
limits its utility. Furthermore, as the initiation rate strictly depends on the photons absorbed by the 
initiator, the weak absorbance profile of I2959 restricts its usefulness for polymerization in a narrow 
UV-vis region centered at 365nm; in contrast, LAP absorbs also in the visible range (400-420nm). The 
main benefits on using LAP instead I2959 are not only due to a higher extinction coefficient of LAP, but 
also higher quantum yield and initiation efficiency (𝜙  and 𝑓 respectively in the equation).[136] 
 
 
2.2.1.3 Photo-polymerization of PEGDA hydrogel through projector light 
According to the reported considerations about LAP properties and its utility on photo-polymerization 
process, one should also consider the light source that mostly satisfies the requirements for hydrogel 
fabrication. As previously reported, the curing of PEGDA gels is UV-light-assisted and simple 
equipment is used for their processing. Solutions of polymer and photoinitiator are dispensed into well 
plates and protected from light until intended crosslinking.  
The entire well plate is located inside a photo-reactor which is mainly composed of a series of UV-
lamps on the top and bottom of the chamber (Figure 2.13A). Therefore, the curing process takes place 
on both interfaces of each well. For hydrogel crosslinking, a traditional UV-aligner may be also 
employed: this machine is normally used for microlithography purposes and its functioning consists in 
positioning the sample in the stage, align and put it in contact with a mask which presents desired 
features, and expose the sample to UV-light at 365nm (Figure 2.13B). Both techniques are relatively 
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simple, ease to handle and they do not require specific sample manipulation. However, these two 
approaches are not suitable for the fabrication of our intended PEGDA hydrogels, as they should be 
able to create 3D-structured hydrogels without damaging gel properties. The use of a photo-reactor is 
consistently limited to a complete crosslinking of the poured solution and 3D-structures are 
impossible to form with this technique due to the diffused UV-light all over the chamber. Contrariwise, 
the use of a UV-aligner permits to selectively crosslink certain areas within the solution according to 
the pattern designed on the mask. 
 
 
 
Figure 2.13 Schematic illustration of the equipment used for photo-polymerization process. (A) A photo-reactor based on a 
series of UV-lamps is used to polymerize multiple solutions without particular 3D-structures; (B) a traditional UV-aligner is 
employed to create 3D-structured PEGDA hydrogels on glass slides, and (C) a micro 3D-printer machine is utilized to 
simultaneously polymerize multiple pre-polymer solutions illuminating them with visible light generated by a modified 
projector with a maximum emitting light at 410nm. On the enlargements are reported a home-made support which permits to 
exactly fit a 96 well-microtiter plate on the printer stage (on top), and the tools required for visible-photopolymerization, a 
projector and a support where pre-polymer solutions are contained (on bottom).  
 
60 
 
 
 
To achieve this goal, the sample has to be in contact with the mask, thus thick supports like well-
microtiter plates or Petri dishes cannot be used for this purpose. The main advantage on using well 
plates is the ability to crosslink multiple solutions at the same time in a rapid step; therefore, when 
using an aligner, a proper support needs to be used, such as glass slides, wafers and any kind of flat and 
thin surface. Moreover, when the sample is in contact with the mask an appropriate confinement of the 
solution on the support should be adopted since when in contact mode, the solution will tend to be 
squeezed out and its final thickness will be difficult to control. It is clearly needed to use a different 
method for the simultaneous crosslinking of multiple polymer/photoinitiator solutions having desired 
3D-structures. Since the LAP photoinitiator absorbs not only in the UV range (maximum peak 
absorption at 375nm) but also in the visible region (between 400-420nm), a visible light source can be 
considered. As illustrated in Figure 2.13C, the EnvisionTEC Perfactory® Micro 3D-printer is utilized for 
in situ visible-light photopolymerization. The equipment is composed of a projector on the bottom of 
the instrument which is modified to have a maximum emitting light at 410nm based on a LED light 
source, a stage where the sample is located, a light-protected box which is moved during the 
polymerization process to protect the sample from external light, and a computer connected to the 
machine (Magics Desktop Software). A home-made support to exactly locate 96 well-microtiter plates 
on the stage is used to polymerize simultaneously 12 wells in a single step, as depicted on the 
enlargement (top, Figure 2.13C). When the sample is placed on the support, the polymerization starts 
as the projector light coming from the bottom of the sample is turned on. In addition, any desired 3D-
structure may be produced in each well: digital masks, based on a grayscale graphic file (with a final 
resolution of 650dpi), are designed and directly projected onto the sample. Hence, through a simple 
and cheap light source like a projector, multiple hydrogels can be fabricated in a single step and with 
desired 3D-structures. Further, many types of support may be used: well-microtiter plates with 
various shapes and sizes, Petri dishes, glass slides, coverslips, etc.; the only requirement for a 
successful process is the need of completely transparent supports to permit projected light to pass 
through it.  
 
2.2.1.4 Characterization of PEGDA hydrogels  
When solutions of PEGDA and photoinitiator are mixed and poured into a certain support and exposed 
to projected light, the entire volume of the solution is crosslinked. According to the initial volume of 
mixture, a certain exposure time is needed to achieve a complete cured gel. Besides that, the final 
morphology of the hydrogel is basically controlled by the shape of the support in which the volume is 
poured, meaning that desired shapes of gel maybe be obtained by changing the support. However, by 
varying the morphology of the solution support one can control only the appearance of the edges of the 
gel, for instance square, circle, needle-like shapes may be produced. The exposure to digital masks 
presenting characteristic features permits to create multiple 3D-structures having various 
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morphologies within the gel with a great resolution. A preliminary study for the fabrication of PEGDA 
hydrogels through visible-light photo-polymerization is conducted using the micro-3D printing 
technology. In a 96 well-microtiter plate, pre-polymer solutions with the same total volume composed 
of PEGDA700Da and LAP are poured in each well. In order to evaluate the patternability of gels with 
desired structures, two simple digital masks are designed: one consists of a semi-circle (half in white 
and half in black), and the second is a completely white circle.  
 
 
Figure 2.14 Illustration of visible-light projection technology: in a 96 well-microtiter plate the pre-polymer solutions are poured 
and a modified LED-light projector that has a maximum emitting light at 410nm, is used to cure the solution (on the left). Two 
digital masks are designed to create 3D structures on the gels: a semi-circle and circle structures are tested (in the panel on the 
right). A schematic of the top view of projected mask, exposed solutions and the obtained hydrogel 3D-structures having a 
thickness of 1.5mm are reported.  
 
These two masks are then projected onto the bottom surface of the well plate; so, the corresponding 
white areas of digital masks are projected while black areas not (top view of projected feature in 
Figure 2.14). The solutions are exposed for 1min to visible light through digital masks. The final 3D-
structures of hydrogel correspond to a semi-circle and an entire circle as also confirmed by the 
obtained shaped PEGDA hydrogels in Figure 2.14 (top view 3D-hydrogel structure and PEGDA 
hydrogel structure). The entire volume of solution is completely crosslinked in the case of circle 
design, while only half solution volume is cured when a semi-circle pattern is applied.  
An important parameter that should be also evaluated is the thickness of the final structured 
hydrogels, and how it changes when different times of exposure and solution volumes are employed. 
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To investigate that, in a 24 well-microtiter plate different volumes of the mixture 20%w/v PEGDA and 
0.5%w/v LAP are poured in each well; then the solutions are exposed to a semi-circle shaped digital 
mask for increasing exposure time (15, 30, 60 and 120 seconds). The fabricated hydrogel thicknesses 
are measured through a caliber and they are plotted as function of the exposed solution volume (in 
microliter) and exposure time (in second) (Figure 2.15A). As reported in the graph, when the volumes 
are illuminated for 60seconds, a linear increase of hydrogel thickness is found suggesting that a 
complete crosslinking of the exposed area is occurred. However, when solutions are exposed to visible-
light for more than 60s for example 120seconds, a substantial decrease of hydrogel thickness is 
observed. In Figure 2.15B a possible explanation to this behavior is suggested. In fact, a prolonged 
exposure of PEGDA/photoinitiator solutions through the semi-circle digital mask results on an over-
crosslinking; in other words, in the solution not only the exposed areas are crosslinked but also those 
which should not be cured (since corresponding to black regions on the digital mask).  
 
 
Figure 2.15 (A) Hydrogels thickness plotted as function of the exposed volume of 20%w/v PEGDA and 0.5%w/v LAP solutions 
and as function of exposure time. Each 24-well is illuminated through a semi-circle shaped digital mask for different period of 
curing. (B) Hydrogels obtained after prolonged exposure times using the semi-circle shaped mask. An over-crosslinking is 
observed when pre-polymer solutions are cured for more than 60s and the desired shape (semi-circle) is lost when the exposure 
time rises up to 10 or 20min. 
 
Indeed, as the exposure time increases a larger area of the well is photopolymerized indicating that a 
short curing time may be optimal for 3D-patterning. Since during light-exposure the molecules of 
photoinitiator absorb photons, a diffusion of radicals from the crosslinked areas may cause a 
polymerization of the non-illuminated regions. Moreover, the emitted light may be scattered on the 
already crosslinked gel and thereby is also directed into the nominally dark areas.  
The wettability of PEGDA hydrogels formed by visible-light photo-polymerization is also evaluated. De-
hydration (loss of water content) and hydration (uptake of water content) processes are sequentially 
conducted on hydrogels formed by different PEGDA and LAP amounts in order to evaluate whether the 
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gels can be maintained in a humidified environment once the drugs are embedded within the matrix. A 
total volume of 2mL of PEGDA/LAP mixture is crosslinked for 1minute without any particular 3D-
structure in a Petri dish and the formed gels have a final thickness of 2.2mm. The weights of empty 
Petri dish, solution-Petri dish, and hydrogel-Petri dish are measured to evaluate the water loss and 
uptake. The water exchange through the gels is determined studying the de-hydration and hydration 
processes. The crosslinked hydrogels in the Petri dishes are incubated in the oven in dehumidified 
atmosphere at 60˚ C over time, and every certain interval their weight is measured. As shown in Figure 
2.16D, once the evaporation of water from hydrogels takes place, a delamination and shrinkage is 
observed. After 19hours, a box containing water is located inside the oven which is always maintained 
at 60˚ C and gels hydration is estimated again by measuring their weight. Three different compositions 
of PEGDA and three different amounts of LAP are tested: 0.05 – 0.1 - 0.5%w/v of LAP and 10 – 20 – 
30%w/v of PEGDA700Da.  
 
 
Figure 2.16 Graphical description of water exchange from visible-photopolymerized hydrogels cured for 1minute. (A, B and C) 
Three different concentrations of PEGDA (10-20-30%w/v) and three variable amounts of LAP (0.05-0.1-0.5%w/v) are tested. 
The loss of water is induced by evaporation in an oven at 60˚ C over time in a de-humidified atmosphere, and the water uptake is 
ensured by introducing a bath of water inside the oven. To evaluate the content of loss and uptake of water content, the weights 
of samples are measured before and after polymerization and during the de-hydration and hydration processes. (D) Photos of 
hydrogels after 19h of de-hydration: the evaporation of water induces a shrinkage of hydrogels on their support. 
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In Figure 2.16A, B and C, the plots of water exchanged over time are reported including two physical 
phases pointed out: an initial phase in which water is lost from polymeric networks and a second stage 
where gels uptake water from the environment. Within the first 19hours, the networks show a rapid 
loss of water and the water evaporation content is inversely proportional to the PEGDA concentration 
composing the gels. This behavior is mainly due to a different amount of water in the initial solution 
prior crosslinking, thus on gels where the polymer concentration is 10%w/v a higher volume of water 
is included in the matrix. The evaporation process is followed by the uptake of water from the 
environment which is rapid within the first 4hours and slower during the remaining period. At the end 
of the hydration process, almost all the prepared hydrogels reach an equilibrium state meaning that 
the amount of water up-taken from gels is in equilibrium with that present in the environment and no 
more water can enter the matrices. However, from the plot in Figure 2.16A it is notable that when 
hydrogels are crosslinked with a concentration of 0.05%w/v LAP after 70hours they do not reach an 
equilibrium state, rather a liner increasing amount of water up-taken from the environment is 
detected. These hydrogels are particularly soft and maybe the presence of a low concentration of 
photo-initiator results on a diminished crosslinking degree of gels. The entire process of water loss and 
uptake depends on the experimental conditions inside the oven (for instance temperature and 
humidity). Therefore, once the gels are loaded with various drugs, they can be stored in humidified 
atmosphere to keep them in a wet state. 
 
2.2.1.5 3D-structured PEGDA hydrogels 
One of the important issues for the final goal of fabricating hydrogels for drug release purposes is the 
patternability of PEGDA material in 3D hydrogel structures. The main parameters that need to be 
considered are the shape of these 3D-structures according to the intended use and the support that 
will be employed for hydrogel fabrication. The hydrogel platform for drug screening applications must 
be fabricated in a cytocompatible support because cell culture experiments will be conducted onto the 
hydrogel surface, and it should be as small as possible in term of size in order to maximize the number 
of hydrogel structures on the same support. The shape and size of hydrogels are directly defined by the 
designed digital mask, the volume of PEGDA/photoinitiator solution and the time of visible-light 
exposure. Various shapes, sizes and supports are tested in order to have an idea of which combination 
of these parameters is mostly suitable for our purpose. In Figure 2.17 some examples are reported: all 
the obtained structures are prepared through visible-light photopolymerization of solutions composed 
of 20%w/v PEGDA (700Da) and 0.5%w/v LAP illuminated for 1min using a specific digital masks.  
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Figure 2.17 Pictures of some examples of PEGDA hydrogels obtained by visible-light photopolymerization with different digital 
mask designs. All the 3D structures are obtained exposing for 1min a solution of 20%w/v PEGDA and 0.5%w/v LAP.  (A) A photo 
of a circle shaped hydrogel 6.2mm in diameter with (B) holes of 500µm in diameter. (C) A photo of a circle shaped hydrogel 
composed of four segments loaded with four food colors, and (D) a photo of different volumes of hydrogel (25-50-75 and 100% 
of the total well area) loaded with calcein.  
 
 
Rectangular, circle, segments and holes may be fabricated of different sizes; further, they can be 
prepared in Petri dishes, or glass slides or well plates of various dimensions. Figure 2.18 shows a 
hydrogel composed of 20%w/v PEGDA and 0.5% LAP exposed for 1min with a digital mask. The design 
is a bit more complicated than those showed in Figure 2.17 because in this case the gel is formed by 
multiple concentric circles (where the larger measures 6.2mm) and with a central hole (Ø = 600µm) . 
The particularity of this structure is that on the digital mask (Figure 2.18C) each circle has a different 
greyscale value; therefore less or more light intensity will pass through each concentric circle. The 
application of this design results on a rounded hydrogel with a hole in the center and a gradual slope 
along the structure (3D-plot of hydrogel in Figure 2.18D). This construct is particularly useful when 
culturing cells, like spheroids; due to the poor cell attachment properties of PEGDA hydrogel, 
spheroids may be seeded into the central hole facilitating their handling and characterization since 
cultured on a confined area.  
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Figure 2.18 (A) and (B) fluorescence micrographs of a PEGDA hydrogel obtained by visible-light photopolymerization using a 
particular digital mask design. The 3D structure is obtained exposing for 1min a solution of 20%w/v PEGDA and 0.5%w/v LAP. 
(C) The mask is made of multiple concentric circles which have different grayscale values. In that way, the sample will be 
exposed to different light intensities and (D) a final 3D structure with a slope will be obtained. 
A digital mask with three concentric circles which completely cover the entire well area may be also 
used (Figure 2.19A) and it could be useful to confine multiple compounds within various hydrogel 
volumes. Contrarily to the design showed above (Figure 2.18), the three circles are fabricated in three 
steps: an external ring is exposed for 1min to visible-light, a second ring with smaller diameter than 
the previous one is also formed, and the remaining volume is crosslinked by a third circle with an even 
smaller diameter. The resulting 3D hydrogel is shown in Figure 2.19B and for a better visualization of 
the three structures the pre-polymer solutions are mixed with dyes: the external circle is labeled with 
Rhodamine-labeled albumin, the circle in the middle is composed of un-labeled hydrogel and the last 
central circle is visualized through embedding of FITC-labeled albumin. The final hydrogel is the result 
of three constructs which cover the entire well area and have a constant thickness of 1mm.  
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Figure 2.19 Fabrication and visualization of three-circle shaped PEGDA hydrogel loaded with two different dyes and fabricated 
through a multi-step process. An external ring structure (radius1 =3.1mm; area ring1 =10mm2; thickness =1mm) is produced by 
illuminating a solution of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa), 0.5%w/v LAP and 5µM Rho-labeled albumin for 
1min. A second circle-shaped hydrogel is formed by illuminating a solution of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa) 
and 0.5%w/v LAP using a smaller ring structure (external radius2 =2.5mm; internal radius2 =1.8mm; area ring2 =10mm2; 
thickness =1mm). A third circle is produced by illuminating a solution of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa), 
0.5%w/v LAP and 5µM FITC-labeled albumin (radius3 =1.8mm; area ring3 =10mm2; thickness =1mm). (A) Digital masks used for 
the multi-step hydrogel fabrication. (B) Photo of the produced hydrogel and corresponding enlargement obtained through 
confocal microscope. The dimensions of structures are defined by the digital masks (A) while the thickness of each gel is 
controlled by the pre-polymer solution volume.  
 
The network is visualized through confocal laser scanning microscope to detect the fluorescent dyes 
embedded within the external and internal circles. Rhodamine-labeled albumin is detected using an 
excitation light at 543nm and collecting the fluorescence at wavelengths longer than 560nm, whereas 
for FITC-labeled albumin detection, an excitation light at 488nm is used and emitted light is collected 
for wavelengths longer than 505nm. As shown in the two panels on the bottom of Figure 2.19, the 3D-
fluorescence profile of FITC-albumin embedded within the internal circle is reported (on the left), and 
the 3D-fluorescence profile of Rho-labeled albumin embedded within the external ring structure is 
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described on the right panel. No fluorescence is detected corresponding to the circle structure in the 
middle.  
 
2.2.2 Molecule and drug release study from PEGDA hydrogels 
In general, the diffusion of molecules embedded within hydrogels depends on several parameters 
including the physical-chemical properties of the molecule and polymeric network and the 
crosslinking degree of the matrix, thus on the network pore size.  Considering these factors, according 
to the mesh size of gel, small molecules will diffuse faster than larger ones, such as proteins or nucleic 
acid. Moreover, the photoinitiator concentration, exposure time, or hydrogel thickness are parameters 
that affect the release rate of targeted compounds. To evaluate whether PEGDA hydrogels are suitable 
as releasing systems, different model compounds are considered; these molecules are chosen in such 
way that various molecular weights and physical-chemical properties are investigated. A preliminary 
study is conducted by encapsulating a concentration of 50µM calcein within 20%w/v PEGDA (700Da) 
and 0.5%w/v LAP photo-crosslinked for 1min. Calcein is a small and hydrophilic molecule (MW 666.50 
g/mol) usually employed as fluorescent dye because of its excitation at 495nm and emission at 515nm. 
The hydrogels are formed without a digital mask, thus all the area is exposed to projected light. 
Moreover, cylindrical gels are produced in various well plates (12, 24, 48 and 96-well microtiter plate) 
using pre-polymer solution volumes which are of the same height but different area (corresponding to 
the well area). After polymerization, homogeneous and colored gels are produced demonstrating the 
presence of calcein entrapped within the matrix. The gels are then washed with MQ water and a 
certain volume of buffer is added to each well promoting calcein release into the supernatant. The 
release of calcein from PEGDA hydrogels is measured over time through UV-vis spectrophotometric 
characterization of the collected supernatants until complete release. As reported in Figure 2.20A, a 
rapid release of calcein is found within the first 90minutes of release experiment, while almost no 
increase of released molecules is observed during the following 18h. In fact, as depicted in the panel, 
the hydrogels lose their coloration already after 90min due to calcein release. Moreover, it is possible 
to observe that the maximum cumulative release reachable corresponds to 50% of the total embedded 
calcein. Since the hydrogels have clearly lost their coloration after 90min of release study, it is highly 
probable that most of the compound is wasted during the prior washing steps because of the rapid 
diffusion of calcein. Figure 2.20B also shows the UV-vis spectra of supernatants obtained from the 
measurement of calcein absorption at 495nm; the spectrum related to the released calcein after 90min 
confirms a decreasing amount of compound into the supernatant. 
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Figure 2.20 (A) Cumulative release profile of calcein from PEGDA hydrogels. The gel is composed of 20%w/v PEGDA (700Da), 
0.5%w/v LAP and 50µM calcein solution which is crosslinked for 1min without using digital mask to form a cylindrical gel. 
Different well sizes are used to produce gels of same thickness but various areas (which corresponds to the well area). The 
pictures of a calcein-embedded gel at time zero and at time 90min of release study are also reported. (B) After washing, a certain 
volume of supernatant is added to each well (1000µl in 12 wells, 580µL in 24 wells, 326µL in 48 wells and 110µL in 96 well). At 
different intervals the supernatants are collected and replaced with fresh solutions. The UV-vis spectra of calcein content 
released into supernatants collected over time is measured at 495nm. 
 
Therefore, small and hydrophilic molecules such as calcein embedded within this specific hydrogel 
composition are rapidly released because they are smaller than the gel pore size and their diffusion 
through the gel rapidly occurs. In the light of these considerations, the behavior of small but 
hydrophobic compounds is also explored: in particular, SN-38 is chosen as model molecule. SN-38 is 
one of the drugs used for the treatment of colorectal cancer (CRC); it is a small molecule (MW 
=392.4g/mol), hydrophobic and poorly water-soluble. In a 96 well-microtiter plate, a solution of 
20%w/v PEGDA (700Da), 0.5%w/v LAP and 200µM SN-38 is cured for 1min without any digital mask. 
The hydrogels are extensively washed with MQ water and the release of drug is collected over time 
into the supernatants. The released SN-38 molecules are quantified through UV-vis measurement 
recording the absorption at 374nm (Figure 2.21B). The cumulative profile (Figure 2.21A, black line) 
shows that the drug is slowly released and the 90% of total embedded molecules is obtained after a 
week of release study (data not shown). Because of that, the composition of PEGDA hydrogel is 
modified by introducing longer PEG chains: different concentrations of PEGDA 5kDa (0.1-0.5-1-
1.5%w/v) are added to the main precursor solution (20%w/v PEGDA 700Da and 0.5%w/v LAP). In 
Figure 2.21A, an enhancement of drug release is achieved as the concentration of PEGDA 5kDa 
increases. Although no difference is observed between the release profile of SN-38 in presence of 
0.1%w/v or 0.5%w/v PEGDA 5kDa, or when it is used a concentration of 1%w/v or 1.5%w/v 
PEGDA5kDa, a remarkable difference is shown between 0%w/v and 0.1%w/v PEGDA 5kDa. A further 
enhancement of drug release results when 1%w/v PEGDA 5kDa is used. The presence of longer PEG 
chains induces an increase of the pore size on the polymeric network,[138] thus promoting the diffusion 
of hydrophobic molecules such as SN-38. A complete release of drug is then achieved in a shorter time 
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compared to the partial release obtained from PEGDA hydrogel free of PEGDA 5kDa which requires up 
to a week. 
 
 
Figure 2.21 (A) Cumulative release profiles of SN-38 embedded within PEGDA hydrogels in 96 well plate. Different gel 
compositions are tested: 20%w/v PEGDA (700Da), 0.5%w/v LAP, 200µM SN-38 plus 0-0.1-0.5-1-1.5%w/v PEGDA (5kDa). (B) 
After washing, a specific volume of supernatant (110µL) is added to each well and at different intervals the supernatants are 
collected and replaced with a fresh solution. The UV-vis spectra of supernatants collected after 1h release (black line) and after 
40h release (red line) from a gel composed of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa), 0.5%w/v LAP and 200µM SN-38 
are measured. SN-38 has a maximum absorption peak at 374nm. The experiment is replicated three times (n=3). 
 
The embedding of larger molecules in terms of high molecular weight is studied by entrapping a 
concentration of 5µM FITC-albumin within PEGDA hydrogel. The labeled-protein has a molecular 
weight of ~ 66kDa and an amphiphilic behavior. Because of the protein dimensions, the molecule is 
photopolymerized within hydrogels composed of 20%w/v PEGDA (700Da), 0.5%w/v LAP and 1%w/v 
PEGDA (5kDa) based on the results obtained without including PEGDA (5kDa) in which no release is 
observed (data not shown). The release profile of FITC-albumin is reported in Figure 2.22: the protein 
content is collected into the supernatants which are measured through UV-vis spectrophotometry and 
the amount of dye molecules is quantified at 495nm. Although the protein is bigger than the 
compounds previously tested (calcein and SN-38), within a period of circa 5 days an almost complete 
release of the protein is obtained. An increase of PEGDA 5kDa concentration may facilitate further 
molecules diffusion, thus reducing the time needed for a complete release. From these preliminary 
studies it emerges that the release of a certain compound from PEGDA hydrogels can be easily 
optimized by tuning gel composition. In that way, even bigger molecules like proteins may be released 
in a reasonable time without their damage, since the spectra of released molecules are identical to 
those of free compounds.  
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Figure 2.22 Release profile of 5µM FITC-albumin embedded within a hydrogel composed of 20%w/v PEGDA (700Da), 0.5%w/v 
LAP and 1%w/v PEGDA (5kDa). The content of released protein is characterized by UV-vis spectrophotometry recording its 
absorbance at 495nm. 
 
The application of this hydrogel is intended for drug release purposes and in specific, on the release of 
relevant chemotherapeutics commonly used for the treatment of colorectal cancer (CRC). Since, as 
already discussed in the introduction, the application of such hydrogels is intended for drug release 
purposes, the release profile of various drugs is characterized: SN-38, already described above, 
Oxaliplatin, 5-FU and Folinic acid (FA). Oxaliplatin (MW =397.3g/mol), 5-FU (MW =130.1g/mol) and 
FA (MW =511.5g/mol) are relatively small and hydrophilic drugs. Hence, each individual drug is 
entrapped within gel composed of 20%w/v PEGDA (700Da) and 0.5%w/v LAP, except for SN-38 which 
is embedded in a hydrogel made of 20%w/v PEGDA (700Da), 0.5%w/v LAP and 1%w/v PEGDA 
(5kDa). The precursor solutions are crosslinked for 1min in a 96 well-microtiter plate without the use 
of digital mask, thus all the liquid is cured to form cylindrical gels with dimension of 6.2mm in 
diameter and thickness of 1mm. After photopolymerization, the gels are washed and the released 
molecules are collected into the supernatants. The contents are then evaluated through UV-vis 
spectrophotometry for SN-38 (at 374nm), 5-FU (at 288nm) and FA (at 300nm), whereas oxaliplatin is 
quantified via inductively coupled plasma mass spectrometry (ICP-MS). 
As shown in Figure 2.23, 90% of 5-FU is released within 30 h, circa 90% of FA already after 5 h is 
diffused into the supernatant and SN-38 is completely released after 1 day. Contrariwise, oxaliplatin 
reaches a value around 65% after 2 days releasing. All the experiments are terminated when no 
molecule signal is detected into supernatant; in fact, even if the maximum release reachable by OxPt is 
around 65%, no drug is detected after 2 days. This behavior may be due to a loss of drug during the 
washing step which cannot be prevented with the tested PEGDA composition. An eligible approach to 
prevent loss of compounds during washing step is the use of drug-loaded nanoparticles, such as 
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liposomes which can be used to encapsulate oxaliplatin into their aqueous cavity, embed them within 
polymeric network and on demand, release drug molecules by applying a proper trigger. 
In the next paragraphs, the release of oxaliplatin when loaded into liposomes is characterized. In 
particular, the effect of thermal triggering of OxPt-loaded liposomes is investigated. 
 
Figure 2.23 Release profiles of various chemotherapeutics from PEGDA hydrogels. 1mM 5-FU (a), 200µM FA (b), and 200µM 
oxaliplatin (c) are embedded within hydrogels composed of 20%w/v PEGDA (700Da) and 0.5%w/v LAP; 200µM SN-38 (d) is 
entrapped in a gel made of 20%w/v PEGDA (700Da), 0.5%w/v LAP and 1%w/v PEGDA (5kDa). All the solutions are crosslinked 
for 1min by visible-light exposure. The released molecules are collected into the supernatant and quantified through UV-vis 
spectrophotometry (374nm for SN-38, 300nm for FA, and 288nm for 5-FU), and ICP-MS for oxaliplatin. All the experiments are 
repeated three times (n=3).  
 
 
2.2.3 Drug-loaded liposomes and their embedding within PEGDA hydrogels 
After a molecule is embedded within a polymeric network an extensive washing step is crucial. In fact, 
after polymerization, even though the entire solution is crosslinked to form homogeneous gels, radical 
species and un-reacted compounds must be removed to avoid interference with the encapsulated 
molecules which may affect the release. These reasons lead us to consider the use of nanoparticles as 
drug carrier; the main advantages on using drug-loaded nanoparticles are due to the ability of nano-
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carriers to protect compounds from the chemical and physical environment, control their release by 
applying a certain trigger and the possibility to load a high concentration of molecules into small 
vesicles (around 100nm in diameter). In this work, liposomes are used as oxaliplatin carrier. Two 
different stocks of oxaliplatin-loaded liposomes are synthesized according to the protocol described in 
the Experimental section of the manuscript in Appendix 1. One liposomal formulation is composed of 
DPPC/HSPC/cholesterol/DSPE-PEG2kDa components (thermo-sensitive liposomes which have an 
average diameter of 112.7nm with a polydispersity of 0.022), while the other composed of 
DSPC/cholesterol/DSPE-PEG2kDa (stealth liposomes which are characterized by an average diameter 
of 132.5nm and polydispersity of 0.016).  The main difference between these two suspensions is their 
response to heat treatment: thermo-sensitive liposomes become leakier when heated up at a certain 
temperature and their cargo can diffuse outside from the interior aqueous compartment. Stealth 
liposomes are much more stable in terms of bilayer mobility because of the presence of DSPC lipids 
which have a higher phospholipids phase transition temperature. The phase transition temperature 
(Tm) of thermo-sensitive liposomes is determine by embedding in a 96 well-microtiter plate a 
concentration of 100µM OxPt-loaded liposomes is embedded within a hydrogel composed of 20%w/v 
PEGDA (700Da) and 0.5%w/v LAP both dissolved in phosphate buffer solution (PBS) which is 
photopolymerized for 1min and extensively washed with PBS (30min). Figure 2.24A shows a 
schematic illustration of the nano-system used to evaluate the phase transition temperature of thermo-
sensitive OxPt-loaded liposomes. After entrapment of vesicles within the gel, the hydrogels are heated 
at different temperatures for 1h in a thermo-block hotplate. The released OxPt is thus collected into the 
supernatant and the aliquots are measured through ICP-MS.  
 
 
Figure 2.24 (A) Schematic illustration of thermo-sensitive OxPt-loaded liposomes embedded within PEGDA hydrogel; a 
following heat treatment of the nano-platform induces a liposomes leakage and consequent drug release. (B) The phase 
transition temperature of thermo-sensitive liposomes is characterized by heat treatment for 1h at different temperatures when 
vesicles are embedded within gel. (C) The OxPt release induced at 40˚ C at different times of heat exposure is also measured; the 
nanoparticles are always entrapped within PEGDA hydrogels. The concentration of OxPt is collected into supernatants and 
determined by ICP-MS.  
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In Figure 2.24B, the amount of drug leaked from liposomes and diffused from the gel into supernatant 
is plotted against the applied temperature. When the system is heated for 1h the maximum release of 
OxPt is obtained at 40˚ C of heat treatment while almost no leakage is shown between 5˚ C and 30˚ C. 
As the phase transition temperature is passed, a decrease of molecules release is observed: in fact, 
already at 46˚ C the amount of drug leaking out approaches zero. A further investigation consists of 
establishing the heating time required to reach the maximum release. Hence, 100µM of OxPt-loaded 
thermo-sensitive liposomes are entrapped within 20%w/v PEGDA (700Da) and 0.5%w/v LAP 
dissolved in PBS, cured for 1min and subjected to a 30min washing step. The hydrogels are then 
heated up at 40˚ C for different heat exposure times; as before, the amount which leaks out into the 
supernatant is detected by ICP-MS and plotted against the time of heat exposure (Figure 2.24C). As 
previously found, after 1h heat treatment the concentration of OxPt released is almost 50% of the total 
embedded drug whereas the highest leaked amount is achieved after 24h of heating. Also notable is 
that after 30min already more than 20% of the embedded drug is released, suggesting a rapid phase 
transition of lipids within the bilayer. Heat triggering is one of the most interesting strategies for active 
release of content from nano-carriers; indeed, these liposomes are largely used for hyperthermia 
medical applications which are based on lipid formulations having a narrow phase transition 
temperature just above body temperature.  
 
Figure 2.25 Differential scanning calorimetry thermos-grams for different liposomes compositions. Liposomes are composed of 
DPPC/HSPC/cholesterol/DSPE-PEG at the indicated molar ratios. Figure reproduced from [139]. 
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When close to the Tm, heterogeneity in the membrane will occur and the cargo leakage from interfacial 
membrane regions is induced. The thermo-sensitive liposomes used for drug release purposes are 
composed of DPPC/HSPC/cholesterol/DSPE-PEG2kDa at molar ratios of 100/50/30/6. A similar lipid 
composition has been explored by Gaber et al.[139]: the thermotropic transitions for different liposome 
compositions were detected by differential scanning calorimetry (DSC). As shown in Figure 2.25, they 
found that when the molar ratio of cholesterol to phospholipids is higher than 2 or more, there is no 
clear phase transition (Figure 2.25B, C and D), and that the composition which seems to be optimal for 
drug release has a phase transition at 48˚ C (Figure 2.25A, E and F). Moreover, the presence of DSPE-
PEG causes a small increase in the phase transition temperature, 2˚ C higher than the same 
composition in absence of PEG-grafted lipid (Figure 2.24A and E). It is generally recognized that the 
presence of cholesterol decreases the permeability of liposomes and protects them from destabilizing 
environments, while PEG-grafted lipids provide a hydrophilic surface coating (steric stabilization) onto 
liposomes membrane. Gaber et al.[139] also showed the release of doxorubicin from these described 
lipid compositions at three different temperatures (Figure 2.26). The release of doxorubicin in the 
panels from A to D is very low and it poorly increases by raising the temperature from 37˚ C to 42˚ C 
and 45˚ C, indicating that the presence of cholesterol reduces the drug release compare to liposomes 
without cholesterol. In fact, when vesicles are made of only phospholipids (DPPC and HSPC), a high 
release is detected at 45˚ C which corresponds to the phase transition temperature (panel A). As stated 
before, the optimal lipid composition is observed in the panel F that is similar to the thermo-sensitive 
liposomes synthetized for our purposes. Indeed, these liposomes when heated for 30min at 42˚ C or 
45˚ C leak out almost 50% of the loaded doxorubicin. Therefore, in order to have liposomes that are 
stable at 37˚ C but release their content at 42-45˚ C, the phospholipid composition should be prepared 
in such way to undergo a phase transition around 45˚ C.  
Hence, the OxPt release from thermo-sensitive liposomes when embedded within PEGDA hydrogels is 
in agreement with the findings reported in literature. Stealth liposomes instead are composed of 
DSPC/cholesterol/DSPE-PEG2kDa with molar ratios of 55/40/5. These liposomes are more stable than 
thermo-sensitive liposomes simply because formed by an abundant amount of DSPC which has a phase 
transition temperature at 58˚ C. Contrarily, DPPC, the main component of thermo-sensitive liposomes, 
presents a main transition temperature at 41˚ C and a pre-transition temperature at 34˚ C as described 
in Figure 2.27.[140] 
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Figure 2.26 Release kinetics in buffer of doxorubicin-loaded liposomes with different molar ratios of liposome components. 
Temperatures at 37˚ C, 42˚ C and 45˚ C are tested for release study. Figure reproduced from [139]. 
 
 
Figure 2.27 Table reported by Yelling et al[140] representing some phospholipids transition temperatures and enthalpy changes. 
 
Thus, the heat treatment of stealth liposomes at 40˚ C, that corresponds to the temperature at which 
thermo-sensitive liposomes release the highest concentration of drug, results on a stable state and a 
weak leakage (according to transition temperature of DPPC and DSPC in Figure 2.27). The lipid 
composition of liposomes affects also the stability of vesicles suspension since after their synthesis, 
liposomes naturally tend to aggregate and precipitate. The presence of cholesterol and PEG-grafted 
lipids together enhance liposome stability for a prolonged time. However, when drug-loaded liposomes 
are stored for extended periods a possible leakage may occur even without heat treatment. Therefore, 
the stability of both OxPt-loaded liposomes (thermo-sensitive and stealth) is evaluated over a period of 
100 days; in specific, 100µM OxPt-loaded liposomes are embedded within a hydrogel composed of 
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20%w/v PEGDA (700Da) and 0.5%w/v LAP cured for 1min. The entrapped liposomes are kept for 100 
days at 5˚ C and 22˚ C (room temperature) in a wet state (supernatant); aliquots are taken at different 
intervals and the amount of OxPt into supernatant is measured through ICP-MS. As expected, the 
leakage of thermo-sensitive and stealth liposomes embedded within PEGDA hydrogels at 5˚ C over a 
period of 100 days is very low (circa 10% of the total encapsulated drug). No relevant difference is 
observed for the two liposome stock suspensions (Figure 2.28A), meaning that liposomes are very 
stable for prolonged time when stored at 5˚ C. A diverse scenario is found when both liposome 
suspensions entrapped within gels are maintained at room temperature (22˚ C): the OxPt leakage is 
above 60% and this value seems to increase over time, while a lower but still large leakage is measured 
also from stealth liposomes (Figure 2.28B). The collected supernatants are also analyzed through 
dynamic light scattering (DLS) to evaluate the possible presence of liposomes into the supernatants by 
measuring the average diameter of aliquots. An average diameter of 4.6nm (polydispersity index 
=0.017) for thermo-sensitive liposomes and 4.14nm (polydispersity index = 0.035) are detected when 
the system is stored at 22˚ C. These values indicate that no liposomal vesicles are escaped from 
hydrogel network and that the oxaliplatin detected into supernatants is mainly due to leakage process. 
Taking into account all the obtained results, a given instability of vesicles over prolonged storage is 
observed; however, the suspensions can be kept in a stable state for long periods at 5˚ C with a loss of 
loaded compound of around 10%.  
 
 
Figure 2.28 Oxaliplatin leakage from stealth and thermo-sensitive liposomes embedded within 20%w/v PEGDA (700Da) and 
0.5%w/v LAP after 1min curing; the liposomes embedded within hydrogels are kept at 5˚ C (A) and 22˚ C (B) over a period of 
100 days. The content of released drug into supernatant is characterized by ICP-MS. 
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2.2.4 Digital drug dosing 
The release profiles of chemotherapeutics (SN-38, 5-FU, Oxaliplatin and Folinic acid) from PEGDA 
hydrogels (reported in Section 2.2.2) demonstrate the possibility to entrap within certain volumes of 
gel, specific concentration of compounds and completely release them into an aqueous compartment 
over a certain period (maximum in 24h). A rapid diffusion of oxaliplatin from the polymeric network is 
prevented by including OxPt-loaded nanoparticles into the gel and promoting drug release by applying 
heat treatment. As stated in the introduction of this thesis, the colorectal cancer chemotherapy is based 
on a combination of multiple drugs: FOLFOX (5-FU, Folinic acid and oxaliplatin) and FOLFIRI (5-FU, 
Folinic acid and Irinotecan). These drug combinations are thus embedded within hydrogels and their 
release and cytotoxicity are evaluated. A relevant question that could be interesting to answer is 
whether these drugs when entrapped together into the matrix are still stable and efficient. Further, 
how the concentration of embedded compounds can be controlled in order to reach the therapeutic 
doses after release? The simplest approach when the release profile of a certain compound is known 
consists of encapsulating a certain concentration of drug within the gel to release the desired 
therapeutical dose into the supernatant. In general this approach is the easiest way to proceed when 
the release profile of a certain compound is known. However, here a smart and reproducible method 
based on digital photo-polymerization and drug dosing processes is proposed. To give an idea of how 
the process works, two model molecules are considered: FITC-labeled albumin and Rhodamine-labeled 
albumin. As reported before, albumin is a medium size protein and its diffusion through PEGDA 
hydrogel has been optimized to guarantee a sustained release. Indeed, gels composed of 20%w/v 
PEGDA (700Da), 1%w/v PEGDA (5kDa) and 0.5%w/v LAP are employed for protein encapsulation. In 
a 96 well-microtiter plate, hydrogels of 6.2mm in diameter and 1mm in height are polymerized by 
visible-light exposure using a digital mask with a design made of three concentric circles (the same 
that has been adopted to create 3D-circle shaped hydrogels in the paragraph 2.2.1.5, Figure 2.19). 
These circles are prepared in such way that different combinations of hydrogel areas are produced and 
in each circle a different compound is embedded: FITC-albumin within the external circle, bare 
hydrogel in the middle, and Rhodamine-albumin within the internal circle. Figure 2.29A shows a 
schematic of the three concentric circles produced on the hydrogel and the molecules embedded: in 
orange the FITC-albumin gel, in light blue the bare hydrogel, and in magenta the Rho-albumin gel.  
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Figure 2.29 (A) Schematic of digital molecule dosing method. Three-circle shaped PEGDA hydrogels are used to embed two 
labeled compounds: 200µg/mL of FITC-albumin and Rhodamine-albumin both dissolved in PBS. Combinations of different areas 
of embedded FITC-albumin (in orange), Rhodamine-albumin (in magenta) and bare hydrogel (in light blue) are fabricated to 
determine the resulting molecules release. (B) The cumulative amounts of FITC-albumin and Rho-albumin into the supernatants 
after 48h of release are plotted as function of the area in which they were originally entrapped. The experiment is triplicated 
(mean ± SD, n=3). 
 
The final 3D circle shaped hydrogel is obtained through a multi-step process: first, a solution of FITC-
albumin, PEGDA (700Da and 5kDa) and LAP is cured for 1min using the corresponding digital mask 
(external circle, Ø =6.2mm); then the formed structure is washed and the second circle is fabricated 
polymerizing a PEGDA and LAP solution, and a Rho-albumin, PEGDA and LAP solution is cured to 
create a third structure. Since the thickness of these three structures is constant (1mm), only their area 
will change; the chosen hydrogel areas, as reported in the x and y axis of Figure 2.29A, correspond to 
10 – 30 – 100% of the total well area. The release of compounds entrapped within various areas is 
evaluated by collecting the supernatants over a period of 48h and measuring the UV-vis absorption of 
FITC and Rhodamine at 490nm and 540nm, respectively through a microplate reader (Figure 2.29B). 
As already mentioned earlier, normally when considering drug releasing systems one should increase 
the initial compound concentration to obtain a desired released amount on the basis of known release 
kinetic. With this method, the released concentration is controlled mainly by changing the area of 
hydrogel in which the compound is embedded; in other words, the number of molecules that are 
released into a supernatant is directly proportional to the area in which molecules are confined. 
Another benefit from this technology is that multiple compounds may be embedded in a hydrogel 
produced in a single well through a multi-step process, where each specimen is confined in a certain 
area. In order to test the cytotoxic effect of combinations of chemotherapeutics, the hydrogels are 
produced by entrapping multiple drugs within 3D-structured circles of the same area (10mm2) and 
thickness (1mm). In the following paragraph, these three-circle shaped hydrogels are used to test the 
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cytotoxicity effect of combined drugs that are released in cell culture media when human colorectal 
adenocarcinoma cells (HT29) are cultured onto the shaped gels. 
 
 
2.3 Drug screening of individual and combined free 
chemotherapeutics 
A preliminary study of the cytotoxic effect of SN-38, 5-FU, Oxaliplatin and Folinic acid (FA) as 
individual and combined treatment is conducted. Different concentrations of each drug are explored in 
order to test the inhibition degree on proliferation of human colorectal adenocarcinoma cell line 
(HT29) as function of drug doses. A simple illustration of the method used to evaluate drug cytotoxicity 
on HT29 is shown in Figure 2.30. 
 
Figure 2.30 Illustration of the approach adopted to evaluate free drug cytotoxicity on HT29 cell line. Cells are initially cultured 
at a concentration of 100 000 cells/mL on a 96 well-microtiter plate and after 24h growth, a certain concentration of drug is 
added to the medium. The drug dose effect is evaluated by measuring the cell viability after 48h from drug treatment. 
 
The protocol consists on culturing the HT29 cells in Dulbecco´s Modified Eagle Medium (DMEM) in a 
96 well-microtiter plate. A concentration of 100 000 cells/mL and kept in the incubator for 24h in 
order to allow cell adhesion on the well surface. Cells are then exposed to different concentrations of 
individual drugs (SN-38, 5-FU, Oxaliplatin and FA). These drugs are dissolved in dimethyl sulfoxide 
(DMSO) except for FA which is solubilized in water. It is well-known that organic solvents such as 
DMSO are cytotoxic (as also reported in Figure 2.31). Therefore, concentrated stock solutions of drugs 
are prepared in order to add the minimum volume of DMSO-solubilized drug and limit the solvent 
toxicity. In particular, 1µL of each concentrated drug solution is added to the adherent cells and 1µL of 
DMSO is used as control. The 96 well-microtiter plate is maintained in the incubator for 48h. To 
determine the cell viability after drug exposure, the commonly used [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay is performed. 
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Figure 2.31 Cytotoxic effect on HT29 proliferation of different concentrations (logarithmic scale) of dimethyl sulfoxide (DMSO) 
which is used to solubilize drugs. An increasing volume of solvent is added to 100 000 cells/mL and incubated for 48h. Cell 
viability is evaluated through MTS bioassay. 
 
The MTS substrate is bio-reduced into a colored and soluble formazan product only when 
metabolically active cells are present (Figure 2.32A). 
 
 
Figure 2.32 (A) Chemical reduction of MTS substrate into a formazan product; this conversion is achieved only when 
metabolically active cells are present and is therefore proportional to viable cells concentration. (B) Absorption spectra of a 
formazan solution which has a maximum absorption at 490nm, while the negative absorption at 382nm corresponds to the 
disappeared MTS compound. Figures reproduced from Promega CellTiter 96® AQueous Assay protocol. 
 
 
The absorbance spectrum of the formazan product resulting from reduction of the MTS tetrazolium 
compound shows a maximum absorbance at 490nm. The negative absorbance values correspond to 
the disappearance of MTS due to its conversion to formazan (Figure 2.32B). A microplate reader is 
used to measure the absorbance of each well at 490nm and the resulting coloration of the well will be 
proportional to the number of viable cells. Figure 2.33 shows the effect of different drug doses 
(logarithmic scale). In panel A, the SN-38 cytotoxicity is shown and a clear anti-proliferative effect is 
detected; already at a concentration of 0.5µM of SN-38 almost half of cell population is dead. A 
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different scenario is observed when folinic acid is added, since an increased cell viability results when 
FA doses in the range between 0.5-7.5µM are used (panel B).  
 
 
Figure 2.33 Cytotoxic effect induced by different doses of (A) SN-38, (B) folinic acid, (C) 5-FU and (D) oxaliplatin on 
proliferation of human colorectal adenocarcinoma cell line (HT29). In a 96 well-microtiter plate, 24h after seeding, different 
drug doses are added to adherent cells (100 000 cells/mL) and incubated for 48h. The MTS assay is used to evaluate cell 
viability. All the experiments are run three times and values are represented by mean and SD (n =3). On the bottom panel, phase 
contrast microscope pictures of HT29 cells incubated for 48h with free oxaliplatin are reported (E). The scale bar value 
corresponds to 50µm.  
 
The addition of 5-FU or Oxaliplatin to the seeded cells causes a detrimental cell death (panel C and D, 
respectively) comparable to that induced by SN-38 doses (panel A).  However, the cytotoxic effect 
provoked by SN-38 is two orders of magnitude more efficient than 5-FU or Oxaliplatin because a two-
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fold lower concentration produces a similar effect. In Figure 2.33E, phase contrast microscope images 
of HT29 cells incubated for 48h with 50µM and 100µM oxaliplatin are reported: when cells are 
exposed to the drug a morphology change is observed, including cell rounding, shrinkage, blebbing, 
lower cell density, an enlargement of cell bodies and abnormal cell morphologies. All these cell 
features suggest an apoptotic state of cells after drug exposure.  
Although the in vitro cytotoxicity of individual therapy on cell viability is significant, except for folinic 
acid that seems to have a pro-proliferative effect, many studies reported in literature and from FDA 
approvals demonstrate a higher anti-proliferative effect when these drugs are used in a combined 
therapy. Thus, the cytotoxic effect of combined therapeutics is also measured on HT29 cell line. 
 
 
Figure 2.34 Cytotoxic effect of drug combination therapy on proliferation of human colorectal adenocarcinoma cell line (HT29). 
Cells (100 000 cells/mL) cultured for 24h in a 96 well-microtiter plate, are exposed to chemotherapeutics for 48h. (A) 5-FU 
therapy potentiated by the addition of FA at two different concentrations (2.96µM and 7.41µM); (B) OxPt therapy in association 
with 5-FU (5µM) and FA(7.41µM); (C) the SN-38 cytotoxicity is further augmented by the addition of 5-FU (5µM) and FA 
(7.41µM). Cell viability is evaluated through MTS assay measuring the absorbance at 490nm. Values are represented by mean 
and SD (n =3). 
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In Figure 2.34, all combined drug treatments are reported: in panel A, the 5-FU toxicity (black line) is 
enhanced when FA is added (red line, 2.96µM and blue line, 7.41µM, respectively) by decreasing cell 
viability down to 20%; in panel B, the combination of oxaliplatin and 5-FU demonstrates a strong anti-
proliferative effect (red line). In fact, when 5µM 5-FU is combined together with oxaliplatin, a decrease 
of 40% viability is caused already at 0.01µM oxaliplatin dose. This cytotoxic behavior is additionally 
potentiated when FA is combined to OxPt and 5-FU (blue line). A similar outcome is observed for SN-
38 therapy (panel C) where doses in the range of nano-molarity induce a further reduction of cell 
viability. As expected, all combined treatments have a detrimental effect on cell viability and the role of 
folinic acid is relevant only when associated to the other drugs. Due to its vitamin activity, the folinic 
acid itself does not induce toxicity because it possesses a vitamin activity;[141] whereas when used as 
adjuvant in chemotherapy against colorectal cancer it prolongs the bioavailability of 5-FU and enhance 
thymidylate synthase inhibition (more details about FA and 5-FU interaction can be found in Chapter 
I). 
The effect of FOLFOX and FOLFIRI chemotherapy (blue lines in Figure 2.34b and c, respectively) has 
been validated for the selected cell line (HT29) and the results are totally in agreement with those 
found for the same and other colorectal cancer cell lines.[92] The main challenge is to evaluate whether 
these drug combinations are able to induce a similar cytotoxic effect when embedded within PEGDA 
hydrogels. In particular, the FOLFOX and FOLFIRI compounds are entrapped within three-circle 
shaped hydrogel 3D-structures and the toxic effect of released drugs on HT29 cells cultured onto the 
hydrogel surface will be determined. 
 
2.4 Cytotoxic effect of triggered OxPt-loaded liposomes 
So far, the release profile of oxaliplatin from PEGDA hydrogel has shown a rapid diffusion of OxPt 
through the matrix and a waste of drug during the washing process. Hence, the cytotoxicity induced by 
embedded oxaliplatin will be lower than that expected because of drug loss. This issue, as previously 
reported, can be circumvented using oxaliplatin-loaded liposomes which protect the drug during the 
manipulation of hydrogels and discourage OxPt waste. The cytotoxicity of OxPt-loaded thermo-
sensitive and stealth liposomes must be also assessed. In particular, stealth liposomes are used as 
negative control, meaning that from their heat treatment at 40 ˚ C no release of oxaliplatin should be 
induced, thus no effect on cell viability is expected. In Figure 2.35, the characterization of liposomes 
effect on proliferating HT29 cells is described: in panel A, a schematic illustration of the procedure 
adopted to test liposomes toxicity is shown. Briefly, different concentrations of OxPt-loaded liposomes 
are added to the medium and heated up at 40˚ C for 1h in a thermo-block in sterile conditions.  
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Figure 2.35 Cytotoxic effect induced by thermal triggering of thermo-sensitive and stealth OxPt-loaded liposomes. (A) 
Illustration of the procedure adopted to evaluate liposomes effect on proliferating HT29 cell line. (B) Cytotoxicity induced by 
different doses of stealth OxPt-loaded liposomes (negative control) and thermo-sensitive OxPt-loaded liposomes with and 
without heat exposure prior cells seeding. A concentration of 100 000 cells/mL is incubated in each 96-well and cells are 
exposed to liposomes for 48h under culture conditions. The MTS assay is used to evaluate cell viability. Values are represented 
by mean and SD (n =3). (C) Phase contrast microscope images of cells exposed for 48h to various liposomes suspensions at the 
same OxPt dose (50µM) (the scale bars correspond to 20µm). 
 
 
For negative control, the same concentrations of liposomes in the medium are incubated at 37˚ C for 1h 
in order to evaluate also the effect of leakage when cells and liposomes are maintained under culture 
conditions. After heat treatment of stealth and thermo-sensitive liposomes, they are cool down at room 
temperature and a concentration of 100 000 cells/mL is seeded in each 96-well. HT29 cells are 
exposed to thermal un-triggered and triggered stealth and thermo-sensitive liposomes for 48h, and cell 
viability is evaluated through MTS assay. In Figure 2.35B, the cytotoxic effect of different doses of OxPt-
loaded liposomes is reported: stealth liposomes (negative control) show a similar cytotoxicity when 
triggered and un-triggered (in Figure 2.35B, open red circles and filled red circles, respectively), 
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meaning that the lipid composition of stealth liposomes prevents oxaliplatin leakage even upon heat 
treatment. However, as the concentration of liposomes increases a significant cell death is observed. A 
different scenario appears when various doses of thermo-sensitive liposomes are added to cells: un-
triggered OxPt-loaded thermo-sensitive liposomes induce a toxic effect similar to that caused by 
stealth nanoparticles (filled black squares), while triggered thermo-sensitive liposomes produce a 
significant cytotoxicity with about 100% cell death when 75µM of OxPt-loaded liposomes are used 
(open black squares).  
These results are also confirmed by the phase contrast microscopy in panel C where a clear apoptotic 
effect is induced by thermo-sensitive OxPt-loaded liposomes after their heat triggering.  
The heat treatment of drug-loaded liposomes successfully induces the release of oxaliplatin. The toxic 
effect caused by un-triggered liposomes is mainly ascribed to partial lipid toxicity; an improvement 
may be made by synthetizing liposomes with a higher concentration of loaded drug. In that way, the 
same anti-proliferative effect due to the drug can be achieved by using a lower volume of vesicles 
suspension, therefore a smaller number of nanoparticles. 
 
 
2.5 Three-circle shaped PEGDA hydrogels for combined-drug 
release 
In the light of the results showed above, the toxicity of FOLFOX and FOLFIRI is also determined when 
drug combinations are embedded within three-circle shaped PEGDA hydrogels. Firstly, the effect of 
bare PEGDA hydrogels resulting from visible-light polymerization of various concentrations of PEGDA 
(700Da) and LAP is tested. In a 96 well-microtiter plate, different mixtures of PEGDA (700Da) and LAP 
are crosslinked for 1min without digital mask in order to obtain cylindrical gels of 6.2mm in diameter 
and 1mm in thickness. The gels are washed extensively to remove un-reacted precursors and a 
concentration of 100 000 cells/mL is seeded onto the surface of each gel. HT29 cells are incubated for 
48h onto polymeric networks and their viability is evaluated by MTS bio-assay.  
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Figure 2.36 Cell bio-compatibility of PEGDA hydrogels on HT29 proliferation. Gels are produced by exposing the precursor 
solutions to visible-light for 1min without digital mask, thus cylindrical networks are formed (Ø =6.2mm; thickness =1mm). All 
the solutions are illuminated to visible light even though one of the reagents, LAP or PEGDA, is missing. After hydrogel 
fabrication, a concentration of 100 000cells/mL is seeded onto gel surface and incubated for 48h; cell viability is evaluated 
through MTS bio-assay. The experiment is repeated three times and the values are represented by mean and SD (n =3). 
 
 
As reported in Figure 2.36, different concentrations of PEGDA (700Da) without photoinitiator solution 
are illuminated with visible-light, and they induce equal toxicities due to the acrylate groups which are 
known to be cytotoxic.[32] Solutions of LAP exposed to visible-light in absence of polymeric monomers 
cause a decrease of cell viability proportional to photoinitiator concentration. When PEGDA and LAP 
solutions are mixed and exposed for 1min to projector light, cell viabilities are found to be in the range 
between 80%-95% suggesting a good bio-compatibility of PEGDA and LAP when in a hydrogel state. 
Also notable is that when the concentration of LAP is increasing while PEGDA concentration is 
constant, a higher cell viability is measured. As the photoinitiator amount increases, the number of un-
reacted acrylate groups is reduced whereas more covalent monomer interactions are formed. On the 
basis of these results and the characterized drug release kinetics, the concentrations that are selected 
for the fabrication of three-circle shaped gels are 20%w/v PEGDA (700Da) and 0.5%w/v LAP with the 
addition of 1%w/v PEGDA (5kDa) for the entrapment of SN-38. In the light of that, the toxicity induced 
by free drugs in the medium is compared to the anti-proliferative effect caused by combinations of 
drugs embedded within shaped hydrogels. FOLFOX and FOLFIRI therapeutics are therefore embedded 
within PEGDA hydrogels using three-circle shaped structures which are fabricated through a multi-
step process, as previously described. In Figure 2.37A, the combination and dose of drugs, the area and 
radius of each circle, and the hydrogel composition for each formed circle are reported. These values 
are chosen in agreement with our previously described findings, in particular considering the release 
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profiles of drugs from un-structured PEGDA hydrogels and the HT29 cells response when exposed to 
individual and combined drugs. The final gel structure is thus composed of three hydrogel circles 
containing each of them a drug. The gels are produced in a 96 well-microtiter plate and during the 
fabrication for every polymerization step, an extensive washing is conducted. The 3D drug-embedded 
hydrogel has a total diameter of 6.2mm and a thickness of 1mm. HT29 are then seeded onto the surface 
of each polymeric system at a concentration of 100 000cells/mL, and cells are exposed to the releasing 
platforms for 48h (illustration in Figure 2.37B). The viability of HT29 is then determined though MTS 
assay (Figure 2.37C). As expected, the empty structured hydrogel has a cytotoxic effect comparable to 
that observed from un-structured gel (Figure 2.36), while the cytotoxic effect induced by embedded 
OxPt/5-FU/FA (FOLFOX) is less pronounced than the toxicity caused by the free drugs (Figure 2.34b). 
On the contrary, the cell death resulting from the treatment of embedded SN-38/5-FU/FA (FOLFIRI) is 
remarkable and similar to that induced by free drugs (Figure 2.34c). The poor potency of embedded 
OxPt/5-FU/FA is mainly determined by the loss of oxaliplatin during the washing step, thereby a 
partial effect of its toxicity is measured together with 5-FU/FA. According to the release profiles 
showed in Figure 2.23, a complete passive release of SN-38, 5-FU and FA is obtained after 24h; cells are 
therefore exposed to drugs for the entire period of incubation. The embedding of drugs (SN-38, 5-FU 
and FA) and OxPt-loaded liposomes is also conducted by using three-circle shaped PEGDA hydrogels in 
which combinations of drugs and liposomes are employed. In Figure 2.37A, the parameters considered 
for the embedding process are reported. Each drug or liposome formulations is entrapped within a 
certain circle structure, washing each structure after gel polymerization, and then the platform is 
heated up at 40˚ C for 1h in sterile conditions. OxPt and the other drugs will diffuse in the medium and 
HT29 cells are seeded onto hydrogel surface at a concentration of 100 000cells/mL just after cooling 
down the sample from 40˚ C to room temperature. The system is incubated for 48h and cell viability is 
measured. 
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Figure 2.37 Cytotoxicity induced by passive release of combinations of drugs embedded within three-circle shaped PEGDA 
hydrogels produced in a 96 well-microtiter plate with a multi-step fabrication process. (A) The table summarizes the drug 
combinations, drug concentrations, area and radius of each circle structure and hydrogel composition that are employed to 
evaluate multi-drug release system toxicity. (B) Schematic of the procedure adopted to test HT29 viability onto hydrogel 
surfaces. 3D circle shaped PEGDA hydrogels are fabricated, washed and a concentration of 100 000cells/mL is seeded onto the 
surface of the gel. After 48h of incubation, cell viability is evaluated through MTS assay. (C) Comparison of cell anti-proliferative 
activity induced by combinations of free drugs (dispersed in the medium) and embedded compounds; the growth of cells onto 
the surface of empty hydrogel is also presented (mean ± SD, n=3).  
 
The combinations of OxPt-loaded liposomes with 5-FU and FA are tested for both stealth and thermo-
sensitive liposomes when exposed and not exposed to a thermal trigger (Figure 2.38B). The toxicity 
induced by un-triggered liposomes/5-FU/FA is around 50% for thermo-sensitive liposomes and 60% 
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for un-triggered stealth liposomes; here a cell viability decrease results from the effect of 5-FU and FA. 
When liposomes are heated at 40˚ C, a different situation is observed: stealth liposomes/5-FU/FA 
cause a comparable cell death when in triggered and un-triggered state, while thermo-sensitive 
liposomes/5-FU/FA heated up produce a consistent reduction of cell proliferation that is higher than 
that induced by combined free drugs.  
 
 
Figure 2.38 Cytotoxicity induced by the combinations of embedded free drugs and liposomes (OxPt-loaded liposomes/5-
FU/FA). (A) Illustration of the procedure utilized for liposomes leakage and cell drug exposure. (B) The HT29 anti-proliferative 
activity induced by passively released drugs upon heat treatment and without triggering is measured. 
 
The use of drug-loaded liposomes is a great tool to prevent the fast diffusion of oxaliplatin from the 
polymeric matrix, and the combined effect of drugs can be detected when HT29 cells are cultured 
together with the hydrogel releasing systems. These results are important not only because a cytotoxic 
effect is reached after passive release, but especially because the drug releases are temporally 
controlled and tuned according to the hydrogel and drug properties. 
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2.6 Conclusion 
The nano-technology platform presented here offers the possibility to overcome some of the 
limitations characterizing the existing drug screening approaches. Usually, the application of drug 
screening assays requires high doses of drugs and small volumes of tumor tissues. Moreover, the need 
of new drugs for the treatment of many pathological diseases is gradually increasing. The major 
benefits of using this technology is the possibility to modulate the desired concentration of released 
compounds by varying the volume of the hydrogel in which they are embedded, and to study the 
combined cytotoxic effect of multiple FDA-approved drugs.  
The use of PEGDA as biomaterial for the evaluation of individual and combined drug treatment on 
cancer cell lines is very useful. A smart method for PEGDA hydrogel fabrication has been explored and 
optimized in order to match the features necessary for drug screening purposes and to create a 
miniaturized platform. The choice of an appropriate photoinitiator compound, light source and 
polymerization conditions are crucial parameters to ensure a spatial and temporal control of releasing 
molecules. The visible-light photopolymerization of hydrogels ensures the fabrication of homogeneous, 
reproducible and structured gels at a small scale with a low-cost and rapid process. The use of 
projector light as photo-crosslinking source with an emitting light centered at 410nm together with an 
initiator absorbing in this wavelength range (LAP), allow the encapsulation of molecules within 
hydrogels reducing the fabrication time and controlling the initial embedded concentration of 
molecules. Moreover, digital masks which consist of graphics files are designed to selectively 
polymerize certain volumes of precursor solution in a short time (from few seconds to few minutes 
depending on the solution height). The release kinetics of several molecule types has been explored: 
compounds having various molecular weights and chemical-physical properties have been studied. 
Thereby, the chemical and physical features of PEGDA hydrogels were tuned to control the compounds 
release profile. Two main approaches were explored to limit or augment molecules passive release: the 
introduction of long PEG chains within PEGDA network resulted on an accelerated SN-38 release, 
otherwise slowly diffusing due to its hydrophobicity. On the other hand, a rapid passive diffusion of 
oxaliplatin was avoided by encapsulating the drug into nanoparticles (liposomes). These nano-vesicles 
not only protect drug from the environment and from its elimination through washing step, but also 
permitted to temporally control the oxaliplatin release. In particular, thermo-sensitive OxPt-loaded 
liposomes have been used for this purpose, thus the application of a thermal trigger provokes drug 
release from vesicles. Finally, the cytotoxicity on human colorectal adenocarcinoma cell line (HT29) 
caused by the release of combined drugs entrapped within PEGDA hydrogels was evaluated.   
Ideally, once the compounds of interest are embedded within desired polymer structures, the entire 
platform (such as a 96 well-microtiter plate) may be stored in a humidified environment until needed 
and a specific cell line may be seeded onto pre-fabricated drug-loaded hydrogels to evaluate 
92 
 
 
 
chemotherapeutic effect. The use of PEGDA hydrogels to passively release different and multiple 
molecules represents a smart designed platform for drug screening purposes. 
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2.7 Experimental section 
Fabrication of PEGDA hydrogels using IrgaCure 2959 photoinitiator 
The fabrication of PEGDA hydrogels performed through photopolymerization was optimized by 
evaluating different parameters: polymer concentration, I2959 concentration, exposure time to UV-
light and volume of pre-polymer solution. Poly(ethylene glycol) diacrylate (PEGDA) with an average Mn 
700Da and IrgaCure 2959 (1-[4-(2-Hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one) 
MW=224.25g/mol were purchased from Sigma Aldrich (Brøndby, Denmark). For light exposure of pre-
polymer solutions, a custom built photo reactor with a broad illumination maximum from 330–380 nm 
(Philips Cleo S-R fluorescent tubes) was utilized: it is composed of a large chamber presenting UV-
lamps on the top and bottom sides, and a transparent support where the sample is located. In that way, 
the crosslinking process should be homogeneous on both solution interfaces. A stock solution of 
80%w/v PEGDA700Da was dissolved in milliQ water and a stock solution of 10%w/v I2959 was 
prepared by dissolving it in acetone/milliQ water (volume ratio 1:1). In a 24-well microtiter plate 
(Nunc, Thermo Scientific, Roskilde, Denmark) different combinations of PEGDA and I2959 
concentrations were tested: 15 – 20 – 25 – 30%w/v PEGDA and 0.1 – 0.5 – 1 – 2%w/v I2959 for a total 
volume of 300µL. The well plate was exposed to UV-light in the photo-reactor for 60min (32 J/cm2) 
including a reservoir of water to limit evaporation, and the formed hydrogels were washed extensively 
(30min) with milliQ water. The UV-vis absorption of different concentrations of IrgaCure2959 
dissolved in acetone/milliQ water (1:1) was measured using a Nanodrop spectrophotometer (model 
2000c, Thermo Scientific) without exposing the solutions to UV-light. A quartz cuvette (Fisher 
Scientific, Thermo Fisher Scientific, Germany) was used to collect the UV-vis spectra of I2959 in the 
range of 300-500nm. 
 
Fabrication of PEGDA hydrogels with different PEG chain lengths using IrgaCure 2959 photoinitiator 
PEGDA hydrogels were produced also by adding longer PEG chain lengths to the main component 
PEGDA700Da: stock solutions of 40%w/v PEGDA Mn=1kDa, 5%w/v PEGDA Mn=5kDa and 10%w/v 
PEGDA Mn=6kDa (all obtained from Iris Biotech) were dissolved in milliQ water. In a 24 well-
microtiter plate, various combinations of PEGDA concentrations were mixed to a 1%w/v IrgaCure 
2959 dissolved in acetone/milliQ water (1:1). The tested amounts of each PEGDA solution were: 15, 
20, 25, 30%w/v of PEGDA700Da, 1 – 5%w/v of PEGDA1kDa, 0.5 – 1%w/v of PEGDA5kDa and 1 – 2%w/v of 
PEGDA6kDa. A total volume of 300µL of polymer-photoinitiator mixture was poured in each well and 
exposed to UV-light for 1 hour in a photo-reactor. Then hydrogels were washed for 30min with milliQ 
water. 
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Fabrication of 3D-structured PEGDA hydrogels defined by static mask motifs 
The patternability of PEGDA hydrogels was evaluated creating 3D structures on solutions made of 
PEGDA700Da, I2959 and a fluorescent dye, fluorescein. Stock solutions of 80%w/v PEGDA700Da dissolved 
in milliQ water, 10%w/v I2959 dissolved in acetone/milliQ water (1:1) and a solution of 100µM 
fluorescein sodium salt dissolved in milliQ water (MW= 376.27 g/mol, obtained from Sigma Aldrich, 
Brøndby, Denmark) were prepared. Different concentrations of PEGDA and I2959 were tested: 20, 25, 
30%w/v PEGDA and 0.5, 1, 2%w/v IrgaCure 2959. For polymerization process, a GeneFrame® with a 
dimension of 1.5 x 1.5 cm (obtained from Thermo Scientific, Waltham, Massachusetts), was stuck in a 
glass slide. Then 200µL of PEGDA/I2959/10µM fluorescein mixture was poured within the frame and a 
coverslip was placed onto the gene frame to squeeze the solution within the cavity. Exposure 
proceeded using 365nm light at ~6mW/cm2 in a mask aligner (Karl Süss MA4, Munich, Germany) used 
together with a chrome-on-glass photo-mask. Two different chrome masks were employed: one of 
them consisted of square grids of different dimensions and spacing, and the other mask was made up 
of dual sets of interdigitated electrodes 200µm wide, 3.5mm long and with 200µm spacing. The gene 
frame was exposed for 10min to UV-light in the aligner to reach a dose of 4 J/cm and using a 
photomask; the obtained structures were washed several times with MQ water to remove un-exposed 
compounds. To visualize the structures, the samples were rinsed with water and sealed with a glass 
cover slip; then, confocal laser scanning microscopy (LSM700, Zeiss, Germany) was used to analyze the 
3D structures resolution (excitation light at 488nm and collecting the fluorescence at wavelengths 
longer than 505nm). 
 
Embedding of SN38 drug within PEGDA gels 
To evaluate the release kinetics of small molecules from PEGDA hydrogels, SN38 (obtained from Sigma 
Aldrich, Brøndby, Denmark) was chosen as model molecule. In a 24-well microtiter plate, a constant 
concentration of SN38 dissolved in DMSO (100µM) was mixed with various amounts of PEGDA700Da 
dissolved in milliQ water (at a concentration of 15, 20, 25, 30%w/v) and I2959 dissolved in 
acetone/milliQ water (1:1) (at a concentration of 0.4, 0.6, 0.8, 1%w/v) for a total volume of 300µL. The 
well plate was exposed to UV-light in the photo-reactor for 1 hour to obtain gels with a thickness of 
1.5mm and they were extensively washed with milliQ water. Then, 600µL of milliQ water was added to 
each well as supernatant volume in which the molecules of drug were passively released and collected 
over a period of 24 hours. The supernatants were characterized by UV-vis spectrophotometry 
(Nanodrop 2000c, Thermo Scientific) using a quartz cuvette and acquiring the spectra between 300-
500nm.  
 
95 
 
 
 
Photo-polymerization of PEGDA solutions with LAP initiator 
According to the discussed features of I2959 in Chapter II, an alternative photo-initiator (lithium 
acylphosphinate salt, LAP kindly provided by Dr. Esben Larsen and Dr. Sergey Chernyy) was tested for 
the fabrication of PEGDA hydrogels. Stock solutions of 80%w/v PEGDA700Da and 2%w/v LAP both 
dissolved in MQ water were prepared and in a 24 well-microtiter plate various amounts of them were 
tested: 0.1, 1, 5,  10, 20, 30%w/v PEGDA700Da and 0.01, 0.05, 0.1, 0.5, 1, 2%w/v of LAP. A total volume of 
300µL of pre-polymer solutions were exposed to UV-light using the photo-reactor for 10min. Already 
after 2min completely cured gels were formed. The obtained gels were washed in water and analyzed 
through spectrophotometry. Gels were transferred into a cuvette in such way that they were adhering 
to the cuvette wall and their spectra were acquired between 300-500nm in water.  
 
Apparatus used for visible-light photo-polymerization 
Among the available methods described in Chapter II to photo-polymerize hydrogels (photo-reactor or 
a conventional aligner), the gels were crosslinked with the photo-initiator LAP using a visible-light 
emitting system. In detail, an EnvisionTEC Perfactory® Micro 3D-printer (Gladbeck, Germany) was 
utilized for in situ visible-light photopolymerization. The equipment is composed of a projector 
modified to have a maximum emitting light centered at 410nm (Direct Light Projection technology 
from Texas Instruments®, based on a LED light source); a stage where the sample is located; a light-
protected box which is moved during the polymerization process to protect the sample from external 
light; and a computer connected to the machine. A home-made support to exactly locate 96 well-
microtiter plates on the stage was used to simultaneously polymerize 12 wells in a single step. When 
the sample was placed on the support, the polymerization started as the projector light coming from 
the bottom of the sample was turned on and all the exposed volume of pre-polymer solution was cured 
within 30-60s to form a homogeneous gel. In addition, any desired structure was easily produced in 
each well: digital masks were designed and directly projected onto the sample. These digital masks 
consisted of a graphical picture (.png file) with a dimension of 1024 x 768 pixels drawn in a greyscale. 
When the desired picture was projected on the bottom of the sample, it was crosslinked on the basis of 
the mask greyscale. In other words, the resulting thickness of the gel was higher in the areas 
corresponding to a white mask and it decreased according to the grayscale of the mask, until 
completely black mask corresponded to no cured solutions. Therefore, by simply designing such digital 
masks was possible to tune the light intensity across the pre-polymer solution and define the final 
thickness of the gel. 
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Characterization of hydrogel morphology and thickness 
To evaluate the efficiency of light projection to create 3D structures on pre-polymer solutions, different 
digital masks were designed according to the final application of the hydrogel. A preliminary test to 
determine the final morphology and thickness of gels was conducted. In a 96-well microtiter plate, 
200µL of 20%w/v PEGDA (700Da) and 0.5%w/v LAP both dissolved in MQ water were exposed for 
1min to two different digital masks: one consisted of a semi-circle (half white and half black, Figure 
2.39A), and the other was a white circle (Figure 2.39B). The dimension of each picture was 1024 x 768 
pixels, and the diameter of the circles was drawn to completely cover the area of a 96 well- microtiter 
plate (Ø = 6.2mm).  
 
Figure 2.39 Two examples of digital masks drawn with CorelDraw X3 (.png files). (A) A semi-circle structure in which only half 
of the circle was projected, thus the corresponding pre-polymer solution was crosslinked only in correspondence of the white 
area. (B) A white circle was used to polymerize the entire volume of PEGDA/LAP since the diameter corresponds to the 96-well 
area. 
 
When the solutions were exposed to visible-light for 1min, a corresponding hydrogel structure was 
obtained and its thickness was evaluated. Solutions of 20%w/v PEGDA700Da and 0.5%w/v LAP 
dissolved in MQ water were exposed to projected light through the semi-circle shaped digital mask to 
determine their thickness. In a 24 well-microtiter plate, different volumes of mixture (300, 350, 400, 
450, 500, 600µL) were exposed to the half circle digital mask for various exposure times (15s, 30s, 60s, 
2min, 5min, 10min and 20min). The thickness of the obtained gels was then analyzed and plotted as 
function of initial volume of pre-polymer solution and exposure time. 
 
Hydrogel de-hydration and hydration processes 
Swelling of the polymer network influences the ability of a hydrogel to release molecules embedded 
within its matrix. A study of the de-hydration (loss of water content) and hydration (uptake of water 
content) processes was conducted by using different amounts of PEGDA700Da and LAP. Stock solutions 
of 80%w/v PEGDA700Da and 2%w/v LAP both dissolved in MQ water were prepared. In a Petri dish 
with diameter of 3.4cm, 2mL of various PEGDA/LAP concentrations were poured and crosslinked for 
1min with projected light without using any digital mask; thus, the entire solution volume was cured 
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obtaining a final thickness of 2.2mm. The weights of empty Petri dish, pre-polymer solution-Petri dish, 
and hydrogel-Petri dish were measured. The water exchange through the gels was determined 
studying the de-hydration and hydration processes. For the de-hydration mechanism, the crosslinked 
hydrogels in the Petri dishes free of lid were incubated in the oven in dehumidified atmosphere at 60˚ 
C over time, and every certain interval their weight was measured. After 19 hours of water loss from 
films, a box containing water was located inside the oven which was always maintained at 60 ˚C over 
time, and the gels hydration was estimated again by measuring the weight of samples. 
 
Embedding of various compounds within PEGDA hydrogels 
The release kinetics of different molecules in terms of size and chemical properties from PEGDA 
hydrogel were characterized. The hydrogels were all produced in a 96 well-microtiter plate by pouring 
a volume of 60 µL of pre-polymer solution together with a certain concentration of targeted molecule; 
the volumes were crosslinked for 1 min by visible-light exposure without using any digital mask and 
gels with a final diameter of 6.2 mm and thickness of 1mm were obtained. The hydrogels were washed 
with MQ water for 30 min and 240 µL of supernatant were added into the well. Stock solutions of 
80%w/v PEGDA700Da, 40%w/v PEGDA5kDa, 2%w/v LAP all dissolved in MQ water were prepared. In 
specific, the pre-polymer mixtures for releasing studies were prepared as follows: 
 Embedding of calcein within hydrogels: calcein disodium salt (MW =666.50g/mol) was 
purchased from Sigma Aldrich (Brøndby, Denmark). A solution of PEGDA700Da, LAP and calcein 
was prepared to have a final concentration of 20%w/v, 0.5%w/v and 50µM, respectively. In a 
12 well plate, 500µL of this mixture were poured; in a 24 well plate, 290µL; in a 48 well plate, 
165µL; and in a 96 well plate, 60µL. The volumes of pre-polymer solution in various well 
plates had the same height but different area. The calcein absorbance was recorded through 
Nanodrop by measuring the supernatants at 495nm. 
 Embedding of SN-38 within hydrogels: 60µL of a solution composed of 20%w/v PEGDA700Da, 
(0.1, or 0.5, or 1, or 1.5%w/v) PEGDA5kDa, 0.5%w/v LAP and 200µM SN-38 were poured into a 
96 well-microtiter plate and after a washing step, 240µL of supernatant were added onto the 
hydrogel surface. For UV-vis detection of SN-38, the absorbance of collected supernatants was 
measured at 374nm. 
 Embedding of FITC-albumin within hydrogels: albumin from bovine serum (BSA) conjugated 
to FITC (MW~66kDa, dissolved in PBS) was obtained from Life Technologies, Thermo Fisher 
Scientific, Naerum, Denmark. A solution of PEGDA700Da, PEGDA5kDa, LAP and FITC-albumin was 
prepared to have a final concentration of 20%w/v, 1%w/v, 0.5%w/v and 5µM, respectively. In 
a 96 well-plate, 60µL of the mixture were crosslinked to form the gel and after washing, 240µL 
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of supernatant (PBS) were added to collect the released molecules into it. For the UV-vis 
detection of molecules into collected supernatants, the absorbance was measured at 495nm. 
 Embedding of 5-fluorouracil (5-FU) within PEGDA hydrogels: 5-fluorouracil (MW 
=130.1g/mol, dissolved in DMSO) was obtained from Sigma Aldrich, Brøndby, Denmark. A 
solution of PEGDA700Da, LAP and 5-FU was prepared to obtain a final concentration of 20%w/v, 
0.5%w/v and 1mM, respectively. 60µL of the mixture were cured and after washing a 
supernatant was added (240µL). For UV-vis detection of 5-FU into collected supernatants, the 
absorbance was measured at 288nm. 
 Embedding of Folinic acid (FA) within PEGDA hydrogels: folinic acid calcium salt hydrate (MW 
=511.5g/mol, dissolved in DMSO) was obtained from Sigma Aldrich, Brøndby, Denmark. 
Solutions of PEGDA700Da, LAP and FA were mixed to obtain a final concentration of 20%w/v, 
0.5%w/v and 200µM, respectively. 60µL of the mixture were cured and after washing a 
supernatant was added (240µL). For UV-vis detection of FA into collected supernatants, the 
absorbance was measured at 300nm. 
 Embedding of Oxaliplatin (OxPt) within PEGDA hydrogels: oxaliplatin (MW =397.3g/mol, 
dissolved in DMSO) was obtained from Lianyungang Guiyuan Chempharm Co. LTD, Jiangsu, 
China. A solution of PEGDA700Da, LAP and OxPt was prepared to obtain a final concentration of 
20%w/v, 0.5%w/v and 200µM, respectively. 60µL of the mixture were cured and after 
washing a supernatant was added (240µL). For quantification of oxaliplatin into collected 
supernatants, the UV-vis characterization was not used since the compound does not absorb 
in the UV-vis range. Therefore, mass spectrometry ICP-MS, ICAOq, Thermo Scientific, 
Hvidovre, Denmark, was used to evaluate the concentration of OxPt released. 25µL of 
supernatant was added to 2.5mL of a solution of Iridium in phosphate buffer as internal 
standard.  
 
Characterization of thermo-sensitive OxPt-loaded liposomes and their embedding within PEGDA 
hydrogels 
Two different compositions of Oxaliplatin-loaded liposomes were synthesized by Dr. Fredrik Melander 
(the detailed procedure is reported in the Experimental section of the manuscript in Appendix 1) and 
characterized through ICP-MS and DLS (Thermo Scientific and Brookhaven Instruments Corporation, 
respectively). The ability of thermo-sensitive liposomes to release their content, oxaliplatin, after 
thermal trigger was evaluated by entrapping 100µM OxPt-loaded liposomes (thermo-sensitive) within 
gels composed of 20%w/v PEGDA700Da and 0.5%w/v LAP both dissolved in PBS. The hydrogels were 
formed in a 96 well-microtiter plate by visible-light exposure (1 min) of 60µL mixture. Then gels were 
extensively washed with PBS and a supernatant of 240µL was added to each gel. The samples were 
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heated up at different temperatures for 1h in a thermo-block hotplate keeping the plate sealed during 
the process. The supernatants were then collected and analyzed through ICP-MS to evaluate the 
content of OxPt released during thermal triggering. The same procedure was adopted to determine the 
period of heat exposure needed to obtain the maximum amount released of OxPt; therefore, the 
hydrogels were heated up at different times for a maximum of 24h at which it corresponded the 
highest drug release (almost 100%). The stability of liposomes when embedded within gels for 
prolonged periods was also characterized. 100µM of OxPt-loaded liposomes were embedded within 
20%w/v PEGDA700Da and 0.5%w/v LAP, both dissolved in PBS, by exposing 200µL of mixture to 
visible-light for 1min in a 24 well-microtiter plate. The gels were then washed with PBS and 400µL of 
PBS were added to each sample as supernatant. Both OxPt-loaded liposomes stock suspensions were 
tested: thermo-sensitive and stealth. Four different 24-well plates were prepared: two containing 
stealth liposomes within the hydrogels, and the other two presenting thermo-sensitive liposomes 
within gels. Then, one plate of each type of liposome suspension was kept at 5˚ C and at 22˚ C. The 
supernatants were collected at different intervals for a total of 100 days by replacing the supernatant 
with equal volumes of fresh PBS. The amount of OxPt released into supernatants was evaluated 
through ICP-MS using an Iridium solution as internal standard (2.5mL of Iridium solution + 25µL 
supernatant), and via DLS (1.5mL PBS + 15µL supernatant).  
 
Digital molecule dosing 
The use of visible-light photopolymerization technology was applied for the confinement of multiple 
compounds within different hydrogel areas. With this method we wanted to prove that to achieve a 
desired concentration of released compound, it was possible to vary the area of the hydrogel in which 
it was embedded, rather than increase the initial molecule concentration. For that reason, a solution of 
FITC-albumin (200µg/mL) and Rhodamine-albumin (200µg/mL, obtained from Life Technologies, 
Thermo Fisher Scientific, Naerum, Denmark) both dissolved in PBS buffer were prepared and 
embedded within gels. For the fabrication of hydrogels a digital mask composed of three circles was 
employed: an external ring structure (radius1 =3.1mm; area ring1 =10mm2; thickness =1mm) was 
produced illuminating for 1min a solution of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa), 
0.5%w/v LAP and 200µg/mL Rho-labeled albumin (60µL total volume). A second circle-shaped 
hydrogel was formed crosslinking a solution of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa) and 
0.5%w/v LAP (60µL total volume) using a smaller ring structure (external radius2 =2.5mm; internal 
radius2 =1.8mm; area ring2 =10mm2; thickness =1mm). A third circle was produced photo-crosslinking 
a solution of 20%w/v PEGDA (700Da), 1%w/v PEGDA (5kDa), 0.5%w/v LAP and 200µg/mL FITC-
labeled albumin (60µL total volume) using a digital mask with specific dimensions (radius3 =1.8mm; 
area ring3 =10mm2; thickness =1mm).  
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By using these digital masks, three equal areas of hydrogel with different embedded molecules were 
obtained. The same procedure was adopted to produce hydrogels composed of three circle structures 
of different areas (10 – 30 – 100% of the total well area). Therefore, the molecules were embedded 
within various areas and their release was reported as function of embedded gel area. After washing, 
240µL of PBS were added to each gel and the release of multiple compounds into the same supernatant 
was collected over a period of 48h. The absorbance of FITC-albumin and Rhodamine-albumin released 
into supernatants were measured using a microplate reader (Victor3, PerkinElmer, Denmark) by 
measuring the absorbance of FITC at 490nm and Rhodamine absorbance at 540nm. The moles of 
compounds released were then plotted as function of the hydrogel area in which the initial moles were 
embedded. 
 
Effect of free drugs and combinations of free drugs on HT29 proliferation activity 
The cytotoxic effect of different doses of drugs (SN-38, 5-FU, OxPt and FA) used as free compounds was 
evaluated on human colorectal adenocarcinoma cell line (HT29, ATCC, Rockville, USA). Different stock 
solutions of drugs were prepared by dissolving them in DMSO solvent, except for FA that was 
solubilized in MQ water. Due to solvent toxicity induced on HT29 proliferation, highly concentrated 
solutions of drugs were made. For drug screening on HT29 cells, an experimental protocol was 
established: HT29 cells suspended in Dulbecco´s Modified Eagle Medium (DMEM obtained from Sigma 
Aldrich) with 100µg/mL penicillin, 100µg/mL streptomycin and 10%v/v heat-inactivated fetal bovine 
serum (FBS) (all purchased from Sigma Aldrich) were seeded in a cultivation flask. Cells were 
maintained in the incubator at 37˚ C in a humidified atmosphere with 5%CO2, and their passaging took 
place upon approximately 90% confluence. For drug treatment, cells grown in a cultivation flask were 
washed twice with PBS and harvested with 0.1% trypsin-EDTA (from Sigma Aldrich) for 5min kept in 
the incubator. Then, fresh medium was added to the detached cells and centrifuged at 1000rpm for 
5min. After removal of supernatant, the pellet was re-suspended in fresh medium and cells 
concentration was evaluated by automated cell counter (ORFLO Technologies, USA). In a sterile 96 
well-microtiter plate, a concentration of 100000cells/mL was seeded into each well and kept in the 
incubator for 24h in order to reach cell adhesion. Cells were then exposed to different concentrations 
of single drugs (SN-38, 5-FU, OxPt and FA) by adding 1µL of different drug stock solutions which were 
dissolved in DMSO. Cells were incubated in presence of chemotherapeutics for 48h. The cytotoxic 
effect of compounds was evaluated by using the MTS bio-assay (CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay, from Promega Biotech, Sweden), by adding 20%v/v of MTS substrate ([3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]) to each well. 
After 1h incubation of cells with MTS, the absorbance of wells was measured at 490nm using the 
microplate reader. At this wavelength (490nm) the bio-reduced product resulted from the 
metabolically activity of living cells converting MTS substrate into a colored compound, was detected. 
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The higher the value recorded at 490nm and the higher was the concentration of viable cells after 48h 
drug treatment. A well containing only cells (100 000cells/mL) and another with cells exposed to 
DMSO (1µL) without drug were used as controls. The percentage of cell viability was then plotted as 
function of drug doses in logarithmic scale.  
The same protocol was adopted to evaluate the cytotoxicity induced by combinations of drugs, where a 
maximum of three drugs were simultaneously added to adherent cells (HT29). Briefly, cells were 
seeded into a 96 well-microtiter plate and after 24h incubation a volume of 1µL of each drug was 
added to the medium as free compound. As control, an equal volume of DMSO was introduced with 
cells to test the effect of solvent on cell viability. 
 
 
Effect of thermal trigger on OxPt-loaded liposomes when cultured with HT29 cells 
The cytotoxic effect of OxPt-loaded liposomes, both stealth and thermo-sensitive, was evaluated by 
suspending different doses of liposomes in a 96 well-plate containing medium (DMEM + 1%v/v 
penicillin/streptomycin + 10%v/v FBS). Then the samples (thermo-sensitive and stealth liposomes) 
were heated up at 40˚ C for 1h in sterile conditions to induce oxaliplatin leakage from vesicles. The 
same procedure was adopted for thermo-sensitive and stealth liposomes without exposing them to 
thermal trigger, rather their plates were kept at room temperature until cell seeding. After cooling 
down the plates that were heated up, a concentration of 100 000cells/mL was seeded in each well and 
incubated for 48h. The viability of HT29 cells was evaluated by using the MTS bio-assay. 
 
 
Effect of multi drugs release from 3D-shaped hydrogels on HT29 proliferation 
3D-circle shaped hydrogels were produced according to the procedure used for digital drug dosing 
experiments. In specific, different drugs were embedded within various hydrogel structures having the 
same area (10mm2) and same thickness (1mm). As reported in Figure 2.37A, each circle structure was 
loaded with a certain compound concentration or OxPt-liposomes. After hydrogels were fabricated, 
HT29 cells were incubated onto their surface at a concentration of 100 000cells/mL in DMEM + 1%v/v 
penicillin/streptomycin + 10%v/v FBS for 48h. The combined cytotoxic effect of drugs was detected by 
measuring the absorbance of MTS at 490nm. A slightly different procedure was followed when drugs 
and liposomes were embedded within gels: before cell seeding, the hydrogels were kept in a wetted 
state (medium) and heated up at 40˚ C for 1h in sterile conditions. Then, the samples were cooled 
down at room temperature and the same concentration of cells (100000 cells/mL) was incubated with 
the releasing system. Also in this case, after 48h of drugs exposure the cell viability was measured by 
adding 20%v/v MTS to each well and recording the absorbance at 490nm. 
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3 PEDOT-N3 micro-electrodes for drug-loaded 
liposomes and cells immobilization 
This chapter describes another micro-/nano-technological platform which consists of micro-fabricated 
PEDOT-N3 electrodes on a PEG-coated support that are post-fabrication functionalized via covalent 
coupling with various molecules to ensure the immobilization of drug-loaded liposomes onto the 
electrodes surface (Figure 3.1). The liposomes intended to use for this scope are similar to those 
applied for drug embedding and release within PEGDA hydrogels, and in addition they contain 
functional groups in their bilayer which permit the chemical bonding to the fabricated polymer 
surface. Ideally, once the nano-particles are immobilized onto the electrodes, a certain current may be 
applied to induce local resistive heating that will release the encapsulated drugs. During the 
development of such platform many challenges were encountered and some of them were essential for 
the final achievements success. Alternative methods for the optimization and future development of 
the intended technology will also be discussed. Therefore, in this chapter it will be described the 
method that we have used to create micro-electrodes of PEDOT-N3 and the approach involved on 
liposomes immobilization onto polymer electrodes. Further, a detailed description of the materials, 
equipment, and procedures adopted for the fabrication of the micro- and nano-platform are found at 
the end of the chapter in the Experimental section. 
 
Figure 3.1 Schematic of the polymer-based platform designed for drug screening purposes. PEDOT-N3 electrodes are fabricated 
in a protein repellent coating deposited on a support. These electrodes (100µm in width, 3.5mm long and 100-150nm thick) are 
functionalized through ´click-chemistry` reaction in order to immobilize drug-loaded liposomes onto their surface. A second 
chemistry may be utilized to immobilized antibody molecules in the neighboring regions between the electrodes. The incubation 
of human colorectal adenocarcinoma cell line (HT29) with the described platform could result on cells capture onto the surface 
due to antigen-antibody complexation. Ideally, the application of a specific potential to the electrodes may induce a local thermal 
increase which represents the trigger for inducing drug release from drug-loaded liposomes. (The image is not to scale).  
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With the development of such platform we should be able to immobilize drug-loaded liposomes and 
specific cell populations onto the same surface. The application of a proper trigger will then enhance 
the release of drugs from immobilized particles and the captured cells will be exposed to these 
compounds. For the realization of such platform, various issues have been considered and we selected 
the main components to build our platform. First, conductive polymer wires can be fabricated to 
immobilize drug-loaded nanoparticles onto their surface. A proper chemical functionalization of 
polymer wires for enhancing a stable attachment of liposomes is needed; moreover, a second chemical 
modification allows the functionalization of the areas between wires to introduce cell-capture 
molecules (for instance antibodies). Multiple processes for platform functionalization are involved, 
therefore a proper chemical modification of the support must be adopted in order to avoid non-specific 
binding of drugs or cells onto the support surface. 
 
3.1 Conductive polymers 
Conductive polymers have been extensively studied during the last few decades because of their great 
suitability in chemical and biological applications used as sensors,[142] organic solar cells,[143] or organic 
light-emitting diodes.[144] In general, polymers have very poor electrical conductivity and most of them 
find applications as electrical insulator, such as polytetrafluoroethylene which has a conductivity of  
10-18 S cm-1.[145] As an example, natural rubber is an excellent insulator and its conductivity could be 
significantly increased by adding carbon black or acetylene black which is used as antistatic device in 
hospitals. On the other hand, polymers able to transport electrons have conductivity in the range of 10-
106 S cm-1 like polysulfurnitride that has a conductivity of ~103 S cm-1. Conductive polymers in the 
neutral state (uncharged) show almost no conductivity, whereas their intrinsic conductivity results 
from the formation of charge carriers upon oxidizing (p-doping) or reducing (n-doping) their 
conjugated backbone.[142] Some examples of doped polymers are poly(p-phenylene), polypyrrole, 
polythiophene, polyaniline, and polyacetylene which is usually doped with electron donor (alkali-metal 
ion) or electron acceptor leading its conductivity to values comparable to that of conductive metals like 
copper (104 S cm-1).[145]  
A key property that makes conductive polymers suitable for electron transport is the presence of 
conjugated double bonds along the backbone of polymer, as shown with some examples in Figure 3.2A. 
The conjugation of localized σ-bonds that form strong chemical bonds and π-bonds which are weaker 
than single bonds, constitutes the chemical structure of conductive polymer. However, the conjugation 
of such bonds is not enough to guarantee conductivity to the material. The doping process induces an 
electron imbalance along the polymer structure and the extended π-conjugated bond system allows 
the new electron population to migrate a long distance along the backbone when an electric potential 
is applied (Figure 3.2B). In general, metals have a high density of electronic states meaning that 
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electrons can easily move from an atom to another one under an applied electric field. Since the 
electrical properties of a material are ascribed to its electronic structure, in metals the orbitals of a 
certain atom are overlapped with those of neighboring atoms. Typically, the energy spacing between 
the highest occupied (valence band) and the lowest unoccupied (conduction band) electronic states is 
called the band gap. Therefore, the conductivity of metals is due either to a partially filled valence or 
conduction bands, or to a band gap that is near to zero; so, even for weak electric field the electrons 
easily redistribute along the orbitals (Figure 3.3B).[146] Hence, the conductivity increases with 
decreasing band gap which is the energy required to promote an electron to move from the highest 
occupied energy level to an empty level immediately above it (conductive band). While metals have 
almost zero band gaps, insulators such as many polymers have large band gaps in the 1.5 – 4eV range 
which impairs electron flow. By a proper charge injection (doping) it may be possible to reduce this 
band gap value to 0.5 – 1eV.[142] The doping of conductive polymers leads to interesting phenomena 
which can be useful in various applications. For instance, the change of the electronic band structure is 
accompanied by a change of physical features like the optical properties in the UV-vis and NIR-regions 
which are exploited in electrochromic displays and optical sensors. Furthermore, the 
electroluminescence of some conductive polymers is used for OLEDs, while photoluminescence is 
applied for the fabrication of fluorescence-based biosensors.[142] 
The doping process of conductive polymers can be achieved either chemically or electro-chemically. In 
chemical charge injection the polymer is exposed to oxidizing vapors, like iodine. Chemical doping is an 
effective method but it is poorly reproducible because it is difficult to quantitatively control the 
polymer oxidation. Another approach is the electro-chemical doping that provides fine tuning of the 
doping level through electrical potential adjustment.[142] 
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Figure 3.2 (A) Chemical structures of main classes of conductive polymers,[142] and (B) p-doped PEDOT (poly(3,4-
ethylenedioxythiophene)) containing tosylate anions (TsO). A ratio of one tosylate per 3-4 PEDOT monomers is typically found; 
the electron acceptor tosylate is negatively charged while a dislocated positive charge results in the conjugated system of 
polymer (shown in red). 
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The fields in which conductive 
polymers find a great applicability are 
many and with various purposes. 
Polypyrrole for example is used as pH 
sensor due to its pH and potential 
dependencies; in fact, the protonation 
of polymer enhances its conductivity, 
whereas deprotonation leads to a lower 
conductivity.[147] Otherwise, some 
conductive polymers show an intrinsic 
affinity for a variety of metal ions, as 
polycarbazol that provides a selective 
potentiometric response to Cu(II) 
ions,[148] or PEDOT that has a great 
affinity for Ag+-ions due to the 
coordination of ions to the sulfur atom 
of polymeric monomer.[149] Conductive 
polymers may be used as receptors for 
detection of organic molecules like 
dopamine,[150] saccharides[151] or ATP.[152] Conductive polymers are widely studied also as transducers 
or as components of transducers because of their ability to change electrical and optical properties 
upon oxidation/reduction, protonation/deprotonation and conformational changes induced by the 
binding of different analytes.[142]  
One of the more attractive challenges on using conductive polymers is the possibility to modify and 
immobilize molecules onto or within the polymer matrix.[153] Nowadays, the immobilization 
procedures commonly used are based on non-covalent interactions (physical adsorption, electrostatic 
assembly, hydrophobic interactions), or covalent binding of molecules to the conductive polymer. The 
physical adsorption is rarely adopted because generate weak bonding that consequently leads to a loss 
of molecules, despite its practical easiness.[154] Another approach is based on the Langmuir-Blodgett 
technique that is a relatively simple technology used to obtain highly ordered films functionalized with 
desired molecules. However, the resulting system may be unstable and the film may contain a lot of 
defects; thus, this technique has been replaced by technologies of self-assembly based on layer-by-
layer deposition, or modification by silanization and covalent immobilization. The layer-by-layer 
deposition method requires an alternate electrostatic adsorption of molecules and opposite charged 
polymer layers onto a solid support. This method is governed by multiple effects such as shielding, 
hydrogen bonding, dispersion forces that determine film thickness and morphology.[155] Due to the 
complexity of the process, the multilayers are extremely sensitive to variations of ionic strength and 
Figure 3.3 (A) Some examples of conductivity values (S/m), and (B) 
the band gaps characterizing insulator, semi-conductive and 
conductive materials. When the gap between the lowest occupied 
conduction band and the highest occupied valence band is closed to 
zero, metal-like features are achieved. Reproduced from [146]. 
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drying processes may occur destabilizing the assembled layers. Mechanical embedding also represents 
a good candidate for non-covalent immobilization: thereby molecules are in the vicinity of electrode 
and consequent electro-polymerization leads to the entrapment of molecules into the growing polymer 
layer. The success of this method depends on the concentration of molecules that should be high and 
the electrodeposition should occur at mild conditions. Nevertheless, the content of molecules finally 
embedded into the film is insufficient and often surfactants need to be added to enhance monomer 
solubility.[156] Among the existing non-covalent immobilization processes, the covalent reaction of 
functional groups of molecules and polymer provides the strongest interaction (Figure 3.4). The 
easiest way is to polymerize monomer derivative bearing receptor molecules (panel 1) or any 
functionality (panel 2) in order to obtain polymers presenting the desired moiety in each monomer or 
with a high functionalization yield. These methods are limited by the availability of synthetic pathways 
to create certain polymeric derivatives; further, the low solubility of modified monomers and low 
conductivity of the resulting polymer can be crucial for biomolecules immobilization.[157] 
 
 
Figure 3.4 Various methods commonly used to chemically immobilize a receptor unit to a polymer. These mechanisms include: 
polymerization of a monomer already bearing receptor unit (path 1); polymerization of functionalized derivatives and following 
chemical receptor immobilization (path 2); post-modification of polymer through functional groups: grafting (path 3), 
incorporation of modified nanoparticles (path 4), and polyelectrolytes (path 5). Reproduced from [142]. 
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To overcome the problem of poor derivative solubility, two general approaches for covalent 
immobilization can be used: one is the post-polymerization grafting (panel 3) that is achieved through 
thermal grafting, wet chemical, organosilanization, UV irradiation, or ionized gas treatment;[158] an 
alternative approach is based on co-polymerization or polymer deposition in presence of modified 
nanoparticles bearing functional groups of interest (panel 4)[159] or polyelectrolytes (panel 5).[160] All 
the presented methods are useful for polymer modification; sometimes the poor compatibility of 
optimal polymerization conditions and the limited stability of biomolecules onto polymer surface can 
be overcome by post-modification based on affinity interactions. The known biotin-avidin conjugate is 
the mostly used system because of high complexation constant;[161] otherwise his-tag moiety,[162] or 
complementary nucleotides sequences may be adopted. 
An important parameter that must be considered when synthesizing polymeric films is their adhesion 
to a certain solid support. The adhesion of polymer depends on many parameters including the 
chemical nature of the polymer and support (for instance the hydrophobicity), the procedure of 
synthesis, solvent and counter-ions. Usually polymer adhesion may be improved by modification of 
either physical (surface area, hydrophobicity/hydrophilicity) or chemical (including chemical anchor 
groups) features of solid surface.[142] For example, a simple chemical modification is based on the use 
of organosiloxanes to promote specific adhesion of polypyrrole and enhance its lateral growth on solid 
insulating support.[163] Otherwise, mono-molecular self-assembled layers for covalent binding of 
synthesized polymers can be adopted; for example, thiol derivatives of monomers form monolayers on 
metallic surfaces (Au, Pd, Ni, Cu, Ag and others) achieving a strong binding of polymers.[164] 
A central aim of this thesis is the fabrication and post-polymerization covalent modification of thin 
films of PEDOT-N3, poly(3,4-(1-azidomethylethylene)-dioxythiophene). One of the major challenges is 
the production of polymer micro-electrodes and consequent functionalization to immobilize drug-
loaded nanoparticles. The need of a fabrication process which has a good biocompatibility and 
guarantees the biological activity of functional moieties is crucial. In the following paragraphs, a 
detailed description of polymerization, covalent modification and liposomes presentation at the 
electrodes surface is found. 
 
 
3.2 PEDOT-N3: properties and applicability 
Conducting polymers are characterized by a lower conductivity compare to that of metals and 
semiconductors, and also a lower long-term stability which renders metals favorable for many 
applications.[165] Nonetheless, conducting polymers are widely applied in various fields because of 
their low cost, ease to handle and fabricate, and moreover their electronic, optical, chemical and 
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biological features can be tuned according to the application requirements. Chemically polymerized 
PEDOT was discovered in 1988,[166] and its first commercial application was its use as an antistatic 
layer in photographic films due to its ability to form transparent and conductive films.[167] Within the 
last two decades, the commercialization of PEDOT have been expanded to many other applications 
including solid electrolyte capacitors, printed wiring boards, packaging films, touch screens, organic 
light-emitting diodes (OLEDs) and organic photovoltaics (OPV).[168] Regarding the biological 
applicability of conductive polymers, including PEDOT, have been found to have a great cell-
cytocompatibility and their conductance can be exploited for electric or electric-mechanical 
stimulation of cells,[169] or electroporation devices.[170] PEDOT as conducting polymer is considered to 
be a semiconductor since native PEDOT has a band gap of ~1.5eV;[165] however, conducting polymers 
can be doped to increase conductivity through partial oxidation of polymer. A net charge is introduced 
in the polymer backbone and counterions will ensure charge neutrality to the material reaching 
conductivity values in the order of 101-103 S cm-1.[165] The choice of counterions influences the 
properties of the material and can thus be used to tune the conductive features of the polymer.  
PEDOT can be prepared by oxidative polymerization of the monomer 3,4-ethylenedioxythiophene 
(EDOT).[171] As illustrated in Figure 3.5, each EDOT monomer loses two electrons and a conjugated 
polythiophene chain is formed.  
 
Figure 3.5 Chemical oxidative polymerization of the monomer 3,4-ethylenedioxythiophene (EDOT) through the oxidation agent 
persulfate and poly(styrene sulfonic acid) (PSS) to form a water-soluble polyelectrolyte complex (PEDOT:PSS). Reproduced from 
[166]. 
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Under traditional oxidation conditions, PEDOT is not in a neutral form, instead it appears positively 
charged. Hence, these charges need to be stabilized by the presence of suitable counterions. It has been 
reported that sulfonic acids like the one reported in Figure 3.5 are the best choice to achieve a stable 
PEDOT/counterions complex.[165] In this chemical process should be noted that the oxidation of 
polymer is not accomplished by the counterions, rather by the oxidation agent. Further, the 
polymerization of PEDOT is normally performed on the surface of a support through the so called in-
situ polymerization where a solution of EDOT monomers and an oxidation agent, such as 
Fe(III)tosylate (TsO), are mixed to form a polymeric film.[172] Alternatively, the evaporation of EDOT 
monomers onto a support surface may be adopted to enhance polymer synthesis; this process can be 
conducted by simultaneously adding the oxidation agent as FeCl3 or through deposition of Fe(III)TsO 
(also an oxidation agent) prior polymerization.[173] The oxidative polymerization may be also 
conducted by involving sulfonic acid in the reaction, such as poly(styrene sulfonic acid) (PSS); a 
polyelectrolyte complex is formed and it appears like a water-soluble stable dispersion.[174] This 
dispersion is characterized by gel particles of PEDOT/PSS polyelectrolyte which have typically a 
dimension of 20-500nm;[168] despite their stability, these dispersions have a really low pH, in the range 
of 1-2 and a base needs to be used to neutralize the acid pH (Figure 3.5). Unfortunately, during the 
neutralization process the PEDOT component is not stable and the complexes result in a changed color 
and films lose their conductivity.[166] Depending on the final application in which PEDOT films want to 
be used, a certain polymerization reaction and counterions should be evaluated; for instance, the 
biological application of PEDOT polymer requires mild reaction conditions. For many chemical 
reactions, specific solvents and elevated temperatures are often needed resulting therefore to be 
incompatible with biomolecules and bio-applications.  
We chose to use 3,4-(1-azidomethylethylene)-dioxythiophene (EDOT-N3) monomer that was studied in 
our group prior the work presented in this thesis. It was found the EDOT-N3 could be chemically 
oxidized to yield p-doped PEDOT-N3 films containing tosylate (TsO) anions as stabilizing 
counterions.[175] These films resulted to be stable, insoluble and chemically modifiable with a wide 
range of alkyne reactants,[175] and their conductivity was found to be ~6.101 S cm-1, a lower value 
compared to the native PEDOT film which has a conductivity of ~7.102 S cm-1.[165,175] Here the PEDOT-
N3 substrates are intended to be used as micro-platform for the immobilization of drug-loaded 
nanoparticles (liposomes) and consequent study of molecules release. In order to achieve this goal, 
PEDOT-N3 micro-electrodes (100µm in width) are fabricated on a protein repellent support (PEG-
coated COC discs) in order to discourage passively adsorption of molecules during electrodes 
modification. Through a selective chemical functionalization of PEDOT-N3 electrodes, based on the 
known “click-chemistry reaction”, drug-loaded liposomes are immobilized onto the polymer surface. 
According to the original idea on developing such system, the employment of an additive modification 
chemistry may be applied to functionalize the areas between the electrodes (also 100µm in width) 
with other molecules such as antibodies that can be used for the recognition of specific cell types. Thus, 
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two main components may be co-immobilized onto the micro-platform (antibodies and drug-loaded 
liposomes). Ideally, the conductive properties of polymeric electrodes may be utilized to induce a local 
thermal increase when a certain voltage is applied onto electrodes surface. Because of the thermal 
sensitivity of our synthesized liposomes, a consequent drug leakage may be induced.  Such technology 
should allow the capture of desired cell type from a mixture of different cell lines according to the 
specific antibody molecules immobilized onto the platform surface, and control the drugs release for 
drug screening purposes. As stated in the introduction of this chapter, many issues were encountered 
and some of them were solved while others still need to be optimized. The main obstacle during the 
development of this platform was the fabrication of micro-electrodes. Even though in our group and 
more in general in our department (DTU Nanotech) clean room facilities for micro- and nano-
fabrication are available, the process required for the production of PEDOT-N3 electrodes should be 
cheap and more importantly should be able to maintain the biological properties of the PEG-coating 
produced onto the solid support prior electrode fabrication.  
The feasibility of such micro- and nano-platform depends on many parameters due to the challenging 
fabrication and modification processes: 
a) a stable and efficient protein repellent coating of the support is needed in order to avoid passively 
adsorption of chemicals and molecules during the functionalization processes; in particular, this step 
has to be conducted prior electrodes fabrication; 
b) a suitable technology for electrodes fabrication that preserves the chemical and physical properties 
of the support and its coating is required; 
c) stable and selective chemical reactions conducted upon mild conditions that permit to anchor drug-
loaded liposomes to the electrodes surface and antibody molecules onto the coated support surface, 
respectively are required; 
d) a proper liposomes trigger should be applied without altering the physical-chemical properties of 
the platform and of captured cells; 
e) the overall micro- and nano-platform must be cytocompatible. 
All these issues will be considered in the following sections, with a particular focus on the chemistries 
adopted for the specific binding of nanoparticles and the fabrication methods used to create 3D-
microelectrodes. 
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3.3 Deposition and fabrication of thin PEDOT-N3 electrodes 
3.3.1 Thin film deposition of PEDOT-N3 
A thin film can be described as a uniform layer of material ranging from a nanometer to few 
micrometers in thickness. The applications of these films include telecommunications, micro electro 
mechanical systems (MEMS), bio-MEMS, flat screen displays such as LCDs, flexible OLEDs, laser diodes 
and magnetic read/write heads.[176] Currently, the deposition techniques available for thin films 
fabrication are based on vacuum and non-vacuum methods. Vacuum techniques include physical vapor 
deposition and chemical vapor deposition technologies which permit to fabricate films and coatings 
with a thickness in the range of 10nm-1µm.[177] Non-vacuum methods are normally adopted for low-
cost processes especially when larger thicknesses are required (more than 1µm). Further, non-vacuum 
techniques like polymer spray coating, spin coating, metal electroplating, roll-to-roll deposition or 
liquid flame spray nano-coating are more convenient for large scale production. In any case whatever 
technique is adopted, the deposited film must possess some specific characteristics that are essential 
for the final purpose.[177] Firstly, the uniformity of a film is required to meet both electrical and 
mechanical specifications; for instance, the deposited thin film must be continuous, free of pin holes, 
flat and smooth in order to minimize cracking and its adhesion to the support surface should be 
optimized. The presence of cracks into the film generates a surface roughness and allows 
contamination of polymer.[178] 
In this thesis, PEDOT-N3 films are produced by using spin-coating technology which is one of the most 
commonly used techniques for deposition of thin film onto supports. At present, the use of spin-coating 
is widespread in organic electronics and nanotechnology fields because of the easiness and fast 
process and its ability to produce very uniform films from few nanometers to few micrometers in 
thickness. Moreover, a simultaneous deposition and polymerization of polymer in self-assembled 
layers occurs during the casting process.[179] The spin coating process involves the deposition of a 
certain polymer dissolved in a solvent (ink) onto the support surface while it is rotating (Figure 3.6A, 
panel 1). The support is rotated at high speeds and the majority of the ink solution is flung off the 
edges of the support (panel 2); most of the solvent is then dried by airflow (panel 3) and after a while a 
complete evaporation of solvent occurs and a dry film remains attached onto the surface (panel 4). The 
rotation of substrate at high speed, normally higher than 600rpm (revolutions per minute), pulls the 
liquid out due to a centripetal force combined with the surface tension of the solution. Therefore, the 
thickness of a spin coated film is proportional to the inverse of the square root of the spin speed, as 
shown in Figure 3.6B and as expressed by Equation 3.1, where t is the film thickness and 𝜔 is the 
angular velocity. 
𝑡 ∝
1
√𝜔
 Eq. 3.1 
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Figure 3.6 Spin-coating of thin films. (A) Schematic illustration of the spin coating process: the ink solution (in red) is subjected 
to a high speed through horizontal rotation (minimum 600rpm) of the support and after evaporation of the solvent a thin film is 
obtained. (B) Graphical relation between the spin coating speed (rpm, revolutions per minute) and resulting film thickness (nm). 
 
The PEDOT-N3 films are produced through spin-coating technique on cyclic olefin copolymers (COC) 
supports. Topas® is the trade name for advanced polymers´ cyclic olefin copolymers (COC)[180] which 
consists of amorphous, transparent copolymers based on cyclic olefins and linear olefins (Figure 3.7A). 
Cyclic olefin copolymers are a new class of FDA-approved polymeric materials with a unique 
combination of features that can be varied by changing the chemical structure of the copolymer. Topas 
resins are suitable for the fabrication of transparent moldings in the field of optical data storage, optics, 
and industrial products. Currently, different COC grades are commercially available and they mainly 
differ on their heat deflection temperature, which is determined by the ratio of co-monomers, and on 
their flowability that decreases with increasing viscosity number. In fact, the various grades of COC are 
normally indicated by 4 digit number, where the first two indicate the viscosity and the last two digits 
describe the heat deflection temperature. The COC resin is a clear thermoplastic material with high 
strength, rigidity and according to the grade, heat deflection temperature (in the range of 75˚ C - 170˚ 
C); moreover, the high transparency of the material remains unaffected by temperature changes. 
Further, COCs are very good electrical insulating material with a dielectric constant of 2.35 and a 
surface resistivity > 1014 Ω. The high transparency of Topas in the visible and near ultraviolet regions 
coupled with a refractive index of 1.53 makes these polymers attractive for high-quality optical 
components.  
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Figure 3.7 Topas® cyclic olefin copolymers (COC). (A) Chemical structure of co-monomers used to synthesize cyclic olefin 
copolymers. The ethylene and norbornene monomers form the COC copolymer through chain co-polymerization. (B) Illustration 
of a standard injection molder used for the fabrication of macro-scale objects but also different micro- and nano-structures. The 
main components of the machine are reported: to produce COC 5013 discs of 5 cm in diameter and 2mm in thickness, shims with 
completely flat surfaces are employed.  
 
Regarding COC chemical properties, it is a water-repellent (hydrophobic) material and thus exhibits 
only negligible swelling when immersed in water; COCs are also resistant to hydrolysis, acids and 
alkalis, as well as to polar solvents such as methanol. However, Topas is attacked by non-polar solvents 
like toluene. The specific grade of COC that is employed for spin-coating of PEDOT-N3 films is the COC 
(5013) which has a glass transition temperature at 130˚ C and it is particularly suitable for accurate 
molding replication. The injection molding process is used to fabricate COC discs with a diameter of 5 
cm and thickness of 2mm; in this fabrication process the nozzle-cylinder components are heated up at 
a temperature above the glass transition temperature of polymer granulates (between 240˚ C and 280˚ 
C). Then the polymer is melted until it reaches the nozzle exit and fills the cavity between the two mold 
shims which are also at a temperature above the glass transition temperature. The system is cooled 
down and an external pressure is applied to balance the shrinkage or expansion of polymer during the 
cooling. Since the melted polymer fills completely the micro- and nano-voids on the shims, high fidelity 
replica can be obtained. For our purpose a completely flat shim is used to fabricate multiple COC 
(5013) discs in a short time.[181,182]  
116 
 
 
 
Hence, PEDOT-N3 films are obtained by spin-coating onto COC support a polymer mixture composed 
of: monomer solution (EDOT-N3), Fe(III)TsO shortly tosylate which is the oxidation agent, and the 
solvent (butanol). The solution volume is spin-coated at a spin speed of 1000rpm for 30 seconds in 
order to obtain a final film thickness around 150nm. After spin-coating, the coated supports are heated 
up at 70˚ C to enhance homogeneous solvent evaporation and already after 2 min a completely 
polymerized PEDOT-N3 is obtained (Figure 3.8). Therefore with these processes, spin-coating and 
baking, an in situ polymerization of thin PEDOT-N3 films is allowed. 
 
 
Figure 3.8 Photo of a Topas COC 5013 disc (on the left) and a spin-coated PEDOT-N3 film on COC support after polymerization 
(on the right). Both discs have a diameter of 5cm and a thickness of 2mm. The final polymer thickness is around 150nm. A pencil 
is introduced to compare object sizes.  
 
 
 
3.3.2 Fabrication of micro-electrodes on PEDOT-N3 thin films 
The technologies available for micro- and nano-fabrication of structures are many and presenting 
different benefits and drawbacks. Some of them, such as nanolithography, electron beam lithography 
or reactive ion etching (RIE), are particularly useful for the fabrication of small feature sizes and high 
aspect ratio structures; however, the use of such methods requires expensive clean room facilities and 
materials. Further, since PEDOT-N3 is a polymer and thus sensitive to moisture and chemicals, micro-
fabrication techniques used for patterning metals are most of the times unusable for PEDOT-N3 
patterning. One of the most used techniques for polymer or molecule patterning under mild conditions 
is the micro-contact printing. It is a method largely used because inexpensive, fast, simple and does not 
require clean room instrumentation. Micro-contact printing is based on using a stamp, normally made 
of polydimethylsiloxane (PDMS), which is used to  deposit polymers or molecules onto a flat surface 
(positive stamping), or to remove material from a layer according to the structures presented at the 
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PDMS surface (negative stamping). When certain molecules need to be deposited on a surface, the 
PDMS is incubated with the molecule solution (ink) and the stamp is put in contact with the substrate 
applying a small pressure. Thus, patterned molecules are transferred onto the surface according to the 
original shape and structure of PDMS (Figure 3.9A).  
 
Figure 3.9 Schematic of soft lithography processes normally used for the fabrication of micro-structures on different substrates. 
Reproduced from [183]. (A) The micro-contact printing consists on the use of a PDMS stamp that is incubated with an ink solution 
(1), and it is put in contact with the substrate by applying a small pressure (2); then the stamp is removed and desired structures 
remain deposited onto the substrate surface (3). (B) The PDMS mold can be also applied for the removal of desired layers after 
casting process (1); when the stamp is in contact with the substrate, the layer is removed according to the contact areas exposed 
to the PDMS mold (2). The resulting structures are then cleaned (3).  
 
The stability of these printed molecules depends on the interactions involved between the molecules 
and the surface, hence on the chemical properties of the support. A different approach for the 
fabrication of micro-structures is the casting, where a molecule solution is deposited on a support and 
afterwards a PDMS stamp is pressed against the surface. A temperature increase can help to remove 
molecules or polymer in correspondence of the stamp-layer contact areas (Figure 3.9B). Both 
described techniques, micro-contact printing and casting, are widely used to create chemically micro-
patterned surfaces: for example various structures on PEDOT:PSS layers are produced through PDMS 
casting, although large variations in thickness are found.[183] 
The production of PEDOT-N3 micro-electrodes can be achieved by using the printing approach and in 
particular, a method previously developed in our group, is applied. This technology, called printed 
dissolution is a versatile, simple, cheap and fast procedure adopted to fabricate patterns on PEDOT-
based films. The main benefit on using such method is that it locally removes specific areas of 
conductive polymer from a support, and re-exposes the surface of the underlying support in an un-
perturbed state. The principle of this process in based on the use of an agarose stamp which is 
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immersed in an oxidizing agent solution (sodium hypochlorite, NaOCl) and put it in contact with a 
PEDOT-N3 film.  
 
Figure 3.10 Photos of the main components required for printed dissolution procedure. On the left, the pictures indicate the 
silicon mold used for fabricating the agarose stamp. It contains two sets of inter-digitated electrodes 100µm wide and 100µm 
spacing. On the right, the agarose stamp produced by melting an agarose solution onto the silicon mold. After cooling down a 
negative replica of electrodes is obtained on the stamp surface.  
 
 
 
Figure 3.11 Illustration of the steps involved on printed dissolution. (A) The agarose stamp is soaked into a solution of an 
oxidizing agent (sodium hypochlorite, NaOCl), and is put in contact with a PEDOT film. (B) After removal of the stamp, over-
oxidized and non-conductive polymer residues remain in the gaps between the electrodes. (C) The leftover PEDOT is removed 
by introducing a non-ionic detergent inside the agarose stamp or washing the sample in a solution of detergent. [184] See the 
experimental section at the end of this chapter for more details.  
 
The agarose stamp is formed by melting a polymer solution on top of a silicon mold (Figure 3.10, on 
the left) and cooling down the solution. On the silicon mold, two sets of inter-digitated electrodes 
100µm wide are included; hence, when the agarose solution is cooled down onto the mold surface, a 
negative replica of the electrodes results on the agarose stamp surface (Figure 3.10, on the right).  
In earlier reported works in our group, it was found that when the stamp is immersed in a solution of 
NaOCl (Figure 3.11A), then it can be used to locally remove the conductivity of PEDOT-based films due 
to an over-oxidation induced by the oxidizing agent; thus, it breaks the conjugated system of the 
polymer backbone and the conductivity is lost.[185] When the stamp is kept in contact for a while with 
the PEDOT film, a stable over-oxidized polymer layer remains in the gaps between the electrodes, as 
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shown in Figure 3.11B. Nevertheless, the application of a non-ionic detergent (Triton X-100) directly in 
the agarose stamp or during a subsequent washing step, removes these over-oxidized polymer 
residues from the support which is now available for following functionalization (Figure 3.11C). When 
PEDOT-N3 films are exposed to printed dissolution using the described procedure, a patterned surface 
formed of two sets of inter-digitated electrodes is obtained (Figure 3.12). A detailed description of the 
process is found in the Experimental section of Chapter III. 
 
Figure 3.12 Photo of a spin-coated PEDOT-N3 film (thickness around 150nm) on COC support. The sample is put in contact with 
an agarose stamp and through printed dissolution, two sets of inter-digitated electrodes are obtained (on the left). In the 
enlargement, the optical micrograph of the fabricated electrodes. Light blue areas correspond to the polymer film and the 
transparent areas represent the underlying COC support obtained after agarose stamping. More details are found in the 
experimental section. 
 
The use of printed dissolution for fabricating PEDOT-N3 electrodes permits not only the local removal 
of conductive polymer but also generates a multiple surface chemistries. In fact, on the electrodes 
surface the azido groups are available for subsequent post-fabrication modifications; moreover, the 
underlying COC surface in the gaps between electrodes results accessible to any functionalization.  
 
 
3.3.3 Coating and functionalization of COC support prior PEDOT-N3 micro-
fabrication 
As anticipated just above, when polymer micro-electrodes are produced, in-register surface 
chemistries are presented at the surface (azido groups corresponding to electrode areas and COC 
between polymer structures). Although a post-fabrication functionalization of PEDOT-N3 electrodes 
may be adopted to locally immobilize desired molecules or chemical moieties, the reactivity of COC for 
any functional groups or modification is poor. In other words, the modification of the support after 
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agarose stamping is unlikely achievable unless a physical adsorption is utilized. However, the 
adsorption of molecules onto the electrodes surface may not be selective meaning that the entire 
fabricated film will be modified by the same chemical moiety. Since one of the main advantages on 
using printed dissolution is that it guarantees the chemical reactivity of the polymer surface and also of 
the underlying support, it may be possible to coat prior fabrication, the COC support with functional 
groups or molecules that will be useful for a subsequent modification after electrodes fabrication. 
Many different methods may be applied to modify the COC chemistry including physical adsorption or 
chemical deposition. The way in which the support surface is changed depends on the final application 
and requirements for a certain purpose. Ideally, the platform to be produced for our drug screening 
application, should present functionalizable PEDOT-N3 electrodes to locally immobilize drug-loaded 
liposomes, and eventually it should include a second chemical modification to enhance antibodies 
binding on the areas between the electrodes. As described in the introduction of this chapter, the use of 
EDOT-N3 monomers allows to covalently functionalize the electrodes surface after fabrication through 
`click-chemistry reaction´, thus promoting a local nano-particles immobilization. On the other hand, a 
chemical modification of the support may allow a further functionalization of the electrodes 
surrounding regions.  
In the light of these considerations, different approaches to modify COC surface are presented. In 
general, these procedures involve a physical adsorption of various molecules or polymers in order to 
obtain a surface able to prevent passive adsorption of compounds during post-fabrication 
functionalization, and that has a chemical reactivity toward subsequent modifications. Once the 
support is coated with desired molecules, a film of PEDOT-N3 should be polymerized onto the 
modified-COC; therefore, the chemical reactivity of the underlying layer is evaluated before and after 
printed dissolution in order to compare a preserved functionality of the sample.  
 
3.3.3.1 PS-N3 coating and functionalization of COC support 
One of the approaches that could be adopted to obtain a chemical reactive COC surface is the physical 
deposition of poly(4-(azidomethyl)styrene) shortly PS-N3, through spin-coating process (in Figure 
3.13A, the chemical structure of PS-N3 monomer and COC coating are reported). The azido-modified 
polystyrene creates transparent films when deposited at high spin speed and it can be easily patterned 
through UV-light exposure due to its sensitivity, thus when is illuminated in the UV-range light a 
crosslinking of film will occur. The process by which the azido-polystyrene is crosslinked when 
exposed to UV-light has been proposed by Akhrass et al.[186] Hence, a film of PS-N3 is spin-coated on a 
COC support (see the experimental section for details) and the coating is characterized measuring the 
water contact angle and optical microscopy. In Figure 3.13B, an optical micrograph of a spin-coated 
layer of PS-N3 dissolved in dioxane is produced on a COC support (magnification 20X). A homogeneous 
thin film is obtained and is characterized through water contact angle to evaluate how the 
121 
 
 
 
hydrophobicity/hydrophilicity of the support changes. As depicted in Figure 3.13C, when a film of PS-
N3 is polymerized onto the COC surface, an increase on hydrophilicity is reached. In fact, COC is 
typically really hydrophobic and the subsequent coating creates a more hydrophilic surface as 
indicated by the static, advancing and receding values. However, when spin-coated PS-N3 films are kept 
under environment conditions for a while, many in-homogeneity and particles are generated onto the 
surface and the films fabrication is poorly reliable. Different structures are detected through optical 
microscope: comet, agglomerate and coffee-ring shapes are found. Apparently, the stability of PS-N3 
film is poor over time and it may be due to the solvent 1,4-dioxane which is hygroscopic and therefore 
water molecules up-taken from the environment humidity may affect the film appearance (Figure 
3.14). As the exposure time to environment increases, a large number of defects are provoked into the 
film probably induced by water uptake onto the layer or solvent evaporation. The solution of PS-N3 
dissolved in dioxane is also filtered prior spin-coating (filter Ø=0.22µm) to discourage particles 
deposition.  
 
Figure 3.13 Characterization of spin-coated PS-N3 films on COC support. (A) Illustration of the process involved on the azido-
polystyrene deposition and its chemical structure. The green layer indicates the polymeric coating on COC. (B) Optical 
micrograph of the obtained thin layer of PS-N3 on COC (magnification 20X); a homogeneous film is produced. The picture is 
recorded just after spin-coating and washing. (C) Water contact angle measurement of a clean COC sample and PS-N3 coated 
COC; the static, advancing and receding values are reported as average value of 10 processed samples (n=10). An increased 
hydrophilicity of the surface is achieved when PS-N3 is deposited. 
 
Therefore, an optimization process to obtain homogeneous and stable PS-N3 films for a subsequent 
PEDOT-N3 polymerization is necessary. Due to the solvent properties that are unsuitable for PS-N3 film 
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deposition, a different solvent may be adopted to dissolve the polymer, for example PGMEA (propylene 
glycol monomethyl ether acetate). This solvent is generally used to dissolve photoresists because it 
inhibits fast evaporation and does not tend to form particles. Thus, PS-N3 dissolved in PGMEA is spin-
coated on COC support and, even if not perfectly homogeneous films are produced, the lack of 
consistent defects caused by solvent evaporation or water uptake, leads us to select PGMEA as solvent.  
Once the azido-polystyrene is deposited on the COC support, ideally a thin film of PEDOT-N3can be 
formed on top of it and micro-electrodes fabrication may be conducted. Now, some questions may 
come out: first of all, does the PS-N3 layer introduce a surface reactivity on the underlying PEDOT-N3 
film? Secondly, can the COC coating prevent physical adsorption of molecules for post-fabrication 
functionalization? And finally, do the azido groups of polystyrene permit a local functionalization on 
the gaps areas between electrodes?  
 
Figure 3.14 Illustration of optical micrographs of spin-coated PS-N3 films (dissolved in dioxane) on COC maintained under 
environment conditions. The quality of films is reported as function of time. After spin-coating (2min), a homogeneous surface is 
observed whereas already after 5min some imperfections are found. As the exposure time increases, larger structural defects are 
created: rings, particles and comets morphologies are detected until 1h after deposition process.  
 
The presence of PS-N3 film on COC support confers to the surface a reactivity that is higher than that of 
COC, especially toward alkene species whereas the bare support may be modified through molecule 
physical adsorption. This means that azido groups in presence of alkyne moieties can form stable 
covalent bonding of such compounds onto the PS-N3 surface via ´click-chemistry reaction´. Regarding 
molecule adsorption of PS-N3 layer, a preliminary evaluation of repellency properties of azido-
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polystyrene is conducted by incubating a fluorescent protein (fluorescein isothiocyanate-avidin) onto 
the spin-coated PS-N3 film (Figure 3.15). The results suggest that a high protein adsorption onto the 
surface is encouraged even after 1hour of surface washing (confocal micrograph in Figure 3.15). A 
possible approach that can be adopted to create protein repellent surfaces by taking advantage of 
azido reactivity on PS-N3 film, it consists on covalent modification of the polymer through click-
chemistry reaction. In particular, poly(ethylene glycol) (PEG) moieties can be covalently bound to 
polystyrene in order to discourage protein adsorption. In fact PEG is known to confer higher 
hydrophilicity to surfaces and to prevent molecule and cell adhesion. Different PEG-based molecules 
are selected to evaluate whether PEG assembled layers reduce molecules adhesion on PS-N3; 
furthermore, since polystyrene is sensitive to UV-light, various patterns on PS-N3 films are produced to 
better visualize the specificity of functionalization reaction through click-chemistry reaction with 
different PEG molecules. As depicted in Figure 3.16, a spin-coated PS-N3 film is exposed to UV-light 
with a maximum emission peak at 365nm using a traditional UV-aligner; for the fabrication of defined 
patterns onto the film, a chrome mask presenting square grids with different sized structures, is 
applied. The sample is illuminated for 30min and washed with DMSO, isopropanol and ethanol to 
remove degraded polymer. The areas that are exposed to UV-light (in correspondence of transparent 
regions on the mask) are crosslinked in 3D structures. Ideally using this process, any type of 3D 
structures can be produced on the spin-coated film. 
 
Figure 3.15 Illustration of the procedure used to evaluate the molecule adsorption repellency of PS-N3 films. A COC support is 
coated with a layer of PS-N3 (light green), and after polymerization a solution 20µg/mL of FITC-avidin dissolved in PBS is 
incubated on the polymer surface for 30min (dark green). The sample is then washed with PBS for 30 and 60min and the FITC 
fluorescence is detected through confocal laser scanning microscopy (LSM 5, Carl Zeiss, Oberkochen, Germany) using exciting 
light at 488 nm and collecting emitted light of wavelength longer than 505 nm.  
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Figure 3.16 Illustration of 3D patterning process used to create PS-N3 structures. A coated PS-N3 support is exposed to UV-light 
(with a maximum emitting light at 365nm) by applying a chrome mask composed of squared grids (7 x 7 squares with a 
dimension of 60µm). On the chrome mask, in correspondence of transparent areas the UV-light will pass through inducing a 
crosslinking of polymer film, while in correspondence to chrome regions, the light cannot pass and sample is un-exposed. After 
UV-light patterning the sample is washed with DMSO, isopropanol and ethanol to remove degraded film.  
 
 
Figure 3.17 Illustration of the process used to form 3D patterns on PS-N3 film through UV-light exposure (365nm). A chrome 
mask formed by a grid of squares with a diameter of 66µm (4 x 4) is employed to create the corresponding pattern. After 
washing, the 3D structures are incubated with 20µg/mL of FITC-avidin for 30min in PBS. The un-adsorbed molecules are 
washed away and the FITC fluorescence is detected through confocal microscopy (excitation at 488nm and emission collected at 
wavelengths longer than 505nm). The confocal micrograph is reported: the signal of FITC is homogeneous all over the sample 
meaning that the surface is still prone to adsorb molecules.  
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Defined PS-N3 structures are obtained and their further functionalization with PEG-based molecules 
may prevent protein adsorption. In fact, when FITC-avidin is incubated onto the patterned film and 
washed, the fluorescence is found all over the sample (on exposed COC and on 3D PS-N3 patterns, as 
depicted in Figure 3.17). Thus, as also previously shown for un-patterned PS-N3 surfaces, a high 
protein adsorption still occurs and a PEG-modification of film may overcome this limitation. Two main 
PEG molecules are tested: they differ on PEG chain length and chemical reactivity. PEG-alkyne 
(MW~800Da) and PEG-dialkyne (MW~1kDa) contains one and two alkyne groups, respectively. These 
molecules are particularly reactive against the azido groups which are coupled through click-chemistry 
reaction. The click-chemistry reaction, also known as copper catalyzed 1,3-dipolar cycloaddition of 
alkynes and azides (CuAAC), was originally developed by the groups of Meldal[187] and Sharpless[188]. 
The copper catalyzed reaction (Figure 3.18) is highly selective, tolerates a number of other functional 
groups and in general proceeds in high yields at ambient conditions or at moderate temperatures. 
Depending on the copper source it can be tolerant to oxygen and be performed in a number of solvents. 
The catalyst most often used is Cu(I), added as salt or generated in situ by the reduction of CuSO4 with 
sodium ascorbate (NaAsc), where the latter is preferred due to a lower cost, high purity of the active 
catalyst and stability toward oxygen. CuAAC is largely applied for end group functionalization both by 
post and pre-polymerization strategies. This reaction between an azide and a primary alkyne can take 
place in water, in aqueous mixture and in organic solvents at inert reaction conditions. The mechanism 
of 1,4-triazole formation which is the product of reaction, involves Cu(I) that conjugates to the alkyne 
bond and subsequently coordinates to azide causing the formation of triazole. The scheme in Figure 
3.18 represents the click-chemistry reaction mechanism that is used to functionalized patterned PS-
azide surfaces with PEG-alkyne and -dialkyne species.  
 
Figure 3.18 Schematic of click-chemistry functionalization of patterned PS-N3 films. The available azide groups onto the 
polymer surface (in green) react with the incubated PEG-based alkyne species (in red) to form new covalent bonds that result on 
the production of 1,4-triazole groups. The reaction is conducted in presence of a catalyst, Cu(I) which can be added as salt or is 
generated by in situ reduction together with sodium ascorbate. The mechanism takes place at room temperature and in different 
solvents including water or mixture of water and organic solvents. Different types of alkyne or dialkyne species may be used: for 
our purposes, PEG-alkyne (MW=800Da) and PEG-dialkyne (MW=1kDa) are employed.  
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The process is ensured by incubating a mixture of PEG-alkyne (or PEG-dialkyne), copper salt (CuSO4), 
sodium ascorbate (NaAsc) dissolved in 30%v/v DMSO/water; the reaction takes place for circa 
10hours at room temperature. After reaction the sample is extensively washed to remove un-reacted 
compounds; thus, the alkyne or dialkyne molecules that reacted with the available azide groups onto 
polystyrene surface, are covalently bound to the surface via triazole formation. The reaction of PEG-
alkyne species with azide groups permits to cover the patterned polymer with a thin assembled layer 
of PEG. Nevertheless, introducing PEG-dialkyne molecules is possible to benefit of the PEG coating and 
in addition, insert a chemical reactive group (alkyne) onto the surface that may be useful for a later 
post-functionalization. 
Therefore, both PEG-based molecules (alkyne and dialkyne) are tested on patterned PS-N3 surfaces to 
evaluate the efficiency of click-chemistry functionalization and thus, the ability to generate protein 
repellent surfaces due to covalent PEG coating. From the water contact angle measurement (Figure 
3.19) it seems that the functionalization of patterned PS-N3 surface with PEG-alkyne molecules does 
not confer an increased hydrophilicity to the film as expected; the contact angle of PEG-alkyne coated 
surfaces is similar to the one measured for un-modified patterned PS-N3. According to these findings, a 
concentration of FITC-avidin 20µg/mL is incubated in that surface and confocal microscopy detection 
is used collecting the fluorescent signal from the dye after an extensive washing. Conversely to what is 
observed when FITC-avidin is incubated with un-modified PS-N3 (Figure 3.17) in which the molecules 
are found all over the surface, a different scenario is observed when these structures are functionalized 
with PEG-alkyne. In fact, the patterns are clearly visible meaning that a difference on fluorescence 
signal between modified polymer and underlying COC is detected. A larger fluorescence is recorded on 
the COC areas in which the protein is more likely adsorbed, whereas on the PEG-modified PS-N3 square 
structures a lower FITC signal is found. However, it is also notable that the physical adsorption of FITC-
avidin onto the squares is not completely prevented since a consistent fluorescent signal is still 
detected. There are many possible reasons for that behavior: the concentration of PEG-alkyne 
molecules used for click-chemistry functionalization may be too low; or the PEG chain length is too 
short to create a proper steric hindrance; or the functionalization efficiency is low and partially 
modified surfaces are achieved. Although, the reaction of PEG-alkyne species and azide groups is 
selective and no PEG adsorption is found on COC regions; this means that, due to the lack of azide 
groups on COC surface, the click-chemistry in these regions cannot take place and a consequent protein 
adsorption is detected. A different outcome is observed when PS-N3 structures are functionalized with 
PEG-dialkyne moieties: from water contact angle measurement it comes out that an increase on 
hydrophilicity of these structures is found with a decrease in water contact angle. This result already 
suggests that the click-chemistry with PEG-dialkyne species was successful and a further incubation of 
FITC-avidin (20µg/mL) with the modified surface, results on protein repellent structures. The confocal 
micrograph of PEG-dialkyne modified PS-N3 shows that no fluorescent signal is detected onto the 
surface of square structures while a strong signal of the dye is recorded on bare COC regions. These 
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combined results indicate that protein repellent surfaces can be obtained when a click-chemistry 
reaction is conducted with PEG-dialkyne molecules; the reaction takes place only where the azide 
groups are available and hydrophilic surfaces are generated. Further, PEG-alkyne compounds may be 
also used for this purpose but higher concentrations or PEG chain lengths should be used.  
 
Figure 3.19 Functionalization of patterned PS-N3 surfaces (square structures with a diameter of 20µm) with PEG-alkyne and 
PEG-dialkyne molecules through click-chemistry reaction. The reactions are conducted by incubating a mixture of PEG-alkyne 
(800Da, 2mM) or PEG-dialkyne (1kDa, 2mM), CuSO4 (1mM), NaAsc (15mM) in 30%v/v DMSO/water for 10h at room 
temperature. After washing, the samples are characterized through water contact angle measurement; then, 20µg/mL of FITC-
avidin dissolved in PBS is incubated for 30min onto the surface and washed for 1h in PBS. The confocal micrographs show the 
fluorescence signal of FITC recorded by exciting at 488nm and collecting the emitted signal for wavelengths longer than 505nm.  
 
In the light of these considerations, surfaces of PEG-coated COC can be produced in order to have a 
molecule repellent support; the fabrication of PEDOT-N3 electrodes onto this surface will give the 
possibility to create conductive electrodes produced via printed dissolution and functionalize them 
after polymerization. Hence, the molecule repellent underlying layer will be presented in the gaps 
between electrodes. The surface reactivity corresponding to the areas between electrodes may be 
varied according to the final purpose of the platform; as shown, PEG-alkyne modification confers 
partial adsorption repellency to the COC support, and PEG-dialkyne functionalization induces a great 
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coverage of PS-N3. Furthermore, the PS-N3 modification with PEG-dialkyne molecules creates a 
chemical reactive surface due to alkyne groups available at the end of PEG chains. The chemical 
reactivity of these free terminal groups on PEG-dialkyne molecules is evaluated prior PEDOT-N3 
polymerization onto modified COC support. In specific, the reactivity of free alkyne groups on PEG-
dialkyne functionalized PS-N3 is tested by using multiple reaction steps: firstly, a click-chemistry 
reaction with biotin-PEG(7)-N3 is conducted in order to functionalize the available alkyne groups onto 
the surface; then, after a proper washing step, FITC-avidin is incubated. The second reaction will 
permit to visualize the biotin-PEG-N3 modified surface thanks to the high binding constant between 
avidin and biotin. In Figure 3.20 is reported the schematic of reactions and compounds involved on the 
functionalization process. The sample is then analyzed through confocal microscopy to visualize 
whether fluorescence signal is localized onto PS-N3 surface. The enlargement shows a confocal 
micrograph of FITC-avidin fluorescence on the sample, and on the right a 3D plot of the recorded 
picture is included. The fluorescence signal is highly concentrated onto the surface of PS-N3 square 
structures, especially at the edges of the polymer. This result suggests that, even though a passive 
adsorption of FITC-avidin is still localized on COC support, the immobilization of fluorescent molecules 
onto the patterned polymer is augmented through click-chemistry reactions and biotin-avidin covalent 
interaction. However, the originally square shaped PS-N3 pattern seems to be lost since circle-like 
structures are detected when chemical functionalization takes place. It should be also considered that 
three sequential functionalization processes are conducted on the same polymer area; thus, click-
chemistry ensures a selective modification of azide-compounds and its utility may be applied for 
further functionalization. 
In this study, it was presented an approach based on PS-N3 coating of COC support and subsequent 
functionalization via click-chemistry reaction. Depending on the final purpose of a certain application, 
the polymer film can be modified with different molecules; in particular here it was proposed PS-N3 
functionalization with PEG-alkyne and –dialkyne moieties. As stated just above, according to the goal 
on building our platform, one of these two molecules may be preferred to the other. For example, the 
need of a stable repellent coating onto PS-N3 surface may be achieved by covalently binding PEG-
alkyne species; otherwise, when a certain functionality is required at the surface, PEG-dialkyne 
molecules should be chosen due to their steric hindrance and free available alkyne groups. These 
compounds are only examples of many existing functional groups that may be selected. Although this 
method for COC coating and modification can be adopted for other purposes, our goal is to produce a 
COC surface that is chemically reactive and discourages physical adsorption of compounds whether 
post-fabrication modifications will occur. 
Moreover, the use of UV-light assisted patterning of PS-N3 films permitted to locally functionalize the 
polymer according to the presented clicked molecules. For our application, a homogeneous, molecules 
repellent and chemical reactive PS-N3 film is required. The polymerization of PEDOT-N3 on modified 
COC support requires a flat surface in order to create spatially defined micro-electrodes. In fact, the 
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presence of patterned PS-N3 will have a negative effect on the electrodes fabrication, thus no structures 
of PS-N3 are produced rather a flat thin film of PS-N3 is applied. 
An alternative simple, cheap and fast method for COC coating in order to guarantee the needed 
characteristics is based on the direct coating of support with PEG-based molecules and the method is 
described in the following paragraph.   
 
Figure 3.20 Illustration of the reactions involved on the modification of PS-N3 pattern (squares having a diameter of 10µm) 
through click-chemistry reactions and avidin-biotin covalent bonding. On top it is reported a schematic of the mechanism used to 
functionalize the patterned polymer (the red arrows indicate the chemical groups involved in each functionalization step). A first 
click-chemistry is conducted using PEG-dialkyne (1kDa, 2mM), CuSO4 (1mM), NaAsc (15mM) in 30%v/v DMSO/water; then, a 
second click-chemistry is applied to modified the free alkyne groups of PEG with biotin-PEG(7)-N3 (2mM) using the same reaction 
conditions. The exposed biotin molecules at the surface are thus available for a further interaction with FITC-avidin (20µg/mL). 
The sample is washed with PBS and the fluorescence intensity of FITC is recorded using an excitation wavelength at 488nm and 
collecting the emission at wavelengths longer than 505nm. The confocal micrograph of the surface and the 3D fluorescence plot 
are reported on the bottom part of the figure. A small legend with the chemical structures of the used components is depicted on 
the right side.  
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3.3.3.2 PEG-coating of COC for PEDOT-N3 deposition 
The production of modified COC supports for minimizing nonspecific molecules adsorption can be 
achieved utilizing an alternative process to the one based on PS-N3 coating and functionalization. This 
method consists on the PEG coating of support surface through covalent immobilization. In general, the 
approaches used to create PEG coatings include `grafting to´ or `grafting from´ mechanisms.[189] With 
grafting from the surface, a PEG layer is formed via polymerization initiated at the surface which can 
result on a high yield of grafting but less defined coating thicknesses. Grafting to the surface covalently 
binds PEG molecules onto the substrate which can form a stable coating of defined thicknesses and 
homogeneity but a low grafting density may be induced due to steric hindrance surface during 
coupling.[190] In our group, a one-step `grafting to´ method was developed to produce low-binding PEG 
surface coatings on different surfaces.[190,191] This method is based on photo-chemically immobilizing 
PEG coatings onto a surface in an aqueous environment in presence of a water soluble photo-
sensitizer, benzophenone amine. When PEG and benzophenone (Bz) molecules dissolved in aqueous 
environment are exposed to UV-light, which has a broad illumination maximum from 330-380nm, 
using a one-step process, a covalent immobilization of PEG molecules is achieved (Figure 3.21). The 
coupling of PEG molecules onto the surface is directed by UV-assisted formation of amide bonds 
between the activated NHS ester group on PEG molecules and the amine group of benzophenone. 
Under UV illumination, the benzophenone forms bi-radical species that can extract hydrogen from any 
carbon-hydrogen containing molecules at the surface or in solution, including benzophenone itself.[192] 
These activated radicals can then recombine with other radicals and form a new bond onto the surface. 
Benzophenone can be coupled to the surface via its methylene group. The formation of Bz-PEG 
conjugate is induced by radical species that are responsible for the amide bond arrangement without 
the need of coupling agents, such as ethyl(dimethylaminopropyl) carbodiimide (EDC), which are 
normally used to form amide bonds.  The process of PEG coating of COC surfaces depends on many 
parameters, for instance the UV exposure time, the Bz (4-benzoyl benzylamine hydrochloride) and 
PEG-NHS (poly(ethylene glycol)N-hydroxysuccinimide) concentrations and the PEG chain length. Once 
the support is PEG coated, the propensity of surface to adsorb molecules is evaluated using a protein as 
model molecule. From a previous work in our group (Larsen et al.[190]), a concentration of 2.5mg/mL 
Bz and 7.5mg/mL PEG-NHS (MW= 700Da) were found to be the optimal amounts for coating of 
different supports. A solution of Bz and PEG-NHS is dissolved in PBS and a COC support is immersed on 
that mixture. The sample is exposed to UV-light (emission range between 330 and 380nm) for 30min 
and, after a washing step, the water contact angle is measured to estimate the hydrophilicity degree of 
the surface (Figure 3.22A). Furthermore, Larsen et al. incubated a concentration of BSA between 0-
1mg/mL on treated and un-treated COC surfaces and the nitrogen content of different samples was 
measured by X-ray photoelectron spectroscopy (XPS), as shown in Figure 3.22B.[190] 
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Figure 3.21 Schematic of PEG-coating of cyclic olefin copolymer using UV-light assisted “grafting to” method. A solution of PEG-
NHS and Bz is poured onto COC surface and the sample is illuminated to UV-light (emission range between 330-380nm) for 
30min. After washing a PEG coating is covalently attached onto the support surface. The photochemical immobilization of PEG is 
conducted in aqueous environment at room temperature. When Bz is exposed to UV-light, bi-radical species are produced and 
they are responsible for the extraction of hydrogen atoms from any carbon-hydrogen containing molecules. These radicals can 
recombine with other radicals and induce the formation of new bonds at the surface or in solution. The Bz itself can be bound to 
the surface through its methylene group. PEG-NHS is indicated in red and Bz-amine in blue. 
 
In Figure 3.22A it is reported the water contact angle of various modified COC surfaces. In order to 
compare the hydrophilicity of the surface obtained from the coating described in the previous 
paragraph, COC supports modified with PS-N3 and PEG-dialkyne functionalized PS-N3 surfaces are also 
reported. The covalent immobilization of PEG through photo-sensitizer and UV-light reaction results 
on a hydrophilic COC surface, more hydrophilic than that obtained through PS-N3 deposition and 
consequent functionalization. It should be also considered that the process involving PEG-NHS and Bz 
requires a single-step reaction, whereas the previously described approach implies PS-N3 deposition 
and further PEG functionalization through click-chemistry reaction.   
132 
 
 
 
 
Figure 3.22 Characterization of PEG-coated COC surfaces through water contact angle measurement and X-ray photoelectron 
spectroscopy (XPS). (A) Water contact angle measurement of the reference (bare COC), PS-N3 film deposited onto COC, PEG-
modified PS-N3 layer and PEG-coated support via Bz+PEG-NHS photo-chemical immobilization. The contact angle measurements 
obtained from the method described in the previous paragraph are also reported in order to compare the surface hydrophilicity 
obtained with different strategies. (B) XPS analysis of increasing concentrations of BSA incubated on modified COC supports. 
Results show the difference in nitrogen surface concentration, measured by XPS, before and after incubation with nitrogen-
containing BSA for 4 h on modified COC. This study was conducted by Larsen et al.[190] 
 
In this study conducted by Larsen et al.,[190] the PEG-coated COC surfaces were incubated with 
increasing concentrations of protein (bovine serum albumin, BSA) for 4h. After washing, the surfaces 
were analyzed by XPS: the difference in nitrogen surface concentration before and after incubation 
with BSA was taken as a measure of the amount of adsorbed protein, with the caveat that polyimide 
contains nitrogen in its molecular structure. As reported in Figure 3.22B, the amount of protein 
adsorbed on bare COC increases as the incubated BSA concentration increased. Contrarily, a negligible 
amount of protein was found on PEG-coated COC surface when a Bz and PEG-NHS solution were UV-
exposed to create a protein repellent layer. A similar result was observed when a pre-formed UV-light 
Bz-PEG conjugate was re-exposed onto the surface. In absence of PEG or NHS group, a high amount of 
adsorbed protein was detected suggesting the importance of reagent chemical reactivity and the need 
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of PEG molecules to create a steric hindrance at the surface. Therefore, the application of PEG 
molecules together with a photo-sensitive compound (Bz) permits to obtain protein repellent PEG-
coated COC surfaces when exposed to UV-light using a one-step process in aqueous environment.  
As previously pointed out, the presence of chemical reactive groups onto the modified support surface 
may be useful for further modifications. Although the use of PEG-NHS permits to obtain protein 
repellent and hydrophilic surfaces, the poor reactive groups at the chain end may be not useful for 
certain purposes. However, other PEG-based molecules may be applied for PEG immobilization on COC 
support via Bz-amine photo-chemistry. For this reason, the coating of COC supports is evaluated using 
a solution of benzophenone-amine and PEG-diacrylate (PEGDA) which contains an acrylate group at 
each end of the PEG chain; the solution is exposed to UV-light in order to induce radical species 
formation. As described above, the illumination of Bz-amine molecules enhances the production of Bz-
PEGDA conjugates which are immobilized onto the surface. Once the support is PEG-coated, available 
free acrylate groups are presented at the surface and subsequent functionalization may be applied. A 
preliminary test of PEGDA coating with Bz-amine of COC support is conducted: different 
concentrations of PEGDA (2 – 5 – 10 mg/mL; MW=5kDa) and benzophenone-amine (1 – 2.5 – 5 
mg/mL) are dissolved in PBS and UV-exposed for 30min onto the support surface. After washing, the 
water contact angle of surfaces is measured and 20µg/mL of FITC-BSA is incubated on each sample to 
determine the fluorescent signal coming from passively adsorbed protein (Figure 3.23). After 30min of 
exposure, a thin film of PEGDA is immobilized onto the surface, as confirmed by water contact angle 
measurements of samples. A hydrophilic surface is produced for all combinations of PEGDA and Bz 
amounts even though in the graph it is reported only the contact angle of COC discs prepared with a 
concentration of 5mg/mL PEGDA and various Bz amounts. Further, the values of contact angle 
achieved with PEGDA 5kDa are comparable to those obtained using PEG-NHS as grafted polymer. As 
shown in the plot, despite the increasing concentration of benzophenone, the water contact angle 
remains constant suggesting that the amount of Bz (1mg/mL) is enough to create a PEGDA-coated COC. 
When fluorescent BSA is incubated in each sample, a high signal is observed for bare COC disc while a 
lower fluorescence is recorded for modified surfaces. These results indicate the possibility to use 
PEGDA as coating polymer and a deeper study of the process may permit to produce surfaces with free 
available acrylate groups discouraging molecules adsorption. To further improve the PEGDA grafting 
density onto the surfaces, a multi-step process is adopted: a solution of 5mg/mL PEGDA and 1mg/mL 
Bz is exposed for 30min onto the disc; then it is washed and a fresh solution of PEGDA-Bz (5:1) is 
illuminated again for 30min onto the same sample. The process is repeated for a third time resulting 
on a three-layers coating achieved in multiple steps.  
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Figure 3.23 Characterization of PEGDA-coated COC discs through water contact angle measurement. Different concentrations of 
PEGDA (2 – 5 – 10 mg/mL, MW=5kDa) and Benzophenone (1 – 2.5 – 5 mg/mL) are UV-exposed for 30min onto support surface. 
After washing, the contact angle is measured: in the plot are reported the values obtained when a concentration of 5mg/mL 
PEGDA and three different amounts of Bz are used (including the reference bare COC). These samples are then incubated with 
20µg/mL FITC-bovine serum albumin (BSA) for 30min and after washing, the fluorescent signal coming from protein molecules 
physically adsorbed onto the surfaces is recorded. The confocal micrographs are obtained by using an excitation wavelength at 
488nm and the signal is collected for wavelengths longer than 505nm.  
 
In Figure 3.24, the water contact angles of PEGDA-coated COC discs formed respectively by a single, 
double and triple layers using fresh 5mg/mL PEGDA and 1mg/mL Bz solutions, are reported. As 
before, 20µg/mL FITC-BSA is then incubated for 30min onto each modified surface and the 
fluorescence of adsorbed protein molecules is detected by confocal microscopy. The production of 
multi-layers onto the COC disc does not affect the hydrophilicity of the surface since the water contact 
angle of double and triple layers is comparable to that composed of a single layer. However, a great 
improvement of PEGDA grafting coverage of discs results from the amount of FITC-BSA passively 
adsorbed onto the surfaces of double and triple layers. In fact, as the number of PEGDA coatings 
increases, a consistent reduction of BSA adsorption is observed until almost completely protein 
repellent surfaces are formed (triple PEGDA layers).  
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Figure 3.24 Characterization through water contact angle and confocal microscopy of multi-layer PEGDA coating. PEGDA-coated 
COC discs are produced by a multi-step process in which fresh solutions of 5mg/mL PEGDA and 1mg/mL Bz are exposed for 
30min to UV-light repeating the procedure for one, two and three times (a washing step is included between a coating process 
and the other). The water contact angle values of single, double and triple-layers are really similar since the hydrophilicity 
conferred to the surface is comparable due to equal PEGDA-Bz solutions used, in terms of chemical composition. Then 20µg/mL 
FITC-BSA is incubated on each sample and the fluorescent signal is detected by confocal microscopy. As shown from the confocal 
micrographs, as the number of PEGDA coatings increases, a consistent reduction of adsorbed molecules is found.  
 
In the light of the promising results obtained from COC coating with multiple PEGDA layers, triple 
PEGDA-coated surfaces are used to evaluate the chemical reactivity of free available acrylates onto 
their surface. Therefore, samples composed of three PEGDA layers are produced and incubated with a 
concentration 1%v/v of bromine dissolved in water (Br2) for 30min and after reaction, they are 
washed with water. The incubation of bromine with free acrylate groups onto the surface results on a 
bromination of acrylate moieties through classical halogenation, based on the electrophilic addition of 
bromine atoms to alkene groups (Figure 3.25A). Once the bromine molecules are bound to the 
available acrylates, the modified COC discs are analyzed by X-ray photoelectron spectroscopy (XPS) 
measuring the atomic composition at the surface. The content of oxygen, carbon, nitrogen and bromine 
is thus evaluated (Figure 3.25B). As reported in the plot, an increase of oxygen content is detected 
when COC is coated with PEGDA compare to bare COC (in which oxygen should not be detected since 
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Topas is composed of only carbon atoms). Furthermore, really small percentages of nitrogen are found 
on modified discs, suggesting that low amount of benzophenone may remain entrapped within the 
coating layers and a prolonged washing step may be needed. Particularly interesting it is the content of 
bromine on each sample: as the number of PEGDA layers composing the coating increases, a 
proportional amount of bromine is detected onto the surface. This behavior could be due to a higher 
PEGDA grafting density compare to a single layer, thus a larger number of free available acrylate 
groups is detected. 
 
 
Figure 3.25 Multi-layer PEGDA coatings are characterized by bromination and consequent X-ray photoelectron spectroscopy 
measurement in order to evaluate whether acrylate groups onto surfaces are chemically reactive. (A) Schematic of bromination 
reaction: this process involves bromine atoms incubated at a concentration of 1%v/v in water and free alkyne moieties. Through 
electrophilic addition of bromine atoms to acrylate groups, bromines are bound to the surface in an aqueous environment and at 
room temperature. (B) After washing, the samples are analyzed by XPS and their content of oxygen, nitrogen, carbon and 
bromine is measured. 
 
The photochemical immobilization of PEGDA molecules onto COC discs aided by photosensitizer and 
UV-light exposure is a one-step process that is conducted in aqueous environment at room 
temperature. Hence, the easiness, low-cost and high efficiency of PEG molecules grafting render this 
process extremely useful for fabricating protein repellent coating and chemical reactive surfaces. For 
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these reasons, this surface modification is adopted to produce functionalized COC discs which are 
subsequently utilized for PEDOT-N3 electrodes micro-fabrication. After PEDOT-N3 in situ 
polymerization onto a modified support and printed dissolution of the thin film to produce micro-
electrodes, the underlying PEG-coating should ensure a poor chemicals adsorption and post-
fabrication functionalization. In the next paragraph the process involved on electrodes production and 
spatially-controlled chemical modification of the surface is described in more detail.  
 
3.4 PEDOT-N3 micro-electrodes fabrication on PEG-modified COC 
support 
In the previous paragraphs, a detailed characterization of two main methods for COC coating and 
PEDOT-N3 micro-electrodes fabrication on bare COC was described. The integration of these processes 
will ensure the realization of a platform in which conductive polymer micro-electrodes are generated 
on a low-binding PEG-coated surface. In addition, such system will present in-register surface chemical 
reactivity; this means that corresponding to electrodes areas, azide groups will be presented at the 
surface while in the gaps between electrodes reactive acrylate moieties will be found after printed 
dissolution. The choice of use agarose printed dissolution instead of other micro-fabrication 
techniques is mainly due to the possibility of producing structures on a pre-formed coating without 
damaging its chemical functionality. Therefore, inter-digitated PEDOT-N3 micro-electrodes with a 
dimension of 100µm in width are fabricated through printed dissolution on three-layer PEG-coated 
COC support and the resulting platform is characterized through water contact angle, X-ray 
photoelectron spectroscopy and microscopy. PEGDA-based coating, rather than modified PS-N3 
technology, is chosen because fast, cheap and with sequential steps, low-binding PEGDA-coatings are 
achieved. In Figure 3.26 it is shown a schematic of the process used for the fabrication of PEDOT-N3 
electrodes onto PEG-coated support. By using a multi-step process, COC support is modified with a 
triple layer of PEGDA (5kDa) and Bz upon UV-exposure; after washing, a thin film of PEDOT-N3 is in 
situ polymerized onto the surface through spin-coating deposition. The pre-polymer solution is 
composed of EDOT-N3 monomer, Fe(III)TsO and butanol which form a homogeneous thin polymer 
layer (circa 150nm). The film is then exposed to agarose stamping: 10% w/w agarose stamp is pre-
formed by melting the solution onto the surface of silicon mold. Once the system is cooled down, a 
negative replica of the mold design is found onto the agarose stamp surface. The pattern consists of 
two sets of inter-digitated electrodes 100µm wide, 0.5cm long and with 100µm spacing. The formed 
stamp is soaked in an aqueous solution containing the oxidizing agent (sodium hypochlorite, NaOCl) 
and after 15min in the stamping solution, the stamp is pressed gently onto the PEDOT-N3 surface to 
establish a contact and left there for 1min. After printing the sample is washed with a proper post-
stamping washing procedure which is made of an aqueous solution containing a non-ionic detergent, 
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Triton X-100, and a solution 10%v/v Fe(III)TsO in MQ water. The detailed description of printed 
dissolution procedure is reported in the Experimental section of this chapter. Once the sample is 
washed, the film areas that were in contact with the stamp are removed during the washing, whereas 
the regions of PEDOT-N3 un-exposed to the stamp remain onto the surface to form two sets of inter-
digitated electrodes. 
 
Figure 3.26 Schematic of the process involved on the fabrication of micro-electrodes from a thin layer of PEDOT-N3 polymerized 
on a modified COC support. The Topas disc is functionalized through multi-step process with PEGDA (5kDa) and Bz via UV-
assisted exposure. A thin film of PEDOT-N3 is in situ polymerized onto the functionalized support by spin-coating deposition. An 
agarose stamp is molded according to the pattern design of a silicon mold: two sets of inter-digitated electrodes (100µm wide, 
0.5cm long and 100µm spacing) are formed onto the surface of the stamp. Then, it is immersed into a stamping solution 
composed of aqueous sodium hypochlorite (NaOCl) for 15min. The stamp is quickly dried in a stream of nitrogen and put it in 
contact with PEDOT-N3 surface. After 1min the stamp is detached and soaked again into stamping solution for re-use. The 
printed sample is washed with Triton X-100, Fe(III)TsO and water to remove the degraded polymer regions that were in contact 
with the stamp. The photos show the surfaces contact between the agarose stamp and the sample: from the top side of stamp is 
possible to see when the degradation process starts and completes. The red arrows indicate inter-digitated electrodes onto the 
agarose stamp. 
 
 
Agarose has been chosen as stamping material because of its great mechanical stability and fast 
internal diffusion due to the high water content (85-98%); thus, when it is immersed on the stamping 
solution within few minutes an impregnation of the stamp with NaOCl is achieved. The chemical 
dissolution through sodium hypochlorite is known to over-oxidize and degrade the conductive 
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polymer poly(3,4-ethylenedioxythiophene) (PEDOT) leading also to a consistent loss of conductivity 
corresponding to the areas in contact with the stamp.[185,193] The mechanism by which PEDOT degrades 
when exposed to NaOCl is based on the oxidation of the thiophene ring to thiophene-1,1-dioxide 
followed by ring-opening and loss of SO42- (Figure 3.27).[194] Hypochlorite is also known to degrade 
conductive polymer polypyrrole[195] and in general it attacks double bonds of organic compounds. As 
also reported by Hansen et al., the deactivation of PEDOT films when in contact with the stamp ranges 
from few seconds to minutes depending on the film thickness and polymer support.[185] Furthermore, it 
has been proved that the agarose stamp may be re-used several times by immersing it onto aqueous 
sodium hypochlorite solution between a printing cycle and other one.  
 
Figure 3.27 Chemical structures of 3,4-ethylenedioxythiophene, the building block of PEDOT (in the left), and the thiophene 
ring-opening and splitting off of SO42- (in the right). This process is caused by the contact of sodium hypochlorite (NaOCl) during 
printed dissolution, and it results on a chemical over-oxidation of PEDOT in the areas in contact with the stamp. A degradation 
and loss of conductivity at these points is observed. Reproduced from [185]. 
 
From a previous work in our group, an optimized stamping solution and post-printing washing 
procedure have been established, and these methods were utilized for the removal of PEDOT films 
from COC support.[196] Here, the same conditions are adapted for printed dissolution of PEDOT-N3 films 
on modified COC support and bare COC. Hence, Topas discs are coated with a triple layer of PEGDA 
(5kDa) and a thin film of PEDOT-N3 is formed onto the support surface; then the samples are printed 
through agarose stamping. The same procedure is followed for the fabrication of micro-electrodes on 
an un-coated COC support. In Figure 3.28 it is reported the water contact angle of samples after their 
PEGDA-grafting, PEDOT-N3 spin-coating, and printed dissolution by measuring the contact angle of 
fabricated electrodes and of the underlying modified and un-modified support. As previously 
discussed, the hydrophilicity of COC surface increases when PEGDA molecules are immobilized onto it. 
The contact angle of PEDOT-N3 film on bare and modified support is comparable suggesting that the 
presence of a PEGDA coating does not affect the upper polymer layer. After printed dissolution the 
areas in contact with the stamp are removed and the underlying COC and modified-COC are exhibited. 
The contact angle value of exposed COC indicates a more hydrophobic surface than the native PEDOT-
N3 film; however, the contact angle is lower than that of bare COC. The same outcome is observed for 
the underlying PEGDA-modified support: it is expected a hydrophilic surface while the contact angle is 
really close to the PEDOT-N3 electrodes value. The interpretation of these findings is quite difficult 
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since it may be that the agarose stamping process affects the chemical and physical properties of the 
layers, or it may be that PEDOT-N3 is partially removed in correspondence of the contact areas with the 
stamp. Further, it could happen that the chemicals used for printed dissolution or those that are 
degraded during stamping, remain entrapped on the PEGDA coating and a prolonged washing step 
may be needed.   
 
Figure 3.28 Water contact angle measurement of various samples after PEGDA-coating, PEDOT-N3 polymerization, and printed 
dissolution. Inter-digitated electrodes are fabricated both on modified and un-modified COC supports. After stamping, the 
contact angle of corresponding underlying film is measured (PD: UNDERLYING COC or PEG, where PD = printed dissolution), 
including also that of electrodes surface. In the graph, the red arrows indicate the regions of underlying layer in which the 
contact angle is acquired, and the green arrow corresponds to the area of electrode that is considered for the measurement.  
 
 
In order to understand which of these hypotheses is plausible, X-ray photoelectron spectroscopy (XPS) 
measurement is conducted across the fabricated electrodes. For the analysis of surface atomic 
composition, a line scan mode is applied (spot size 50µm) and it is based on drawing a line of a certain 
length across the electrodes; at defined intervals (30µm) along the line, the atomic composition is 
recorded within the spot size. Thus, it is expected to see a profile of the atomic percentage across 
micro-electrodes since the spots selected along the line are partially overlapped (20µm) and a 
continuous signal is detected. In Figure 3.29, the optical micrograph of printed PEDOT-N3 on bare COC 
and the corresponding XPS analysis are reported (A); in Figure 3.29B, the optical and spectroscopic 
characterization of electrodes on PEG-coated COC is included. The optical micrographs show an 
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electrode width and spacing that are circa 100µm; nevertheless, the structures formed onto PEG 
coating present some residues on PEDOT-N3 surface and their coloration is not exactly the same of the 
original film. A clear difference between the two samples on the local atomic composition comes out 
from the two XPS plots: even though the optical picture of electrodes on COC suggests that defined 
structures and complete degradation of polymer in the gaps may be occurred, the XPS profile 
contradicts this observation. Corresponding to the electrodes areas, carbon, oxygen, nitrogen and 
sulfur are detected, while where the polymer is removed, an increase of carbon amount and a 
substantial decrease of the other atoms is observed. However, on the underlying COC, which is 
composed of 100% carbon, circa 10% of the total atomic composition is represented by oxygen and 
even if a smaller amount, also 2% sulfur. The XPS plot of electrodes formed onto PEG-modified surface 
is even worse than the previous one.  
 
Figure 3.29 Characterization of printed PEDOT-N3 electrodes on bare COC (A) and on PEGDA-modified COC support (B). In the 
optical micrographs, inter-digitated electrodes have a width and spacing of 100µm and colored residues are observed on the 
electrodes surface (B). The red lines indicate the Line scan mode that is used to evaluate the local atomic surface composition of 
both samples through X-ray photoelectron spectroscopy (XPS). The measurement is conducted by drawing a line of a certain 
length across the electrodes. The samples are analyzed at defined positions along the line with an interval of 30µm and a spot 
size of 50µm; thus, for each spot there is a signal overlapping of 20µm. In such way, an atomic composition profile of surfaces 
will be recorded. In the XPS graphs, the atomic composition (oxygen, carbon, nitrogen and sulfur) is plotted against the position 
of the spot along the line. 
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The lack of an atomic composition profile suggests that the polymer is partially removed between 
electrodes. In fact, a constant amount of sulfur is detected across the entire length of the line scan and 
in correspondence of PEG underlying coating it is expected at least a reduction of nitrogen and sulfur 
content. Unfortunately, from these preliminary results it seems that the procedure of agarose stamping 
adopted for PEDOT-N3 removal needs to be optimized. Moreover, as shown by XPS, the printed 
dissolution works better on bare support than those PEGDA-coated; the presence of immobilized 
PEGDA molecules may hinder the degradation process, or the adhesion of PEDOT-N3 on such modified 
support may be stronger than the film adhesion on hydrophobic support, thus it results more difficult 
to remove. Various parameters affecting the printed dissolution method may be tuned: for instance, 
the oxidizing agent concentration on the stamping solution, or the non-ionic detergent concentration 
during the washing step, or the temperature at which the process takes place, or the stamping 
exposure time and many other factors. For example, as also reported from the experimental study of 
PEDOT stamping,[196] the substrate stamped without detergent in the stamping solution and/or during 
washing procedure, were found to contain a significant amount of oxygen and sulfur between the 
electrodes indicating the presence of a coherent film. When detergent was added either in the stamp 
and/or in subsequent wash, the printed film was dissolved and washed off exposing the underlying 
COC. It was observed that the presence of Triton X-100 in the stamp helped the removal of over-
oxidized PEDOT from COC accelerating also the process. Contrarily, when detergent was included on 
the stamping solution for PEDOT-N3 printing on COC, a deceleration of stamping was observed; thus, 
the role of detergent was found to be related to the oxidation of PEDOT at the interphase with the 
support. A relevant factor that was tested previously in our group, was the selection of a proper 
solvent for the removal of over-oxidized PEDOT from COC.[196] The PEDOT or PEDOT-N3 films were 
observed to be resistant to a number of polar solvents such as water, ethanol, iso-propanol, n-butanol, 
acetone, acetonitrile and 1,4-dioxane. When PEDOT-N3 films were patterned with an agarose stamp 
soaked in NaOCl, an orange-brown film was produced; by washing them after stamping with DMF or 
DMSO solvent, a transparent film was obtained. However, DMF and DMSO are quite effective solvents 
for dissolving a large number of polymers, therefore their applicability for removal of stamped PEDOT 
materials is limited. It was observed that DMSO/water mixtures up to 90%v/v DMSO were able to 
prevent the dissolution of some supports such as polystyrenes. Although many parameters were 
previously tested in our group, few successful results were obtained on the agarose stamping process 
of PEDOT-N3 films. Here, different factors influencing the printed dissolution are considered in order to 
create defined micro-electrodes and also understand the mechanisms involved on the removal of 
PEDOT-N3 films from COC. PEDOT-N3 films on PEGDA-coated COC supports are produced and printed 
by varying some experimental conditions during the stamping and/or the washing processes. Different 
Triton X-100 concentrations, in the stamp and in the washing solution, and various temperatures at 
which the washing step occurs, are evaluated (Figure 3.30). After micro-electrodes fabrication the 
samples are characterized through XPS by measuring the atomic composition of the underlying 
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support. In Figure 3.30, the experimental conditions and the resulting XPS atomic compositions are 
reported. As described in the table, the stamping solution is composed of constant concentration of the 
oxidizing agent (NaOCl) and variable Triton X-100 amount (0.1 or 1%v/v). The washing solution is 
formed of an aqueous solution containing the detergent and Fe(III)TsO. After 5min of stamping, the 
samples are washed for 10min at variable temperatures through direct immersion of discs into the 
washing solution (which is heated up when required).  
 
Figure 3.30 Study of the effect of different experimental conditions on the fabrication of PEDOT-N3 electrodes on PEGDA-coated 
COC surfaces. When high Triton concentrations and elevated temperatures are applied, an increased efficiency on PEDOT-N3 
removal is observed. In the table it is reported also the atomic composition of the reference, PEGDA-coated COC and of the 
underlying modified supports after printed dissolution. 
 
 
From the XPS results and the appearance of fabricated micro-electrodes (the samples are also analyzed 
through optical microscopy), some considerations about the effect of different experimental conditions 
can be drawn. In general, when the samples are washed at increasing temperatures, a lower amount of 
iron, sulfur, chlorine and nitrogen are detected. The presence of iron on the underlying support may be 
due to its adsorption onto the PEG coating and a prolonged washing step with water may be needed. 
Regarding chlorine atoms, they derived from the contact of the stamp with the sample and a small 
amount is found in all samples. The heating at increasing temperatures may enhance the evaporation 
of chlorine molecules resulting therefore on a lower amount of chlorine between electrodes. The 
presence of nitrogen and sulfur are clearly due to a partial removal of PEDOT-N3 between the 
electrodes and, as the temperature and detergent concentration on the washing solution increase a 
lower amounts are observed. More interesting is the percentage of carbon detected in the underlying 
PEG coating: when a combination of high Triton concentration in the washing solution and elevated 
temperatures are applied, an increased carbon signal is found. Moreover, the use of 0.1%v/v Triton in 
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the stamping solution results in a decelerated removal process since the discoloration of polymer in 
the contact areas starts after 3min; on the other hand, a concentration 1%v/v of Triton in the stamp 
enhances the speed of dissolution and already after 1min from the contact, the film starts to be 
removed. However, even if the best results are obtained when high temperature and Triton 
concentration are applied, the fabricated PEDOT-N3 electrodes still present some imperfections such 
as orange residues, and the size of polymer structures, especially the width and spacing, are smaller 
than the expected sizes (between 50 and 80µm rather than 100µm each). As shown in Figure 3.31, a 
colored polymer film is found in the gaps between electrodes when samples are washed at room 
temperature independently from the Triton concentration used in the stamping solution and during 
the washing (Figure 3.31A). More clear and clean surfaces are obtained when samples are heated at 55 
or 65˚ C (Figure 3.31B). 
 
Figure 3.31 Optical micrographs of printed PEDOT-N3 electrodes on PEGDA-coated COC using a stamping solution containing 
1%v/v Triton and 2% NaOCl and a washing solution made of 1%v/v Triton, 4%v/v Fe(III)TsO kept at room temperature (A); 
stamping solution made of 1%v/v Triton and 2%v/v NaOCl and a washing solution containing 5%v/v Triton, 4%v/v Fe(III)TsO 
heated at 65˚ C (B).  
 
The fabrication of electrodes using the experimental conditions adopted in Figure 3.31B (stamping 
solution made of 1%v/v Triton and 2%v/v NaOCl and a washing solution containing 5%v/v Triton, 
4%v/v Fe(III)TsO heated at 65˚ C) is repeated multiple times in order to evaluate the reliability of the 
process. A further washing step of samples is introduced after heating in the washing solution; in fact, a 
concentration of 60%v/v DMSO/water is used to remove the residues found onto the surfaces. 
Unfortunately, a degradation of the PEGDA coating and reduction of electrodes sizes is observed.  
Potential improvements of the printed dissolution process may be achieved for instance, studying the 
interaction of PEGDA-coated COC with the upper film of PEDOT-N3; a strong interaction of the support 
with the polymer may be make the removal process quite difficult. Furthermore, some limitations of 
the proposed stamping method should be considered; a relevant issue may be the risk of partial 
integration of the PEDOT-N3 in the substrate, leading to a more complicated removal of polymer during 
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printed dissolution. For a better understanding of the reasons that lead to a un-complete PEDOT-N3 
removal, many samples consisting of PEDOT-N3 film deposited onto bare COC supports are prepared 
according to the stamping procedure described above. Briefly, a thin layer of polymer is in situ 
polymerized on COC discs and after washing, it is subjected to agarose stamping utilizing the same 
inter-digitated electrodes design. A stamping solution composed of 1%v/v Triton and 2%v/v NaOCl is 
prepared; the agarose stamp is soaked into this solution and employed for electrodes fabrication. Then 
the samples are washed in an aqueous solution made of 5%v/v Triton and 4%v/v Fe(III)TsO at a 
temperature of 65˚ C. In Figure 3.32, the XPS atomic composition of underlying COC presented after 
printed dissolution is reported. Ten samples are stamped using the same agarose stamp and the atomic 
compositions of the areas in which PEDOT-N3 is removed are analyzed. 
 
Figure 3.32 XPS analysis of ten samples composed of PEDOT-N3 film on bare COC which are stamped with the same re-usable 
agarose stamp. The amounts of chlorine and iron are not reported since their values are null. On the bottom of the figure, it is 
shown the atomic composition profile of one of these ten sample (number 4) obtained by drawing a line across the electrodes 
(spot size 50µm; interval spot 30µm). From the enlargement is possible to better visualize the content of sulfur, nitrogen and 
oxygen.  
146 
 
 
 
The resulting data from this experiment are quite promising even though the process is poorly reliable 
due to the high variability of results. However, in many samples the nitrogen composition is negligible 
meaning that PEDOT-N3 film has been removed in the gaps; perhaps, this observation is not completely 
correct since a high amount of sulfur between electrodes is still found (less than 5% of the total atomic 
composition). According to the chemical interaction of NaOCl with PEDOT materials, in addition to the 
thiophene oxidation, the byproduct SO42- is also produced. It may be that SO42- is difficult to remove 
from the polymer electrodes and COC surface, but anyway it is difficult to predict the reason why after 
printing the sulfur is still present between the electrodes. Despite these considerations, from Figure 
3.32 it is notable a clear atomic composition profile across the structures, whereas PEDOT-N3 films 
printed on PEG-coated COC were characterized by a constant atomic composition profile across the 
surfaces. Therefore with these results we may conclude that the presence of PEG-coating below 
PEDOT-N3 film affects somehow the ability of printed dissolution to remove desired PEDOT-N3 areas. 
On the other hand, a low-binding PEG-coating is necessary for further selective molecules and 
nanoparticles immobilization onto electrodes surface. The physical adsorption of molecules onto a 
printed PEDOT-N3 film on PEG-coated COC should be discouraged on the regions between electrodes. 
Thus, a concentration of 20µg/mL FITC-avidin is incubated on patterned PEDOT-N3 electrodes to 
evaluate the localization of molecules across the surface. 
 
Figure 3.33 Incubation of 20µg/mL FITC-avidin onto printed PEDOT-N3 electrodes on bare COC (A) and on PEG-coated COC (B). 
The red arrows indicate the polymer micro-electrodes while the magenta arrows represent the underlying COC or PEG-coated 
COC.  
 
 
As reported in Figure 3.33, when FITC-avidin is incubated onto printed PEDOT-N3 on bare COC, a high 
amount of passively adsorbed molecules are found on the underlying COC (A), while a low fluorescent 
signal is detected when the PEGDA-coating is the underlying support (B). Hence, it seems that after 
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printed dissolution the PEGDA coating below PEDOT-N3 electrodes is maintained functional and 
consistent protein repellency is achieved.  
Although the printed dissolution of PEDOT-N3 films on PEG-coated COC support is not fully optimized 
because of high variability of fabricated micro-electrodes and poor reliability, the data also suggest 
that the PEG-coating underlying electrodes is still functional after polymer removal. Thus, the overall 
study of support modification and electrodes fabrication encouraged us to explore drug-loaded 
liposomes immobilization onto PEDOT-N3 electrodes through chemical functionalization of PEDOT-N3 
via click-chemistry reaction, despite a deeper optimization of electrodes fabrication is still needed. 
 
3.5 Chemical immobilization of nanoparticles onto PEDOT-N3 
micro-electrodes 
Liposomes are excellent drug carrier because of high loading concentration, stability and under proper 
conditions they can release the loaded compounds. As previously described in Chapter 2, the 
nanoparticles in which we are interested consist of nano-vesicles (diameter around 100nm) which are 
thermo-sensitive. It means that when they are exposed to heat treatment at a specific temperature, 
their cargo is released on the surrounding compartment due to an increased mobility of lipid bilayer. 
More details about liposomes and the mechanism involved on molecule release from their aqueous 
compartment are found in Chapter 2. Since the lipid bilayer of liposomes can be functionalized with 
desired chemical groups or molecules, a suspension of nanoparticles presenting biotin molecules 
grafted onto bilayer are synthesized. Further, the liposomes are composed of stabilizing component 
such as cholesterol and PEG-modified lipids; for a preliminary test, fluorescent vesicles are produced 
by including Rhodamine-labeled lipid (Rho-DSPE) into bilayer. The functionalization of PEDOT-N3 
electrodes to enhance liposomes immobilization is realized by multiple steps based on chemical 
coupling via click-chemistry reaction. The presence of free azide groups onto the electrodes surface is 
utilized to introduce PEG molecules onto the PEDOT-N3 surface. In such way, a chemical spacer 
between the surface and nanoparticles is formed; in particular PEG-dialkyne molecules are reacted 
with available azide groups through click-chemistry. A second step of functionalization is employed to 
add biotin molecules at one of the terminal alkyne group of pre-bound PEG-dialkyne; the incubation of 
fluorescent avidin (FITC-avidin) results on a modified PEDOT-N3 surface with protein molecules. 
Rhodamine-labeled liposomes are derived introducing Biotin-PEG-lipid molecules into the vesicles 
bilayer; a strong binding of such nanoparticles should occur when avidin molecules are presented at 
the surface of the polymer platform. These reactions have been already discussed in the Chapter 3 
(Figure 3.20) where is reported the multi-step chemical functionalization. In Figure 3.34, it is 
visualized the schematic of liposomes immobilization onto printed PEDOT-N3 fabricated on PEG-coated 
COC supports. During these multiple reactions, the overall platform surface is exposed to chemicals 
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and solvents. The presence of a PEG-coating onto COC should ensure a low-binding of these 
components. 
 
Figure 3.34 Schematic of the reactions and compounds involved on the functionalization of printed PEDOT-N3 electrodes on 
PEG-coated COC to stably immobilize nanoparticles onto polymer surface. The red arrows indicate where and which are the 
chemical groups participating to the functionalization. A first click-chemistry is conducted using PEG-dialkyne molecules 
(MW=1kDa), CuSO4, NaAsc in DMSO/water; after washing, a second click-chemistry is involved to modify the free alkyne groups 
with biotin molecules. Then, FITC-avidin is incubated onto the surface and extensively washed; when Rho-labeled liposomes are 
added to the platform, the vesicles should be covalently bound to the free avidin sites.  
 
Since avidin and liposomes are labeled with FITC (green emission) and Rhodamine (red emission) 
respectively, the co-localization of dyes is detected through confocal laser scanning microscopy by 
exciting FITC at 488nm and collecting the fluorescence at wavelengths longer than 505nm, and 
exciting Rho at 543nm and the fluorescent signal is collected for wavelengths longer than 560nm. Both 
dyes are immobilized on PEDOT-N3 electrodes surface (light blue arrows), as indicated in Figure 3.35A 
and B, and lower fluorescence intensities are found on the underlying regions, PEG-coated COC 
(magenta arrows). In panel B some dots on the PEDOT-N3 surface are also observed; these small 
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particles may be residues coming from polymer dissolution or they might be liposome aggregates. An 
inadequate electrode fabrication results from the morphology and size of the structures which are 
bigger than the expected size (100µm). 
 
Figure 3.35 Confocal characterization of PEDOT-N3 electrode surface modification. The polymer is deposited on a PEG-coated 
COC support. The electrodes are then functionalized through click-chemistry reactions with PEG-dialkyne molecules, and with a 
subsequent step involving biotin-PEG-azide molecules. FITC-avidin is incubated and after washing, the immobilization of 
Rhodamine-labeled liposomes is ensured via avidin-biotin covalent binding. The FITC is excited at 488nm and its fluorescence is 
collected at wavelengths longer than 505nm, while Rho is excited at 543nm and its fluorescent signal is acquired for 
wavelengths longer than 560nm. The light blue arrows indicate the PEDOT-N3 micro-electrode surface while the magenta 
arrows correspond to the underlying PEG-coated COC support. 
  
Although the poor definition of polymer electrodes and the presence of residues onto the surface, the 
avidin and liposomes seem to be co-localized on the same areas corresponding to the PEDOT-N3 
electrodes. The steric hindrance of PEG molecules onto the underlying coating again, demonstrates to 
be effective against protein physical adsorption. However these results are not reproducible meaning 
that many issues are encountered when trying to immobilize liposomes. For instance, liposomes 
aggregation onto the overall surface is often observed and co-localization of avidin and biotin-
liposomes rarely happens due to defects on stamped electrodes or a complete coverage of the platform 
surface with liposomes. These considerations suggest that a further optimization of printed dissolution 
and reaction conditions needs to be done; the platform should be stable and reliable and defined 
polymer regions must be fabricated, to direct the immobilization of liposomes within precise and 
confined structures. Other improvements may be done changing the surface chemistry, or the 
electrode design, or the stability of liposomes suspension. Printed dissolution is an in-expensive 
process because avoids clean-room processes. The novelty of the method lies in the use of non-ionic 
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detergents to remove polymer films, even though it is not clear if the detergent aids the general 
oxidation of the film in the bulk. In general, a locally over-oxidation and dissolution of a conducting 
polymer thin film induces the exposure of an underlying chemical reactive support; thus, this 
technology might be suitable for other types of polymers. A deeper investigation of PEDOT-N3 
fabrication should be conducted in order to have a clear consciousness of how the previously 
described experimental factors affect the proposed methodology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
151 
 
 
 
3.6 Conclusions 
Originally, the development of such micro- and nano-platform was intended for co-localization of drug-
loaded liposomes and cancer cells (CRC cells). In-register surface chemistries for liposomes 
immobilization and cells capture on the platform surface could be applied ideally for any kind of 
particles or cell lines. During the fabrication of this system, different approaches for support coating 
have been proposed. Depending on the intended application of the platform, a PEG-coating onto the 
support surface can be introduced to discourage molecules physical adsorption. The coating may be 
achieved using various types of PEG-based compounds: for instance, PEG-NHS has been demonstrated 
to be grafted onto a surface when exposed to UV-light in presence of a proper photo-sensitizer (Bz). 
Otherwise, PS-N3 may be deposited onto a surface and subsequently functionalized with PEG mono- or 
di-alkyne species; or PEGDA molecules can be directly grafted onto a support through photochemical 
activation. All these methods are suitable for surface coating and, depending on the intended 
application, one is preferred to the other; for example, the photo-induced PEG grafting is advantageous 
when rapid processes are involved, since it is conducted through a single step reaction in aqueous 
environment. In our case, a stable and high PEG density grafting is necessary because many post-
fabrication processes need to be consecutively applied on the same surface. Moreover the coating 
should remain un-damaged when a printed dissolution process is used for removal of thin PEDOT 
materials. Post-functionalization of micro-structures can be achieved through click-chemistry reaction 
that represents a stable covalent modification of a surface copper-catalyzed in DMSO/water solution. 
In conclusion, the use of printed dissolution for creating polymer structures needs to be optimized for 
our final purposes even though it showed important advantages compare to traditional nano-
fabrication technology. Once the fabricated micro-electrodes are defined in morphology, size and 
composition, a post-functionalization of their surface will permit to immobilize ideally, any type of 
molecules. In future, the possible application of a specific current to conductive electrodes may permit 
to locally induce the release of drugs from thermo-sensitive liposomes due to their sensitivity towards 
temperature changes. 
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3.7 Experimental section 
Fabrication of Cyclic Olefin Copolymer (COC) supports 
Cyclic Olefin Copolymer (COC) supports, also known as TOPAS from the brand, were made using 
injection molding. We applied in-house fabricated circular supports with a diameter of 5cm and 2mm 
in thickness using a commercial injection molding machinery (ENGEL VC 80/45, Schwertberg, Austria). 
TOPAS 5013 supports were made at 130˚ C using a 4min cooling process. 
PEDOT-N3 deposition and in situ polymerization 
The monomer EDOT-N3 was synthesized in accordance with an earlier reported procedure.[175] PEDOT 
and PEDOT-N3 thin films were fabricated by spin-coating and in situ polymerization on injection 
molded cyclic olefin copolymer supports (TOPAS 5013, TOPAS® Advanced Polymers, Frankfurt, 
Germany). The COC were washed before with acetone, iso-propanol, ethanol and water prior to spin-
coating. EDOT-N3 (20mg, 0.15mmol), CLEVIOS C-B40 (0.48mL, 40 wt% Fe(III)tosylate (TsO) in 1-
butanol, H. C. Starck, Goslar, Germany), and 1-butanol (0.48mL) were mixed and spin-coated onto the 
COC surface at 1000rpm for 30s. EDOT (220µL), CLEVIOS C-B40 (6.5mL, 40wt% Fe(III)tosylate (TsO) 
in 1-butanol), pyridine (150µL) and 1-butanol (2.0mL) were mixed and spin-coated at 1000rpm for 
30s. The samples were placed in a hotplate at 70˚ C for 3min and subsequently washed with water and 
ethanol and blown dry in a nitrogen flow, yielding a film thickness of approximately 150nm. 
Agarose stamp preparation  
For the printed dissolution technique, an agarose stamp presenting the negative replica of a silicon 
mold pattern was prepared. The silicon mold was fabricated using conventional photolithography and 
deep reactive ion etching. Prior the use of silicon mold for agarose stamp fabrication, the mold was 
washed in ethanol and rinsed in air plasm to remove residues of organic material. The silicon mold was 
placed in a hotplate at 65˚ C. A solution 10%w/v of agarose (Sigma Aldrich) in MQ water was mixed 
thoroughly and it was heated up in a microwave oven until air bubbles disappeared from the solution. 
To prevent boiling of agarose solution, this was done by using multiple short heating steps. The melted 
agarose was poured directly onto the silicon mold surface aided by a polystyrene Petri dish (Ø 5cm) 
where the bottom was removed in order to contain the solution when melted onto the mold. The 
container was covered with its lid and kept for 10min on the hotplate. The mold was transferred to the 
fridge for 20min to cool down. After fabrication of the stamp, it was usually cut to have a final thickness 
around 1-1.5cm for improved handling. 
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Agarose stamping procedure 
After fabrication, the agarose stamp was soaked into a stamping solution for at least 15min and before 
contact with the sample, it was blown off using air gun. The stamp was gently pressed onto the surface 
of the sample to establish a contact, and left for 5min (1min for PEDOT removal). The stamp was then 
removed and immersed again on the stamping solution for subsequent re-use. The stamping solution 
was composed of NaOCl (stock solution 10-15%w/v, Sigma Aldrich) at a final concentration of 2%w/v, 
and Triton X-100 (Sigma Aldrich) at various concentrations (we tested 0.1 and 1%v/v) in aqueous 
solution. 
Post-stamping washing procedure 
Normally, after stamping the samples were washed for 10min in an aqueous solution of 0.1%v/v 
Triton X-100; then they were washed twice for 10min with MQ water at 50˚ C and 10min in 80%v/v 
DMSO/MQ at room temperature, before rinsing in ethanol and MQ. Some of the samples were washed 
also with various concentrations of Triton X-100 (0.1 – 1 – 5%v/v) and with CLEVIOS C-B40/MQ 
(4%v/v). In some cases the temperature at which the samples were heated up was 55 or 65˚ C.  
Synthesis of 4-(azidomethyl)styrene (PS-N3) 
PS-N3 was synthesized and characterized by Dr. A.E. Daugaard. 
2,2’-Azobisisobutyrylnitrile (AIBN, 71.2 mg, 0.4 mmol), 4-(chloromethyl)styrene (10 mL, 71.0 mmol 
and xylene were mixed in a Schlenk tube and the solution was bubbled through with nitrogen for 30 
min. The polymerization was run under a positive nitrogen pressure at 65°C for 18 h. The polymer was 
precipitated in methanol, filtered and dried in vacuo. The isolated intermediate (poly(4-
(chloromethyl)styrene)) was a white powder and was used for the following step without further 
purification (6.4 g, Mn= 30000 g/mol, PDI= 1.7). FT-ATR-IR (cm-1): 3100-2800 (C-H stretch); 
1612+1510 (aromatic ring stretch); 672 (C-Cl stretch). 1H-NMR(CDCl3, 300 MHz, dH, ppm): 1.39 (m, 
2H, CH2-CH); 1.70 (m, 1H, CH-CH2); 4.52 (s, 2H, CH2-N3); 6.49, 7.05 (2xm, 4H, aromatic H). HSQC 
confirmed the following proton/carbon correlations (dH/dC (ppm)): 1.39/41.6 (CHCH2); 1.70/38.7 
(CH-CH2-ph); 4.52/44.9 (CH2-N3); 6.49/126.4 (aromatic CH); 7.05/127.0 (aromatic CH). Poly(4-
(chloromethyl)styrene) (5.18 g, 34.0 mmol functional group) was dissolved in DMF (100 mL) and 
NaN3 (2.75 g, 42.4 mmol) was added to the solution. The reaction mixture was stirred at 40°C for 18 h 
under nitrogen. After reaction the excess of reagent was removed by precipitation into H2O. The 
precipitate was isolated by filtration and rinsed with copious amounts of H2O and methanol. The solid 
was dissolved in THF and precipitated in methanol to afford poly(4-(azidomethyl)styrene) as a white 
powder (4.62 g, 86%). FT-ATR-IR(cm-1): 3100-2800 (C-H stretch); 2090 (C-N3 stretch); 1612+1510 
(aromatic ring stretch). 1H-NMR(CDCl3, 300 MHz, dH, ppm): 1.39 (m, 2H, CH2-CH); 1.69 (m, 1H, CH-
CH2); 4.24 (s, 2H, CH2-N3); 6.48, 6.97 (2xm, 4H, aromatic H). HSQC confirmed the following 
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proton/carbon correlations (dH/dC (ppm)): 1.39/44.9 (CHCH2); 1.69/40.4 (CH-CH2-ph); 4.24/54.0 
(CH2-N3); 6.48/127.7 (aromatic CH); 6.97/127.7 (aromatic CH). NMR spectroscopy was performed on 
a 300 MHz Cryomagnet from Spectrospin & Bruker (1H-NMR at 300 MHz, 13C-NMR at 75 MHz), at 
room temperature. IR was performed on a PerkinElmer Spectrum One model 2000 Fourier transform 
infrared system with a universal attenuated total reflection sampling accessory on a ZnSe/diamond 
composite. 
PS-N3 film deposition on COC support 
Solutions of PS-N3 were prepared by dissolving 5mg/mL of polymer in 4-dioxane (Sigma Aldrich) or 
PGMEA and they were filtered through Ø =0.22µm pores. The solutions were spin-coated on COC 
supports at 1000rpm for 30s, and they were heated up on a hotplate at 60˚ C to remove residual 
solvent. The films were characterized measuring the water contact angle of surfaces (Data Physics 
OCA20 contact angle system). Prior each measurement, the samples were blow with inert gas to 
remove dust.  
Protein physical adsorption onto different surfaces 
To evaluate the propensity of molecules to passively adsorb onto various surfaces, the samples were 
incubated with a concentration of 20µg/mL of FITC-avidin or FITC-BSA (both dissolved in PBS buffer) 
for 30 minutes using a 10mm x 10mm in situ Gene frame (Thermo Scientific). FITC-BSA and FITC-
avidin were obtained from Life Technologies. 100µL of solution was incubated onto desired surfaces. 
After incubation, the samples were washed three times with PBS and rinsed with PBS. For visualization 
of fluorescence signal, a cover slip (10mm x 10mm) was placed onto the gene frame and confocal laser 
scanning microscopy was used to evaluate fluorescence (LSM 5, Carl Zeiss, Oberkochen, Germany). 
Fabrication of patterns on PS-N3 films 
PS-N3 films were deposited on COC discs and they were exposed to UV-light at 365nm in a MA4 mask 
aligner (Suss Microtec) by using a chrome mask presenting square grids with different sized 
structures. A grid of 7 x 7 squares with diameter of 60µm was used to form the pattern. The samples 
were exposed for 30min and washed with DMSO, iso-propanol and ethanol to remove degraded 
polymer.  
Functionalization of patterned PS-N3 via post-polymerization CuAAC 
In correspondence of fabricated patterns, a Gene frame (10mm x 10mm) was placed onto the PS-N3. 
The functionalization of polymer was conducted using two different molecules: PEG-alkyne 
(MW=800Da) and PEG-dialkyne (MW=1kDa). These molecules were purchased by Creative PEGWorks. 
A mixture of 2mM PEG-alkyne, 1mM CuSO4, 15mM NaAsc and 70mM NaCl dissolved in 30%v/v 
DMSO/water, and a mixture of 2mM PEG-dialkyne, 1mM CuSO4, 15mM NaAsc and 70mM NaCl 
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dissolved in 30%v/v DMSO/water were incubated on the printed PS-N3 surface (100µL total volume). 
The solution was incubated for 10h at room temperature and the samples were washed with water 
and rinsed with MQ water for confocal characterization. The samples that were functionalized with 
PEG-dialkyne were subjected to a subsequent click-chemistry reaction by incubation 2mM azide-
PEG(7)-biotin (Creative PEGWorks), 1mM CuSO4, 15mM NaAsc and 70mM NaCl dissolved in 30%v/v 
DMSO/water. The reaction was stopped after 10h by extensively washing the samples with MQ water. 
Then, 20µg/mL of FITC-avidin was incubated on the sample for 30min. After washing with PBS, the 
surface was rinsed with PBS and a cover slip was placed on top of the gene frame. The fluorescence 
signal of protein was detected through confocal microscopy.  
PEG-NHS and Bz-NH2 coating of COC supports 
Small pieces of COC support were cut and attached with a tape on the bottom of a 24 well-microtiter 
plate (Nunc, Thermo Scientific). The samples were immersed in a solution of 7.5mg/mL PEG-NHS 
(MW=700Da, Iris Biotech) and 2.5mg/mL Benzophenone-amine (FluoroChem, Hadfield, UK) dissolved 
in 80%v/v PBS/MQ water. The plate was illuminated for 30 min in a photo-reactor (Philips Cleo S-R 
fluorescent tubes) at an emission maximum between 330-380nm. The samples were washed with 
water three times and with ethanol. The water contact angle and the X-ray photoelectron spectroscopy 
(XPS) were used to characterize the surfaces atomic composition. Data analyses of the XPS spectra 
were performed using Avantage software package supplied by the manufacturer. For the line-scan 
measurements, the elemental composition of each spot was determined from the high resolution 
spectra, using the build-in add-peak function with a linear background. In the following atomic content 
determination a standard of 0.9 signal to noise threshold was used for all samples. For line-scan 
investigations a 50µm spot size and an interval size of 30µm were utilized. This means that in each 
single 100µm electrode, as well as in each gap area, there will be at least one measurement point 
where the atomic composition will originate entirely from that electrode/spacing area. For all samples, 
flood-gun charge compensation was used.  
PEGDA and Bz-NH2 coating of COC supports 
In a 24 well-microtiter plate, small pieces of COC support were attached to the bottom of each well 
using a tape and different concentrations of PEGDA (MW=5kDa, Iris Biotech) and Benzophenone were 
added to each sample. 2 – 5 – 10 mg/mL of PEGDA and 1 – 2.5 – 5 mg/mL of Bz were the selected 
amounts to be tested; these mixtures were dissolved in 80%v/v PBS/MQ and poured in various wells. 
The entire plate was exposed to UV-light in a photo-reactor for 30min; after washing with water, the 
samples were analyzed through water contact angle. Further, 20µg/mL of FITC-BSA dissolved in PBS 
was incubated in all samples using a gene frame (10mm x 10mm) for 30min. The un-adsorbed 
molecules were washed off with PBS and samples were rinsed in PBS, and a cover slip was placed onto 
the frame. The fluorescent intensity of all surfaces was recorded by LSM confocal microscopy.  
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From the obtained results, the optimal concentrations of PEGDA and benzophenone were found to be 
5mg/mL of PEGDA and 1mg/mL Bz. Multiple layer of PEGDA/Bz were also produced on the same 
support using a layer-by-layer photochemical grafting. As before, small pieces of COC were attached on 
the bottom of 24 well-microtiter plate with a tape. A mixture of PEGDA/Bz (5:1) was poured in each 
well and they were exposed to UV-light in the photo-reactor for 30min. After washing with MQ water 
and blown dry, they were re-immersed in a fresh solution of PEGDA/Bz (5:1). Again, the samples were 
exposed for others 30min and after illumination the pieces were washed with water. A third step using 
the same conditions and concentrations of reagents was conducted. 20µg/mL of FITC-BSA was 
incubated in each surface as previously described and the fluorescence was evaluated. 
 
Bromination of free available acrylate groups 
The chemical reactivity of PEGDA-coated COC supports was evaluated incubating a concentration of 
1%v/v Bromine (Sigma Aldrich) dissolved in water onto the modified surface of COC. After 30min of 
incubation with Br2, the supports were washed with water and analyzed by XPS, since bromine is a 
good XPS marker. The nitrogen, oxygen, carbon and bromine atomic composition was recorded using 
point-mode (point size=20µm).   
 
Fabrication of printed PEDOT-N3 micro-electrodes on un-coated and three-layer PEGDA-coated COC 
support 
A three-layer PEGDA coating on COC support was produced by using the procedure described just 
above; thus, PEDOT-N3 films were produced on bare COC and PEGDA-modified support. After 
polymerization, the agarose stamp was prepared according to the desired pattern: it consisted of two 
sets of inter-digitated micro-electrodes (100µm in width and spacing and 0.5cm long). The negative 
replica was fabricated onto the stamp surface, which was immersed in a solution of 1%v/v Triton and 
2%w/v NaOCl. After 15min of impregnation, the stamp was put in contact with samples. The discs 
were washed using a solution of 1%v/v Triton and 4%w/v CLEVIOS in aqueous solution at room 
temperature. The samples were then rinsed with MQ water and blown off. The XPS was used to 
investigate the elemental composition applying a line-scan measurement (spot size= 50µm; interval 
size= 30µm). Moreover, the water contact angle of the underlying COC or PEGDA coating was analyzed. 
 
Optimization of printed dissolution  
 
In order to evaluate at which conditions was observed a complete removal of PEDOT-N3 from PEGDA-
coated surfaces in the gap regions, different parameters were tested: the concentration of Triton in the 
stamping solution and in the washing procedure, and the temperature at which the washing step took 
place. The Triton concentration tested in the stamping solution was 0.1 – 1 %v/v whereas in the 
washing procedure a detergent amount of 0.1 – 1 – 5 %v/v was tested. Further, a constant amount of 
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NaOCl (2%v/v) and CLEVIOS (4%v/v) respectively in the stamping and washing solutions were 
utilized. Various temperatures of washing were also explored: room temperature, 50, 55, 65˚ C. A glass 
Petri dish containing Triton and CLEVIOS in aqueous solution was used to immerse the sample into the 
washing solution keeping the dish in a hotplate at a certain temperature without lid in order to favorite 
evaporation. The stamp was left on the sample for 5min and placed in the stamping solution for 15min. 
The fabricated micro-electrodes were analyzed through water contact angle and XPS (line-scan mode). 
 
PEDOT-N3 micro-electrodes fabrication on bare COC support 
 
Ten samples of PEDOT-N3 film deposited onto bare COC supports were produced according to the 
protocol previously described. Then an agarose stamp with inter-digitated electrodes was fabricated 
and kept in a stamping solution composed of 1%v/v Triton and 2%v/v NaOCl for 15min. The samples 
were stamped for 5min each using the same agarose mold; they were washed in a washing solution 
made of 5%v/v Triton and 4%v/v CLEVIOS for 15min at 65˚ C. Then they were washed with water and 
blown off with air flow. Their atomic composition was analyzed by XPS (point size= 20µm). 
 
Covalent immobilization of Rhodamine-labeled liposomes on PEDOT-N3 micro-electrodes deposited on 
PEGDA-coated COC support 
 
A liposomes suspension having an average diameter of 117.7nm (polydispersity= 0.118) and a zeta-
potential of -7.09mV (± 0.41mV), were synthesized according to the protocol reported on the 
manuscript (Appendix 1). The lipid composition was formed by: 94.5% DSPC, 4% DSPE-PEG2000Da, 1% 
DSPE-PEG2000Da-biotin and 0.5% DOPE-rhodamine. All lipids were purchased from Avanti Polar Lipids. 
The liposomes were prepared to have a functional group into the bilayer, biotin, and a dye to track 
their fluorescence (Rhodamine).  
PEDOT-N3 electrodes were produced on a three-layer PEGDA-coated COC support and they were 
functionalized according to the protocol previously described (“Functionalization of patterned PS-N3 
via post-polymerization CuAAC”). Therefore, the electrodes were functionalized through a double click-
chemistry to present at their surface, FITC-avidin molecules. The stock suspension of liposomes 
(25mM) was diluted in HEPES buffer 1000-times to have a final concentration of 25µM. Using a Gene 
frame (10mm x 10mm), 100µL of 25µM Rhodamine-labeled liposomes were incubated for 1h onto the 
functionalized surface. Then, the samples were washed with PBS buffer and rinse with PBS. A cover 
slip was placed onto the Gene frame and the FITC-avidin and Rhodamine-liposomes fluorescent 
intensities were analyzed by LSM confocal microscopy. 
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4 Perspectives & Conclusions 
 
In this thesis two main polymer platforms have been developed for drug screening purposes. One of 
these technologies consists on using PEGDA hydrogels for controlled embedding of single drugs and 
combinations of chemotherapeutics commonly used for the treatment of colorectal cancer (CRC). 
Eventually, drug-loaded nanoparticles (liposomes) can be entrapped within the polymer matrix to 
protect and temporally control the release of loaded molecules. The cytotoxicity of such system has 
been tested on human colorectal adenocarcinoma cell line (HT29) comparing the anti-proliferative 
effect of small doses of free drugs (dispersed in the cell medium) with those of compounds embedded 
within PEGDA hydrogel. Furthermore, the application of a home-made technology based on the use of 
visible-light printing has permitted to fabricate spatially defined hydrogel matrices. The production of 
hydrogels having certain architectures and sizes was accomplished through in situ visible-light photo-
polymerization in a rapid, low cost and reliable process. Moreover, the overall procedure has been 
conducted in an aqueous environment limiting the exposure of the cell line to organic or toxic solvents. 
The great outcomes and reproducibility obtained with such platform demonstrate the possibility to 
extend the use of PEGDA hydrogels for other molecules screening. By tuning the chemical and physical 
properties of PEGDA networks and by including drug-loaded liposomes within the gel, was possible to 
temporally control the release of certain molecules. Hence, the use of PEGDA hydrogels may be 
extended towards the screening of various compounds or in different fields. For instance, the 
hydrogels might be fabricated in even smaller scale, and integrated in microfluidic devices for perfused 
rather than static release. In future, PEGDA gels might be used for tissue engineering purposes by 
releasing necessary molecules such as growth factors for the enhancement of cell differentiation. In 
addition, it has been demonstrated that large molecules can be released when hydrogel composition is 
adjusted; thus, a possible future application could be the release study of interesting molecules such as 
antibodies which are largely used in cancer therapy. Although the major focus of this study has been to 
tailor the properties of PEGDA hydrogel for drug screening purposes and cell handling systems, we 
believe that our findings should be of general understanding of PEG-based hydrogels, and that this 
polymer will also be useful for adapting hydrogels to other applications such as tissue engineering. 
 
The second platform that has been studied is based on the fabrication of conductive polymer micro-
electrodes for drug-loaded liposomes immobilization and cell capture purposes. PEDOT-type 
conductive polymer has been selected as candidate for the realization of such system. In particular, 
PEDOT-N3 thin film has been used to create micro-patterns on a support. The presence of reactive 
groups at the polymer surface has permitted to post-fabrication functionalize the micro-structures to 
covalently immobilize drug-loaded nanoparticles onto such surfaces. One of the important 
requirements for succeeding nanoparticle immobilization and cells capture when tuning the surface 
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chemistry of advanced materials for bio-medical devices, is the specificity. The need of a support that is 
repellent meaning that it should discourage molecules physical adsorption is crucial. In fact, the 
unspecific adsorption of molecules, particularly proteins, can change the biochemical properties of a 
substrate. This problem is mostly prominent when the support is being subjected to long-time 
exposure to solutions containing such bio-molecules. Our approach to solve this issue was to engineer 
the support surface by introducing highly hydrophilic molecules in order to prevent unspecific 
adsorption and at the same time presenting functional moieties. We fabricated a support that was 
coated with PEG-molecules containing chemical reactive groups. Photo-chemical immobilization of 
PEG-NHS or PEGDA molecules on COC supports was produced with a fast and reliable process 
involving the use of a specific photo-sensitizer. The support was alternatively coated with PS-N3 
polymer that was functionalized after deposition with PEG molecules. The use of PEG-NHS or PEGDA 
coatings was preferred to the modified PS-N3 because their use was more rapid, reproducible and the 
coating process was entirely conducted in an aqueous environment. To ensure specificity on 
immobilizing nanoparticles, the synthesis of vesicles was optimized to have functional groups into the 
lipid bilayer. Biotin-functionalized liposomes were used to favorite their binding onto PEDOT-N3 
electrodes through specific modification of conductive polymer surface. The click-chemistry reaction 
(CuAAC) has been applied for micro-electrodes modification and liposomes binding was evaluated. 
Another requirement for the development of that micro- and nano-platform was the fabrication 
technique to be applied for integrating bio-components on the polymeric device. In our group, an 
innovative and fast method for PEDOT materials micro-fabrication (printed dissolution) was 
developed and successfully utilized for the production of PEDOT micro-electrodes. Despite the great 
suitability of printed dissolution to pattern conductive polymers and the un-necessary clean room 
facilities, agarose stamping has been proved to be inefficient for patterning of PEDOT-N3 films when 
polymerized onto PEG-modified cyclic olefin copolymers. Inhomogeneous polymeric electrodes have 
been obtained due to a partial dissolution of thin film between the electrode areas, and leftover 
residues were observed at the polymer surface. An extensive optimization of the methodology is 
required: different PEG-modified supports should be tested and the experimental conditions should be 
explored more deeply to understand how and with which importance they affect the stamping process. 
In our efforts to create a platform presenting in-register chemistries for liposomes immobilization and 
cell capture, there are many important issues and approaches that we did not investigate. For example, 
even though liposomes were found to be chemically bound to the polymer electrode surface, 
nanoparticles precipitation and agglomeration was observed. We did not attempt to control the 
surface roughness of our electrodes after conjugation with liposomes. In the light of that, when 
nanoparticles are immobilized onto the polymer, ideally it could be possible to temporally control the 
release of their cargo (for example a drug). We have demonstrated that thermo-sensitive liposomes 
can release loaded molecules by applying a thermal trigger reaching a temperature that corresponds to 
the phospholipids phase transition temperature. Therefore, for future studies should be interesting to 
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monitor the molecule release from liposomes induced by the application of current on the polymer 
electrodes. Despite the charge transfer along electrodes, a local resistive heating might be induced. 
Preliminary studies should be conducted to determine the voltage required to induce a phase 
transition temperature of liposomes; a fluorescent ruthenium complex sensitive to small temperature 
changes may be used to track the local increase of temperature at the electrodes surface when various 
voltages are applied.[197,198] Other improvements of our platform can be studied in future by 
immobilizing cell-capturing molecules on the modified support corresponding to the areas between 
polymer electrodes. For example, specific antibodies for cell capture can be immobilized through 
Protein G or A adsorption onto the support.[199] The conjugation of immobilized antibody molecules to 
antigen moieties presented at the cell membrane may be exploited to capture specific cell lines onto 
the platform. In addition, an important progress of our micro- and nano-platform may be achieved in 
future integrating the support with fabricated electrodes with a microfluidic system. In such a way, the 
two components can be bonded together to have a final micro-fluidic chip in which the presence of a 
channel might be useful for post-fabrication polymerization. With this approach some of the issues 
previously described may be overcome: liposomes aggregation during their immobilization can be 
avoided through a perfused functionalization step and a close system can guarantee the sterility 
required for cells capturing.  
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MULTIPLEXED DOSING ASSAYS BY DIGITALLY 
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Multiplexed Dosing Assays by Digitally Definable Hydrogel Volumes 1 
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multiplexed compound screening, liposomes, cancer   11 
Abstract  12 
Spatially defined projected light photopolymerization of hydrogels with embedded active 13 
compounds is introduced as a flexible and cost-efficient method for producing multiplexed 14 
dosing assays. Stable and cost-efficient multiplexed drug sensitivity assays using small cell or 15 
tissue volumes are in demand for personalized medicine, including cancer patient specific 16 
combination chemotherapy considered here. Here, the high spatial resolution of light projector 17 
technology defines multiple compound doses by the volume of individual compound-embedded 18 
hydrogel segments. Quantitative dosing of multiple proteins are demonstrated using fluorescent-19 
2 
labeled albumins with a dynamic range of 1-2 orders of magnitude. The hydrogel matrix results 20 
from photopolymerization of low cost poly(ethylene glycol)diacrylates (PEGDA), and tuning of 21 
the PEGDA composition enables fast complete dosing of all tested compounds. Dosing of 22 
hydrophilic and hydrophobic compounds is demonstrated using two first-line chemotherapy 23 
regimens combining oxaliplatin, SN-38, 5-fluorouracil, and folinic acid, with each compound 24 
being dosed from a separate light-defined hydrogel segment. Cytotoxicity studies using a 25 
colorectal cancer cell line show equivalent effects of dissolved and released compounds. Further 26 
control of the dosing process is demonstrated by liposomal encapsulation of oxaplatin, stable 27 
embedding of the liposomes in hydrogels for >3 months, and heat-triggered complete release of 28 
the loaded oxaplatin. 29 
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